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ABSTRACT  
Atrial fibrillation (AF) is a major health problem, affecting 1-2% of the population. AF 
reduces quality of life (QoL) and increases morbidity and mortality. Catheter ablation (CA) 
is the most efficacious means of restoring sinus rhythm but is not always successful and is 
occasionally associated with serious complications. Several questions are currently 
unanswered. True procedural effectiveness, particularly long-term, remains uncertain, 
especially in more advanced disease. The best technique for achieving success remains an 
issue of considerable debate and as yet, few, if any, means exist to predict when acute 
electrical success will translate into sustained clinical benefit. CA is indicated for 
symptomatic relief but QoL, both as a treatment outcome and as a guide to patient 
selection, has generally been overlooked in the published literature. Finally, although the 
maxim, “First, do no harm” may often be ascribed erroneously to Hippocrates, it remains a 
central tenet of medical practice. However, little previous research has focussed on 
improving the safety of CA.  
 
I have attempted to tackle these issues from a number of angles. I have performed a 
comprehensive literature review and a retrospective analysis of ablation outcomes at 
Liverpool Heart and Chest Hospital, the largest and longest such data from the UK, to 
ascertain a comprehensive, up-to-date assessment of practice. In an effort to improve 
procedural success, I carried out a multicentre randomised controlled trial testing two 
ablation strategies. A sub-study tests the hypothesis that clinical outcomes can be predicted 
by a novel measure of effective ablation. Two further studies aim to improve safety, 
through use of ultrasound to guide venous access, and to better understand QoL in AF – a 
theme throughout the thesis – which may help improve selection of appropriate patients 
for CA. Together, I hope these studies will help physicians improve the outcomes of CA for 
their patients.  
Page 3 of 266 
TABLE OF CONTENTS  
Abstract ................................................................................................................................................................ 2 
Table of Contents .............................................................................................................................................. 3 
List of Tables ................................................................................................................................................... 11 
List of Figures ................................................................................................................................................. 13 
Publications arising from this thesis ..................................................................................................... 16 
National awards for work contained in this thesis .......................................................................... 17 
Declaration of originality ........................................................................................................................... 18 
Copyright declaration .................................................................................................................................. 19 
Acronyms and abbreviations used in this thesis .............................................................................. 20 
Acknowledgements ...................................................................................................................................... 23 
1. Improving ablation outcomes in atrial fibrillation: introduction and review of the 
literature ................................................................................................................................................................ 24 
1.1. Atrial fibrillation in perspective ................................................................................................. 24 
1.1.1. Atrial fibrillation as a public health problem ................................................................ 24 
1.1.2. The effect of AF on the individual ...................................................................................... 24 
1.1.3. Atrial fibrillation as a disease .............................................................................................. 25 
1.1.4. Current treatment strategies for AF ................................................................................. 29 
1.1.5. Rate versus rhythm control ................................................................................................. 30 
1.1.6. Pharmacological therapy ...................................................................................................... 30 
1.1.7. Non-pharmacological (interventional) therapy .......................................................... 32 
1.2. Questions I hope to answer through this thesis ................................................................... 34 
1.2.1. Theme ........................................................................................................................................... 34 
1.3. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review 
and meta-analysis of evidence from randomised and non-randomised controlled trial .. 36 
Page 4 of 266 
1.3.1. Methods ....................................................................................................................................... 36 
1.3.2. Results .......................................................................................................................................... 40 
1.3.3. Discussion ................................................................................................................................... 67 
1.3.4. Conclusions ................................................................................................................................ 73 
2. Improving patient outcomes by better understanding current practice:  Real life long 
term outcomes after persistent AF ablation; Six year data from a high volume UK centre .. 74 
2.1. Background ......................................................................................................................................... 74 
2.2. Methods ................................................................................................................................................ 74 
2.2.1. Patients ........................................................................................................................................ 75 
2.2.2. Follow-up .................................................................................................................................... 75 
2.2.3. Electrophysiological study ................................................................................................... 76 
2.2.4. Statistical analysis ................................................................................................................... 77 
2.3. Results ................................................................................................................................................... 78 
2.3.1. Patients and baseline characteristics ............................................................................... 78 
2.3.2. Patient journey ......................................................................................................................... 79 
2.3.3. Follow-up .................................................................................................................................... 82 
2.3.4. Procedural complications ..................................................................................................... 82 
2.3.5. Ablation procedures ............................................................................................................... 83 
2.3.6. Outcomes after a single procedure ................................................................................... 84 
2.3.7. Outcomes after multiple procedures ............................................................................... 87 
2.3.8. Longstanding PeAF ................................................................................................................. 90 
2.3.9. Effect of CT integration on freedom from recurrent AF ........................................... 90 
2.3.10. Quality of life (QoL) after CA of PeAF ............................................................................... 92 
2.4. Discussion ............................................................................................................................................ 93 
2.4.1. Implications for clinical practice........................................................................................ 95 
Page 5 of 266 
2.4.2. Limitations ................................................................................................................................. 95 
2.4.3. Conclusion .................................................................................................................................. 96 
3. Methods of the Substrate Modification with Ablation and antiarrhythmic drugs in Non-
Permanent Atrial Fibrillation (SMAN-PAF) Randomised controlled trial ................................... 97 
3.1. Introduction ........................................................................................................................................ 97 
3.2. Original hypotheses/ research question ................................................................................. 98 
3.3. Design .................................................................................................................................................... 98 
3.4. Study duration ................................................................................................................................... 98 
3.5. End Points............................................................................................................................................ 99 
3.5.1. Primary endpoint ..................................................................................................................... 99 
3.5.2. Secondary endpoints: ........................................................................................................... 100 
3.6. Safety ................................................................................................................................................... 102 
3.6.1. Expected complication rates ............................................................................................. 102 
3.6.2. Reporting of Adverse events ............................................................................................. 102 
3.7. Blanking period ............................................................................................................................... 103 
3.8. Patients ............................................................................................................................................... 103 
3.9. Inclusion criteria ............................................................................................................................. 104 
3.10. Exclusion criteria........................................................................................................................ 105 
3.11. Randomisation ............................................................................................................................ 106 
3.12. Study visits and investigations ............................................................................................. 106 
3.13. Follow up ....................................................................................................................................... 107 
3.14. Baseline data ................................................................................................................................ 107 
3.15. Quality of life assessment ........................................................................................................ 109 
3.15.1. AFEQT questionnaire ........................................................................................................... 109 
3.16. Anti-arrhythmic drug protocol ............................................................................................. 109 
Page 6 of 266 
3.17. Anticoagulation ........................................................................................................................... 110 
3.18. Ablation procedure .................................................................................................................... 111 
3.19. Lesion description and definition of success ................................................................... 113 
3.20. Recurrence of AF ........................................................................................................................ 114 
3.21. Repeat ablation ........................................................................................................................... 115 
3.22. Sample size calculation ............................................................................................................ 115 
3.23. Statistical analysis ...................................................................................................................... 116 
3.24. Assessment of primary endpoint ......................................................................................... 117 
3.25. Recruitment .................................................................................................................................. 117 
3.25.1. CONSORT diagram................................................................................................................. 118 
3.25.2. Progress ..................................................................................................................................... 119 
3.26. Ethical considerations .............................................................................................................. 119 
3.26.1. Good Clinical Practice ........................................................................................................... 119 
3.26.2. National Research Ethics Service (NRES) .................................................................... 119 
3.26.3. Confidentiality ......................................................................................................................... 120 
3.27. Flow chart ..................................................................................................................................... 120 
3.28. Trial registration ........................................................................................................................ 122 
3.29. Case record form ........................................................................................................................ 122 
3.30. Sponsor .......................................................................................................................................... 123 
4. Improving patient outcomes though better ablation strategies: Results of the Substrate 
Modification with Ablation and antiarrhythmic drugs in Non-Permanent Atrial Fibrillation 
(SMAN-PAF) Randomised controlled trial ............................................................................................. 124 
4.1. Introduction ...................................................................................................................................... 124 
4.2.     Methods .............................................................................................................................................. 125 
4.3. Results ................................................................................................................................................. 125 
Page 7 of 266 
4.3.1. Patient characteristics ......................................................................................................... 125 
4.3.2. Follow up ................................................................................................................................... 126 
4.3.3. Ablation procedures ............................................................................................................. 127 
4.3.4. Primary endpoint ................................................................................................................... 129 
4.3.5. Secondary endpoints ............................................................................................................ 132 
4.3.6. Safety endpoint ....................................................................................................................... 133 
4.4. Discussion .......................................................................................................................................... 134 
4.4.1. Limitations ............................................................................................................................... 139 
4.5. Conclusion ......................................................................................................................................... 140 
5. improving patient outcomes by better understanding ablation lesion quality:  A novel 
marker to predict early recurrence after atrial fibrillation ablation; The Ablation 
Effectiveness Quotient ................................................................................................................................... 141 
5.1. Introduction ...................................................................................................................................... 141 
5.2. Methods .............................................................................................................................................. 142 
5.2.1. Patients ...................................................................................................................................... 142 
5.2.2. Ablation procedure ............................................................................................................... 143 
5.2.3. Ablation Effectiveness Quotient (AEQ) ......................................................................... 144 
5.2.4. Follow-up and arrhythmia monitoring ......................................................................... 144 
5.2.5. Study endpoint ........................................................................................................................ 145 
5.2.6. Statistical analysis ................................................................................................................. 145 
5.3. Results ................................................................................................................................................. 146 
5.3.1. Patient characteristics ......................................................................................................... 146 
5.3.2. Primary outcome ................................................................................................................... 148 
5.3.3. Comparison of ablation strategies .................................................................................. 149 
5.3.4. Comparison with contact force readings ...................................................................... 150 
Page 8 of 266 
5.3.5. Repeat procedures ................................................................................................................ 150 
5.3.6. Sub-group analysis ................................................................................................................ 150 
5.3.7. Extended follow up ............................................................................................................... 151 
5.3.8. AEQ to predict clinical outcome in the medium term in paroxysmal AF ......... 152 
5.4. Discussion .......................................................................................................................................... 153 
5.4.1. Potential clinical implications ........................................................................................... 156 
5.4.2. Limitations ............................................................................................................................... 157 
5.5. Conclusion ......................................................................................................................................... 158 
6. Improving patient outcomes by improving safety:  a prospective study of the use of 
ultrasound to guide vascular access for catheter ablation for atrial fibrillation ..................... 159 
6.1. Introduction ...................................................................................................................................... 159 
6.2. Methods .............................................................................................................................................. 162 
6.2.1. Vascular Access ....................................................................................................................... 163 
6.2.2. Statistical analysis ................................................................................................................. 166 
6.3. Results ................................................................................................................................................. 166 
6.3.1. Patients ...................................................................................................................................... 166 
6.3.2. Baseline characteristics ....................................................................................................... 167 
6.3.3. Primary outcome measure ................................................................................................. 168 
6.3.4. Secondary outcome measures .......................................................................................... 169 
6.3.5. Effect of learning curve ........................................................................................................ 170 
6.3.6. Predictors of BARC 2+ bleed ............................................................................................. 170 
6.4. Discussion .......................................................................................................................................... 172 
6.4.1. Limitations ............................................................................................................................... 174 
6.5. Conclusion ......................................................................................................................................... 175 
Page 9 of 266 
7. Improving patient outcomes by better understanding quality of life in atrial 
fibrillation:  Validation and Improvement of The European Heart Rhythm Association 
Symptom Classification ................................................................................................................................. 176 
7.1. Background ....................................................................................................................................... 176 
7.2. Methods .............................................................................................................................................. 178 
7.2.1. Phase One .................................................................................................................................. 178 
7.2.2. Phase Two ................................................................................................................................. 179 
7.2.3. Phase Three: ............................................................................................................................ 180 
7.2.4. AFEQT questionnaire ........................................................................................................... 180 
7.2.5. EQ-5D questionnaire (3 Level version) ......................................................................... 181 
7.2.6. Visual analogue scale (VAS) ............................................................................................... 181 
7.2.7. Statistical analysis ................................................................................................................. 182 
7.3. Results ................................................................................................................................................. 182 
7.3.1. Phase One .................................................................................................................................. 184 
7.3.2. Phase Two ................................................................................................................................. 186 
7.3.3. Reproducibility of the mEHRA class ............................................................................... 189 
7.3.4. Phase 3: Prospective validation of mEHRA ................................................................. 190 
7.4. Discussion .......................................................................................................................................... 191 
7.4.1. Limitations ............................................................................................................................... 194 
7.5. Conclusions ....................................................................................................................................... 195 
8. Final Discussion ...................................................................................................................................... 196 
8.1. To what extent did I achieve my aims? .................................................................................. 196 
8.2. What problems were encountered and how were they overcome? ........................... 197 
8.2.1. Chapter 4: Use of a modified intention to treat analysis ........................................ 197 
8.2.2. Chapter 4: Recruitment and retention .......................................................................... 200 
Page 10 of 266 
8.2.3. Duration of follow up in AF trials .................................................................................... 201 
8.3. Areas for future research ............................................................................................................ 202 
8.4. Final conclusions ............................................................................................................................ 204 
9. Reference List .......................................................................................................................................... 205 
10. Appendices ............................................................................................................................................ 231 
10.1. Appendix 1: Funnel plots for analyses carried out in Chapter 1 ............................. 231 
10.2. Appendix 2: Patient information sheet for the SMAN-PAF Trial ............................. 234 
10.3. Appendix 3: AFEQT QoL form (Chapters 3,4 &7) .......................................................... 239 
10.4. Appendix 4: SF-36 QoL questionnaire (Chapters 3 & 4) ............................................. 241 
10.5. Appendix 5: EQ-5D QoL questionnaire (Chapter 7) ..................................................... 246 
10.6. Appendix 6: Permissions information for published work ....................................... 248 
 
 
 
  
Page 11 of 266 
LIST OF TABLES  
Table 1-1: Studies included in the review ................................................................................................ 45 
Table 1-2: Assessment of study quality. .................................................................................................... 49 
Table 1-3: Sensitivity analysis examining the effect of inclusion of non-randomised trials in 
meta-analyses ...................................................................................................................................................... 72 
Table 2-1: Baseline characteristics of patients undergoing catheter ablation for PeAF ........ 79 
Table 2-2: Logistic regression analysis for freedom from recurrent AF after a single 
procedure.. ............................................................................................................................................................ 86 
Table 2-3: Logistic regression analysis for freedom from recurrent AF after multple 
procedures.. .......................................................................................................................................................... 89 
Table 3-1: Study visit schedule.. ................................................................................................................. 106 
Table 3-2: Ablation lesions (and definitions of success) used as part of study protocol ..... 114 
Table 4-1: Baseline characteristics of patients enrolled in the SMAN-PAF randomised 
controlled trial .................................................................................................................................................. 126 
Table 4-2: SMAN-PAF Procedural details ............................................................................................... 129 
Table 4-3: Binary logistic regression analysis of SMAN-PAF results ........................................... 131 
Table 4-4: Overall AFEQT score at baseline and at the six month follow up visit .................. 133 
Table 5-1: Baseline characteristics for AEQ analysis. ........................................................................ 147 
Table 5-2: Univariate logistic regression analysis for predictors of recurrence of atrial 
tachyarrhythmia after atrial fibrillation ablation. ............................................................................... 149 
Table 6-1: Studies of the use of vascular ultrasound to assist cannulation of the Femoral 
(FV) or Internal Jugular Vein (IJV). W ...................................................................................................... 161 
Table 6-2: Baseline Characteristics for the two groups in the study of ultrasound use....... 168 
Page 12 of 266 
Table 6-3: Univariate regression analysis for predictors of a BARC2+ bleed .......................... 171 
Table 6-4: Multivariable logistic regression analysis for predictors of a BARC2+ Bleeds .. 172 
Table 7-1: Modified EHRA (mEHRA) classification. ........................................................................... 180 
Table 7-2: Baseline Characteristics by EHRA Class. ........................................................................... 184 
Table 7-3: Mean (and standard deviation) for each EHRA Class. .................................................. 185 
Table 7-4: Mean (and standard deviation) shown for each mEHRA Class. ............................... 187 
Table 7- 5: Comparison of retrospective and prospective Quality of Life scores, for each of 
the two proposed additional mEHRA classes ....................................................................................... 190 
 
  
Page 13 of 266 
LIST OF FIGURES  
Figure 1-1: An illustration of how I envisage the areas of research presented in this thesis 
overlap ................................................................................................................................................................... 35 
Figure 1-2: PRISMA diagram showing the search strategy results and exclusion steps and 
reasons ................................................................................................................................................................... 41 
Figure 1-3: Forest plot showing ORs and 95%CIs for studies comparing catheter ablation 
with medical therapy ........................................................................................................................................ 52 
Figure 1-4: Forest plot showing ORs and 95%CIs for studies comparing encircling lesions of 
the pulmonary veins with other techniques in which the veins were not encircled ............... 54 
Figure 1-5: Forest plot showing ORs and 95%CIs for studies comparing electrical isolation 
of the pulmonary veins with techniques in which isolation was not a procedural goal or 
endpoint ................................................................................................................................................................. 55 
Figure 1- 6: Forest plot showing ORs and 95%CIs for studies comparing circumferential 
pulmonary vein isolation with a segmental technique ....................................................................... 56 
Figure 1-7: Forest plot showing ORs and 95%CIs for studies comparing ablation strategies 
using linear ablation lesions against strategies of pulmonary vein isolation without linear 
ablation .................................................................................................................................................................. 58 
Figure 1-8: Forest plot showing ORs and 95%CIs for studies in which a comparison was 
made between one strategy using less extensive linear ablation against a strategy of more 
extensive lesions ................................................................................................................................................ 59 
Figure 1- 9: Forest plot showing ORs and 95%CIs for studies reporting the effect of adding 
complex fractionated atrial electrogram ablation to other techniques ........................................ 61 
Figure 1-10: Forest plot showing ORs and 95%CIs for studies comparing a left atrial 
ablation strategy against a strategy using bi-atrial ablation ............................................................. 63 
Page 14 of 266 
Figure 2-1: The procedural journey for our cohort of patients with persistent atrial 
fibrillation. ............................................................................................................................................................ 81 
Figure 2-2: Recurrence curve showing number of patients remaining free from 
documented recurrence over time after a single procedure ............................................................ 85 
Figure 2-3: Recurrence curve showing number of patients remaining free from 
documented recurrence over time after their last procedure ......................................................... 87 
Figure 2-4: Kaplan-Meier curve showing AF-free survival after a single procedure for 
patients grouped according to use of CT integration ........................................................................... 91 
Figure 2-5: Kaplan-Meier curve showing AF-free survival after the final procedure for 
patients grouped according to use of CT integration ........................................................................... 92 
Figure 3-1: Antiarrhythmic treatment algorithm ................................................................................ 110 
Figure 3-2: Study CONSORT diagram ....................................................................................................... 118 
Figure 3-3: Study flow diagram .................................................................................................................. 121 
Figure 3-4: Screen shot of eCRF database .............................................................................................. 123 
Figure 5-1: Box and Whisker chart of AEQ and early recurrence of atrial tachyarrhythmia in 
patients with paroxysmal atrial fibrillation. .......................................................................................... 151 
Figure 5-2: Receiver Operating Characteristic (ROC) curve for AEQ as a predictor of 
freedom from recurrence of atrial tachyarrhythmia over 12 month follow up in patients 
with paroxysmal atrial fibrillation. ........................................................................................................... 153 
Figure 6-1: Two-handed technique for gaining venous access under ultrasound guidance 
and representative image of the femoral vasculature.. ..................................................................... 164 
Figure 7- 1: Quality of Life scores (mean ± SD) by EHRA Class ..................................................... 186 
Figure 7-2: Quality of Life scores (mean ± SD) by mEHRA Class................................................... 188 
Page 15 of 266 
Figure 7-3: AFEQT sub-domain scores (mean ± SD) by mEHRA Class ....................................... 189 
Figure 8-1: Copy of Figure 1-1 .................................................................................................................... 196 
  
Page 16 of 266 
PUBLICATIONS ARISING FROM THIS THESIS  
Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of Catheter Ablation for 
Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis of Evidence from 
Randomised and Non-Randomised Controlled Trials.  Circ Arrhythm Electrophysiol. 
2014;7:841-52. 
 
GJ Wynn, I Haq, J Hung, LJ Bonnett, G Lewis, M Webber, JEP Waktare, S Modi, RL Snowdon, 
MCS Hall, DM Todd, D Gupta.  Improving safety in catheter ablation for atrial fibrillation: a 
prospective study of the use of ultrasound to guide vascular access. J Cardiovasc 
Electrophysiol. 2014 ;25:680-5 
 
GJ Wynn, DM Todd, M Webber, LJ Bonnett, J McShane, P Kirchhof, D Gupta. The European 
Heart Rhythm Association Symptom Classification for Atrial Fibrillation: Validation and 
Improvement through a Simple Modification. Europace. 2014;16:965-72. 
 
GJ Wynn, M Das, LJ Bonnett, MCS Hall, RL Snowdon, JEP Waktare, S Modi, DM Todd, D 
Gupta. A novel marker to predict early recurrence after atrial fibrillation ablation: The 
Ablation Effectiveness Quotient. J Cardiovasc Electrophysiol. 2015, In press. 
 
In addition, thirteen abstracts have been presented and published in peer-reviewed 
journals. 
  
Page 17 of 266 
NATIONAL AWARDS FOR WORK CONTAINED IN THIS THESIS  
2014 British Heart Rhythm Society  Young Investigator Award Winner 
(Clinical)  
Long term outcomes after persistent AF ablation: six year data from a high volume UK 
centre. 
2013 British Cardiovascular Society Highest scoring abstract 
Modification of the European Heart Rhythm Association AF symptom score improves 
discriminative ability: a validation study 
  
Page 18 of 266 
DECLARATION OF ORIGIN ALITY  
The work contained within this thesis is that of the author, produced with the aid and 
guidance of his supervisors. All experimental work and statistical analyses were performed 
by the author, with statistical support and guidance provided by Dr Laura Bonnett, 
University of Liverpool. Where work has been published in the literature, co-authors of that 
work have provided editorial commentary, but final responsibility has remained with the 
author at all times. 
  
Page 19 of 266 
COPYRIGHT DECLARATION  
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence.  Researchers are free to 
copy, distribute or transmit the thesis on the condition that they attribute it, that they do 
not use it for commercial purposes and that they do not alter, transform or build upon it. 
For any reuse or redistribution, researchers must make clear to others the licence terms of 
this work 
  
Page 20 of 266 
ACRONYMS AND ABBREVIATIONS USED IN THIS T HESIS  
Acronym/ 
Abbreviation 
Full text 
AAD Anti-Arrhythmic Drug(S) 
ACT Activated Clotting Time 
AEQ Ablation Effectiveness Quotient 
AF Atrial Fibrillation 
AFEQT Atrial Fibrillation Effect on Quality Of Life Tool 
ANOVA Analysis of Variance 
ARR Absolute Risk Reduction 
Art Arterial 
AUC Area Under the Curve 
AV Atrioventricular  
BARC Bleeding Academic Research Consortium 
BD Twice daily 
BMI Body Mass Index 
CA Catheter Ablation 
CFAE Complex Fractionated Atrial Electrogram(S) 
CI Confidence Interval 
CMR Cardiac Magnetic Resonance 
CPR Cardiopulmonary Resuscitation 
CRF Case Record Form 
CS Coronary Sinus 
CT Computed Tomography 
CTI Cavo-Tricuspid Isthmus 
cTnT Cardiac Troponin T 
CVC Central Venous Catheter 
DAP Dose-Area Product 
DC (CV) Direct Current( Cardioversion) 
dL Decilitre 
ECG Electrocardiogram/ Electrocardiography 
ECHO Echocardiography/ Echocardiogram 
eCRF Electronic Case Record Form 
EF Ejection Fraction 
EHRA European Heart Rhythm Association 
EQ-5D EuroQOL 5-Domain [questionnaire] 
ESC European Society of Cardiology 
FA Femoral Artery 
Page 21 of 266 
FIRM Focal Impulse and Rotor Modulation  
Fluoro Fluoroscopy 
FV Femoral Vein 
g Gram(s) 
HFS High Frequency Stimulation 
HH Harefield Hospital 
HScTnT High Sensitivity Cardiac Troponin T 
IJV Internal Jugular Vein 
INR Internationally Normalised Ratio 
ITT Intention to Treat 
IVC Inferior Vena Cava 
L Litre 
LA Left Atrium/ Atrial 
LAA Left Atrial Appendage  
LHCH Liverpool Heart and Chest Hospital (NHS Foundation Trust) 
LV Left Ventricle 
mg Milligram(s) 
MI Myocardial Infarction 
MIL Mitral Isthmus Line 
mins Minutes 
MR Magnetic Resonance  
ng Nano gram(s) 
NHS National Health Service 
NICE National Institute for Health and Clinical Excellence 
NNT Number Needed to Treat 
NRCT Non- Randomised Controlled Trial 
NRES National Research Ethics Service 
NS Non-significant 
NYHA New York Heart Association 
OD  Once daily 
OR Odds Ratio 
OSA Obstructive Sleep Apnoea 
Paeds Paediatric 
PAF Paroxysmal Atrial Fibrillation 
PeAF Persistent Atrial Fibrillation  
PIS Participant Information Sheet 
PLAX Parasternal Long Axis [Echocardiographic Imaging Plane] 
PV Pulmonary Vein 
Page 22 of 266 
PVI/ PVAI Pulmonary Vein Isolation/ Pulmonary Vein Antral Isolation 
QALY Quality-Adjusted life Year 
QOL Quality Of Life 
RBH Royal Brompton Hospital 
RBHT Royal Brompton and Harefield Hospitals NHS Foundation Trust 
RCT Randomised Controlled Trial 
RF/ RFA Radiofrequency / Radiofrequency Ablation 
ROC Receiver Operating Characteristic 
RRR Relative Risk Reduction 
SAE Serious Adverse Events 
SD Standard Deviation 
secs Seconds 
SF-36 Short Form 36 
SQL Structured Query Language 
SR Sinus Rhythm 
SUSAR Suspected Unexpected Serious Adverse Events 
SusPAF Sustained Paroxysmal AF 
SVC(I) Superior Vena Cava (Isolation) 
TDS Three times a day 
TIA Transient Ischaemic Attack 
TOE Transoesophageal Echocardiography / Echocardiogram 
TTE Transthoracic Echocardiography/ Echocardiogram 
US Ultrasound  
VAS Visual Analogue Scale 
WACA Wide Area Circumferential Ablation 
 
  
Page 23 of 266 
ACKNOWLEDGEMENTS  
Firstly, I would like to thank Dr Dhiraj Gupta for his unwavering guidance and enthusiasm 
through every step of my research endeavour. He has acted as supervisor, mentor and 
friend and helped me through the many highs and lows of clinical research. Without his 
invaluable leadership none of this would have been possible. 
 
Secondly, I thank Professor Sian Harding for guiding me through and, most importantly, for 
extending a hand of friendship and support to a stranger. In doing so she had much to lose 
and little to gain, but I hope her investment in me is now deemed worthwhile, and that she 
has enjoyed our association as much as I. 
 
My thanks also go to the various colleagues who have made this process possible. To 
Sharon Ngai, without whose organisation and help I may never have got out of the starting 
blocks, and to Dr Sandeep Panikker, who worked tirelessly and with amazing good grace to 
help turn an idea in Liverpool into a multi-centre trial. To Maureen and Ben, my research 
nursing team, and all the cardiac physiologists and cath lab staff at Liverpool Heart and 
Chest Hospital, especially the electrophysiology team, who often worked late or fitted in 
extra tasks for my benefit rather than their own. To Dr Laura Bonnet for her statistical 
tutelage, and to all of the consultant Electrophysiologists who have put up with me, and the 
needs of my various studies, throughout my time with them. 
 
Finally thank you, to my darling wife, Anna, and my children, Lara, Emmy and Richie: 
without whom nothing else has any meaning. 
  
Page 24 of 266 
1 .  I M P R O V I N G  A B L A T I O N  O U T C O M E S  I N  
A T R I A L  F I B R I L L A T I O N :  I N T R O D U C T I O N  A N D  
R E V I E W  O F  T H E  L I T E R A T U R E  
 
1.1  ATRIAL FIBRILLATION IN PERSPECTIVE  
1.1.1. ATRIAL FIBRILLATION AS A PUBLIC HEALTH PROBLEM  
Atrial fibrillation (AF) is the most common cardiac arrhythmia occurring in 1-2% of the 
general population1-4. AF approximately doubles mortality rates5. The incidence of AF rises 
with age and it is an important risk factor for stroke6-8.   
Direct treatment of AF consumes 2% of the total NHS budget, of which half is due to 
hospital admissions9. This calculation does not include the cost of stroke rehabilitation and 
other secondary complications. Patients with complications of AF account for ⅓ million 
hospital bed days every year in England and Wales alone (Patient Episode Database for 
Wales and Hospital Episode Statistics – personal communication). The current NICE 
guidance on AF recommends referral of such patients to a ‘specialist’ for consideration of 
interventional treatments such as catheter ablation or pacemaker and AV node ablation7.  
1.1.2. THE EFFECT OF AF  ON THE INDIVIDUAL  
Many patients suffer considerable symptoms associated with a reduced quality of life 
(QoL)10.  This is accompanied by reduced exercise capability11. The effect of AF on QoL is a 
severe as in patients with significant structural heart disease12.   Treatment for AF aims to 
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minimise or abolish these symptoms and to avoid the development of complications and 
improve QoL13. 
1.1.3. ATRIAL FIBRILLATION AS A DISEASE  
1.1.3.1. PATHOGENESIS OF AF 
In AF there is chaotic, rapid electrical activity within the atria resulting in disorganised 
local contraction and ineffective transit of blood to the ventricles.14 Generally, AF cycle 
lengths are shorter in the left  atrium than the right, suggesting this as the chamber driving 
the arrhythmia.15     Multiple hypotheses have been proposed to explain the pathogenesis of 
atrial fibrillation and it remains unclear whether one, true, hypothesis predominates or 
whether a combination of mechanisms can exist, either within a population or an 
individual.16 Evidence for initiation of AF by ectopic foci within the pulmonary veins 
provided the basis for the development of strategies for percutaneous catheter ablation 
(CA) of AF.17 Maintenance of AF may be due to a critical number of self-propagating 
wavelets and/ or to areas of localised microreentry.18,19  Each of these proposed 
mechanisms has been shown to exist experimentally and treatment strategies based on the 
proposed models have been shown to be clinically effective.20-24 On a cellular level, changes 
in ionic currents occur, either due to genetic mutations or in response to cellular stress. 
Abnormalities in cellular calcium handling can occur, particularly due to down regulation 
of the Ica.L current.25 Combined with down regulation of other depolarisation currents, such 
as Ito and INa, there is a reduction of conduction velocity and shortening of the atrial cardiac 
action potential resulting in heterogeneous shortening of effective refractory periods.26  
This dispersion of abnormal electrical conduction properties creates a mechanism by 
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which either re-entry or wavelet propagation can occur. Interestingly, it seems to be the 
alteration of normal myocardial conduction properties or patterns that promotes AF more 
than the specific mechanism. This is evidenced by the fact that some models have shown 
that AF susceptibility can also be increased by ionic changes that are the opposite to those 
described above, such as up regulation of Ica.L in postoperative or hyperthyroidism-
associated AF.27,28 
1.1.3.2. GENETIC ASPECTS OF AF 
The genetics of AF are complex and incompletely understood. Occurrence of atrial 
fibrillation in childhood is rare, and usually associated with congenital structural or 
electrical abnormalities (such as an accessory atrio-ventricular pathway) within the 
heart.29,30 However, certain familial forms seem to exist in which multiple relatives develop 
atrial fibrillation, often in young adulthood, without any clear precipitating comorbidities.31 
Several genes have been identified which appear to be associated with AF development.32  
These can be seen to cause ion channel dysfunction, structural remodelling or abnormal 
cytoskeletal interactions.33 A gain-of- function mutation of the KCNQ1 gene, which encodes 
a subunit of the IKs channel, was the first to be identified as having an association with atrial 
fibrillation.34  Since then abnormalities in several other genes encoding for potassium 
channels, as well as the sodium channel gene, SCN5A. As with Ica.L, described above, both 
gain-of- function and loss-of-function mutations have been described associated with 
increased susceptibility to AF.33  
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One particular non-ion channel locus, which has been studied extensively, is 4q25 which 
encodes PITX2.  PITX2 is critical for left/right asymmetry, including specification of the left 
atrium (LA) and pulmonary myocardium and suppression of a default program for 
sinoatrial node formation in the left atrium. Mutations in genes encoding PITX2 may 
prevent normal differentiation and development of the LA to developing AF.35  As well as 
compatible cellular level abnormalities found in animal/ tissue models, strong associations  
have been seen in population studies.36 Two studies found polymorphisms at 4q25 were 
implicated in both early and late recurrence after CA.37,38 A number of mutations can occur 
and risk, with increasing number of mutations, may be cumulative.39   
 
Polymorphisms of the gene encoding the intercellular gap protein, connexin40, have been 
shown by several groups to be associated with increased risk of AF.40-42 Expression of 
connexin40 is associated with atrial conduction velocities, providing a mechanism by 
which the genotype may be linked with the AF phenotype.43 However, this promising early 
work has been hampered by difficulties obtaining reliable samples and inconsistencies in 
connexion quantification.32,33  
 
A major complicating factor in understanding a potential genetic basis for AF is the late-
onset, acquired nature seen most frequently. Whether genetic predisposition plays a role in 
increasing susceptibility to the disease-inducing effects of associated conditions is hard to 
determine, and incompletely studied, due the considerable confounding that cannot be 
adequately controlled for in older patients. For example, a number of studies have looked 
at genetic components of the rennin-angiotensin system with particular attention paid to 
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the ACE gene, the D(eletion) allele of which seems particularly strongly associated with 
development of AF.44 Associated mutations in the angiotensinogen and angiotensin 
receptor genes have also been shown.45 Abnormalities in any of these aspects of the renin-
angiotensin system can lead to the development of hypertension and pre-existing 
hypertension is strongly associated with occurrence of AF. Classically, hypertension has 
been thought to increase intra-atrial pressure, causing atrial stretch and resultant 
abnormal remodelling is thought to explain this association but it’s possible that both 
diseases can be manifestations of the same genetic abnormality(ies).  
 
It is likely that there is no simple “AF gene” rather a number of genotypes which increase 
risk and, at least in some cases, have an additive risk. It may be that some abnormalities 
(particular ion channel) may be sufficient to be considered monogenic AF whereas other 
abnormalities are polygenic.   In some cases AF would seem to be a direct consequence of 
the genetic abnormality (e.g. abnormal connexion, ion channel loss or gain in function) and 
in others it may be that AF is either a direct genetic consequence or a secondary effect of 
the phenotype. A “two-hit” hypothesis has been proposed in which both genetic and 
acquired risk factors are required for AF to develop.46 
1.1.3.3. CLASSIFICATION OF AF   
Atrial fibrillation may occur intermittently (in paroxysms) or may be present continuously. 
In practice the terms paroxysmal AF (PAF) and persistent AF (PeAF) are widely used. The 
definitions of these terms have changed over recent years suggesting that the distinctions 
are not clear cut.14,47-49 Longstanding PeAF (LsPeAF) describes AF that has been present 
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continuously and without significant interruption for at least twelve months. Although the 
time period of twelve months is an arbitrary cut off the relevance of this subcategory is that 
it tends to represent a point at which a rhythm control strategy may well be significantly 
less successful than in less advanced disease states. There is no accepted consensus as to 
what duration of sinus rhythm can occur after an attempt at cardioversion or ablation 
before AF is no longer considered longstanding. The term permanent AF is also used and 
differs from the other subcategories in that it is defined by a treatment decision rather than 
a disease state. Permanent AF is present when patient and treating clinician have decided 
to accept atrial fibrillation and to no longer pursue attempts to restore sinus rhythm.   The 
term is usually used when AF is present continuously. If a later decision is made to try to 
restore sinus rhythm, permanent AF should be reclassified.  
1.1.4. CURRENT TREATMENT STRATEGIES FOR AF 
Treatment of atrial fibrillation focuses on the avoidance of complications, mainly in the 
form of stroke, and reduction in symptoms. As stated previously, the incidence of AF rises 
with age and it is an important risk factor for stroke.6-8 Thromboembolism occurs in AF due 
to a combination of abnormal blood stasis in the hypocontractile left atrium, and in 
particular the left atrial appendage; abnormal activation of circulating platelets and the 
coagulation cascade; and endothelial dysfunction due various mechanisms such as  
inflammation, abnormal turnover of extracellular matrix and  myocyctic hypertrophy.50 
Thankfully, there are now well established guidelines for the effective prevention of stroke 
with anticoagulation47,51. In addition to the vitamin K antagonist, warfarin, a number of 
new and effective therapeutic agents are now available.52-55 For patients unable to take 
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pharmacological anticoagulation, percutaneous closure of the left atrial appendage is a 
potential alternative.56,57 
 
The second significant issue with AF is that many patients suffer considerable symptoms 
associated with a reduced quality of life (QoL).10 This is frequently accompanied by 
reduced exercise capability11. Symptoms may include palpitations, lethargy, dyspnoea 
chest pain and even personality change.7 The effect of AF on QoL is a severe as in patients 
with significant structural heart disease12.   In addition to the need to avoid embolic stroke,  
treatment of AF aims to minimise or abolish these symptoms and improve QoL.13 
There are two broad categories of treatment.  One option is to accept atrial fibrillation and 
focus simply on controlling the ventricular rate (rate control) and the second is to attempt 
to restore and maintain sinus rhythm (rhythm control).  
1.1.5. RATE VERSUS RHYTHM CONTROL  
There have been five large trials performed to try to establish the optimum treatment 
strategy, rate or rhythm control, for patients with A.F58-62 These trials recruited over 5000 
patients and focussed on important hard endpoints, including mortality, but none showed 
an advantage of one strategy over the other. The management of AF in these trials was 
principally focussed on pharmacological means to control heart rate or rhythm, with a 
limited number of patients moving to interventional (ablation) treatments. Sub analysis of 
these trials showed no difference in quality of life between the treatment strategies63,64 
although successful maintenance of sinus rhythm did appear to confer an improvement.65  
1.1.6. PHARMACOLOGICAL THERAPY  
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Pharmacological treatments can be grouped according to whether they predominately 
work by controlling rate or rhythm. Because of the negative results of the abovementioned 
studies, rate control medications are generally advocated for first line use, with rhythm 
control medications (antiarrhythmic drugs) reserved for those who remain symptomatic 
despite adequate rate control.7 Beta-blockers are the mainstay of pharmacological rate 
control with alternatives predominantly being the negatively chronotropic non-
dihydropiridine calcium channel blockers, verapamil and diltiazem, or digoxin.66 
Antiarrhythmic (rhythm control) drugs licenced for use in the UK include flecainide, 
procainamide, propafenone, sotalol, dronadarone, and amiodarone. These agents are 
classified according to the predominant action they exert on the cardiac action potential 
due to the variety of cell membrane ion channels on which the individual drug acts.  
Unfortunately, these changes may have the unintended side-effect of increasing the 
likelihood of re-entrant tachyarrhythmia, either by increasing the period during which a 
cell is vulnerable to after- depolarisations, or by stabilising re-entry when it occurs.67   This 
tendency is termed pro-arrhythmia and is potentially life-threatening.  Pro-arrhythmia may 
help explain why, at least in AFFIRM – by far the largest of the rate v rhythm studies 
discussed above, the overall beneficial survival effects of sinus rhythm appeared negated 
when it was achieved with antiarrhythmic drugs.68 In addition, anti-arrhythmic drugs are 
limited in the efficacy in which they actually achieve sinus rhythm. At the five year follow-
up point of AFFIRM, 34.6% of patients in the rate control group were nonetheless in sinus 
rhythm, increasing to only 62.6% in the rhythm control arm, an absolute difference of only 
28%.60   
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1.1.7. NON-PHARMACOLOGICAL (INTERVENTIONAL)  THERAPY  
In contrast to the studies of rate v rhythm with medication studies of interventional 
management of AF have shown considerable improvements in QoL. The dramatic 
improvement seen in QoL when it is possible to “cure” AF has been confirmed in studies of 
catheter ablation69-71.  It appears that  if AF can be controlled, without the potentially 
deleterious side effects and pro-arrhythmic risks of anti-arrhythmic medication, there is a 
significant resulting improvement in quality of life72. As interventional treatments for AF 
are both more effective at controlling the rate and rhythm and associated with fewer side 
effects there is a good rationale for presuming that they should produce greater 
improvements in QoL than achieved with medication73-75.  
1.1.7.1. PALLIATIVE ABLATION (PACE AND ABLATE) 
Permanent pacemaker implantation and atrioventricular (AV) node ablation (Pace and 
Ablate, P&A) is a strategy that is designed to definitively control and regulate the heart rate 
without attempting to restore normal (sinus) rhythm. This is achieved by destroying 
(ablating) the AV node which is the electrical connection between the atria and the 
ventricles. Therefore, whilst the atria continue to fibrillate, this is not conducted to the 
ventricles. Because the ventricles’ own intrinsic ability to contract is both unreliable and 
slow: a pacemaker is implanted prior to AV node ablation to ensure an adequate heart rate.  
As such it is sometimes considered as the “ultimate” means of rate control.  P&A has been 
shown to improve quality of life, increase exercise capacity and, in patients with impaired 
left ventricular (LV) function initially, to improve LV function.76,77 However, because of the 
irreversible nature of the procedure, the life-long dependency on a pacemaker – 
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replacement of which is required periodically with each procedure carrying an inherent 
risk of infection or other complication, and the potential deleterious effect  of permanent 
loss of atrioventricular synchrony and non-physiological pacing, P&A is usually reserved 
for patients in whom other treatment options have failed or are considered unsuitable due 
to advanced age or comorbid conditions.47  
1.1.7.2. CATHETER ABLATION 
CA, often called pulmonary vein isolation or PVI, is an attempt to cure AF. In >95% of 
patients AF is triggered by rapid electrical beats within the pulmonary veins which 
stimulate the heart thereby causing AF17. The ablation procedure is designed to prevent 
these pulses of electricity from entering the heart by forming a line of electrical insulation 
between the mouth of the veins and the heart78. Additional burns may also be performed at 
other critical points for AF initiation or maintenance, or in a pattern that attempts to 
compartmentalise the atria to prevent abnormal electrical “short circuits” (re-entry) from 
occurring.  When compared to pharmacological rhythm control therapy CA significantly 
and consistently produces greater freedom from AF.73-75,79-81  
 
1.1.7.2.1 EFFECT OF CATHETER ABLATION ON QUALITY OF LIFE 
Although in the previously mentioned studies of rate versus rhythm control no QoL 
difference was seen between the groups, this may relate to the pharmacological strategies 
employed in these trials. CA has been shown to improve QoL and it appears that rhythm 
control with CA produces a quality of life benefit whereas pharmacological rate control 
does not.69,70,75,80 Even when CA does not “cure” AF, there can still be an important 
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improvement in quality of life.82  Recent work by Reynolds et al showed that patients with 
drug-resistant paroxysmal AF treated with AF ablation showed significant and sustained 
improvements in QoL measured with the SF-36 instrument.83  This improvement was 
shown in the physical component score, mental component score, symptom frequency and 
symptom severity.  The magnitude of improvement was greater than the 2 to 3 point 
improvement that defines a minimum, clinically meaningful difference.11,84  In contrast, 
patients randomised to drug therapy showed little symptomatic improvement.  
Furthermore, those patients who crossed over from drugs to catheter ablation showed 
similar QoL gains to those initially randomised to catheter ablation.   
1.2  QUESTIONS I  HOPE TO ANSWER THROU GH THIS THESIS  
1.2.1  THEME  
The use of CA to treat AF is a relatively new and developing procedure, having only initially 
having been described in the last few years of the twentieth century.17,78,85  Despite the 
advantages of CA over pharmacological therapy, many areas for improvement remain.  
The theme of this thesis will be to investigate how CA, the most advanced of the available 
treatments for AF, can be improved to the benefit of patients. The central aim is that the 
new knowledge gained through the research undertaken will provide novel insights into 
how patient outcomes can be improved. I believe that the outcome for the patient is a 
multi-factorial concept. Freedom from recurrent AF after a CA is undeniably important, but 
is not the “90be all and end all”. Therefore whist some of the work presented in subsequent 
Chapters will focus on arrhythmic success, others will explore issues of patient safety, 
patient selection and a novel means of assessing ablation effectiveness, potentially allowing 
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prediction of appropriate follow up. I will focus on areas where current research is either 
limited of lacking. For example, therefore, when looking at arrhythmic outcomes I will 
focus on PeAF, and/ or substrate-based AF. QoL will be a prevalent theme throughout 
several Chapters. In Chapter two I will investigate how heath status, as a surrogate for QoL, 
is linked with arrhythmic outcome and investigate how CA affects both aspects. Later, I will 
describe and report a randomised trial in which QoL is an important secondary outcome 
measure. Finally, I will show how assessment of QoL can help to select appropriate patients 
with AF for CA.  Together, I hope to present a coherent and complimentary body of work 
which moves scientific knowledge forward towards the goal of optimum patient outcome, 
as illustrated in Figure 1-1, below.  
 
Figure 1-1: An illustration of how I envisage the areas of research presented in this thesis overlap, with a key 
central goal of optimising the overall outcome for patients undergoing catheter ablation   
Optimum patient outcome 
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1.3  EFFICACY OF CATHETER ABLATION FOR PERSISTENT ATRIAL FIBRILLATION :  
A SYSTEMATIC REVIEW AND META-ANALYSIS OF EVIDENCE FROM RANDOMISED 
AND NON-RANDOMISED CONTROLLED TRIAL  
1.3.1   METHODS  
1.3.1.1  SEARCH STRATEGY AND STUDY ELIGIBILITY 
I aimed to systematically review the literature for evidence of the clinical effectiveness of 
CA of PeAF in randomised, quasi-randomised or other controlled trials following 
recommendations for the reporting of meta-analysis of observational studies.86 The initial 
search was performed on 21 June 2012 and was repeated periodically until 20 October 
2013. The searches were performed with the assistance of an information specialist 
librarian. We searched PubMed/ MEDLINE (1/1/1995 until October 2013), EMBASE (1950 
until October 2013) and the Cochrane Central Register of Controlled trials (CENTRAL - up 
until and including Issue 9, September 2013) using the search terms (((atrial) OR 
auricular) AND fibrillation) AND (ablation OR isolation) We cross-checked this search 
using wildcards (((Auric*) OR Atrial) AND Fibrillat*) AND (ablat* OR isolat*) and the MESH 
Headings ATRIAL FIBRILLATION and CATHETER ABLATION mapped to the thesaurus.  For 
the EMBASE search we additionally searched using the Heading HEART ATRIUM 
FIBRILLATION. We excluded those not published in English unless an English version of 
the article was accessible, and applied the filters: Humans AND (Clinical Trial OR Controlled 
Clinical Trial OR Randomized Controlled Trial). In order to attempt to access the grey 
literature we searched using the OpenGrey Database (http://www.opengrey.eu) using the 
terms (Atrial Fibrillation AND (Isolation OR Ablation)) and searched for studies with 
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results available on the online trial registry www.clinicaltrials.gov.  We attempted to 
contact authors to clarify any areas of uncertainty regarding study data. Where data for 
patients with PeAF were presented graphically but explicit figures were not provided in the 
published manuscript we used graphic digitization software (DigitizeIt, Braunschweig, 
Germany).  Potentially eligible studies were assessed independently by two investigators 
with differences resolved by consensus including a third investigator and statistician. 
We included studies of ablation against medical therapy and also those which compared 
one ablation strategy with another. We excluded studies which did not report outcome data 
or where the outcome data was limited to immediate procedural success. We also excluded 
studies which did not contain a comparator group but allowed a wide range of comparators 
such as placebo, randomised control arm, quasi-randomised or non-randomised 
contemporary control or historical cohort. Studies needed to have a comparator group in 
which treatment was different. Studies in which two groups were formed based on the 
outcome of an earlier procedure but then analysed as separate groups (i.e. long term 
success comparing acute procedural failure vs. acute procedural success) were not 
included. We also excluded studies of surgical ablation, and studies of ablation techniques 
other than AF ablation. 
 
 Because of well documented weaknesses in the methodology, accuracy, and completeness 
of conference abstracts we excluded studies published only in abstract form.87,88 We 
supplemented our database searches with hand searches of the reference lists of published 
studies and major review articles. We included one study only available online ahead of 
print and one which was available only on clinicaltrials.gov at the time of our literature 
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search and data analysis, both of which have subsequently been published in peer-
reviewed journals.89,90 
 
 Few studies differentiated between persistent and longstanding PeAF and fewer still 
provided a breakdown of results based on this distinction. In addition, the definition used 
was inconsistent and rarely stated explicitly. Therefore, throughout this manuscript we use 
“PeAF” as a single encompassing term. Only four studies exclusively recruited patients with 
longstanding (>12 months) PeAF.91-94 These studies were included in the pooled analyses 
along with a discussion about any impact this may have had on the results.  
1.3.1.2  AREAS FOR ANALYSIS 
We grouped studies according to the following analysis areas for patients with PeAF.  
1. Efficacy of CA compared to medical therapy 
2. Effect on efficacy of encircling ablation and isolation of the PVs 
3. Efficacy of circumferential versus segmental pulmonary vein isolation (PVI) 
4. Efficacy of linear atrial ablation lesions 
5. Efficacy of ablation of Complex Fractionated Atrial Electrograms (CFAEs) 
6. Efficacy of other peri-ablation techniques and strategies   
Studies were assessed individually as to the most appropriate analysis area but were 
permitted to contribute to more than one if appropriate to the study design (e.g. multi-arm 
study or 2x2 factorial design). 
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1.3.1.3  STATISTICAL ANALYSIS 
A qualitative analysis is provided unless there is sufficient data (at least three comparable 
studies) to perform a meta-analysis. Meta-analysis was performed using random-effects 
modelling, checked against fixed-effects to avoid undue influence of small studies.95  
Because included studies variably reported outcomes as events and non-events we 
presented results as odds ratios (OR) and 95% confidence intervals (95%CI), with 
sensitivity analysis performed to ensure choice of summary statistic was not critical to the 
conclusions of the meta-analysis.95 Heterogeneity was assessed using the I2 statistic. We 
followed the recommendations of the Cochrane Handbook, grading significant 
heterogeneity as moderate (30-60%), substantial (50-90%) or considerable (>75%).95 
Statistical analysis was performed using Comprehensive Meta Analysis software, version 
2.2 (Biostat, Englewood, New Jersey, USA) and StatsDirect version 2.7.8 (StatsDirect Ltd, 
Cheshire, UK).  Where studies enrolled patients with both paroxysmal and PeAF and 
provided details of outcomes split by AF type but did not perform their own analysis we 
compared proportions using the χ2 test. Funnel plots were used as a graphical assessment 
for publication bias. These are provided in Appendix 1. Individual studies which caused a 
marked increase in the heterogeneity and publication bias were assessed for a clinical 
explanation for the differences observed (e.g. substantial differences in the intervention or 
control group), in which case they were described individually rather than pooled with 
other studies. If studies were excluded on this basis we performed and reported a 
sensitivity analysis. Where sufficient data were available we also performed sensitivity 
analyses for outcomes after single or multiple ablation procedures. We found insufficient 
data to perform any sub-group analyses. 
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1.3.2 RESULTS  
1.3.2.1  LITERATURE SEARCH 
Of the 967 potential eligible unique studies identified, 921 were excluded leaving 46 full 
text articles for analysis.  Details of our inclusion and exclusion process are given in Figure 
1-2.  
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Figure 1-2: PRISMA diagram showing the search strategy results and exclusion steps and reasons  
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1.3.2.2. STUDY AND PATIENT CHARACTERISTICS 
We identified 46 studies containing 6085 patients.  Thirty two were RCTs, and 14 were 
NRCTs of which the study design was a cohort study in 12 and case-control in two. Twenty 
three studies included only patients with PeAF and 23 contained a mixed patient 
population with results split by AF type. The median proportion of PeAF in the mixed 
studies was 39% (range 19-72%). The total number of patients with PeAF was 3819. Mean 
follow-up was 13.5±6 months (range 3–36). Five non-randomised studies were of 
sequential cohort design with uneven follow-up between groups. We did not analyse 
individual patient characteristics as most studies reporting results for patients with both 
paroxysmal and PeAF reported these only for the study population as a whole. All studies 
used radiofrequency (RF) alternating current as the ablation energy source. Details of the 
included studies are shown in Table 1-1. 
Author, 
Year 
Study 
type 
N AF Type % 
PeAF 
Control group Treatment group 
Arentz,96 
2007 
RCT 110 Mixed 39 Segmental PVI WACA 
Bansch,97 
2013 
RCT 107 Mixed 35 No waiting 
period after 
PVI 
Prolonged waiting 
period (1 hour) 
Calo,98 
2006 
RCT 80 Persistent 100 PVI + MIL + 
CTI 
As control + SVCI + 
intercaval septal 
and posterior lines 
Corrado,9
9 2010 
RCT 320 Mixed 54 PVAI PVAI + SCVI 
Della 
Bella,100 
2009 
RCT 290 Mixed 29 Fluoroscopy-
guided CA 
Image integration-
guided CA 
Di 
Biase,101 
2009 
Cohort 390 Mixed 32 Manual 
ablation 
Robotic navigation-
delivered ablation 
Di 
Biase,102 
2010 
Cohort 267 Mixed 
(repeat 
CA) 
71 LAA not 
ablated  
LAA ablation 
(focal/LAA 
isolation)  
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Author, 
Year 
Study 
type 
N AF Type % 
PeAF 
Control group Treatment group 
Dixit,103 
2012 
RCT 156 Persistent 100 PVI + ablation 
of non-PV 
triggers  
As control + CFAE 
ablation 
Elayi,91 
2008 
RCT 144 Longstan
ding PeAF 
100 PVAI PVAI + CFAE 
Estner,104 
2008 
Cohort 77 Persistent 100 CFAE PVI + CFAE 
Estner,105 
2011 
RCT 116 Persistent 100  PVI + CFAE PVAI + lines (1-3 of 
roof, MIL, CTI) 
Fassini,10
6 2005 
RCT 187 Mixed 33 PVI PVI + MIL 
Gaita,107 
2008 
RCT 204 Mixed 39 PVI + CTI PVI + lines (MIL, 
roof, CTI) 
Gu,108 
2012 
RCT 123 Persistent 100 Class Ic OR III 
for 2 months 
post-PVI 
Propafenone AND 
amiodarone for 2 
months post-PVI 
Hummel, 
201490 
RCT 210 Persistent 100 AAD +/- DCCV  Phased RF ablation 
Jones,109 
2013 
RCT 52 Persistent 100 Rate-control CA 
Kistler,110 
2006 
Cohort 94 Mixed 51 3D-mapping-
guided CA   
Image integration-
guided CA 
Kumagai,
111 2013 
RCT 100 Persistent 100 Box isolation + 
CFAE 
Box isolation + 
Nifekalant (0.3 
mg/kg) + CFAE 
Lim,112 
2012 
RCT 220 Mixed 39 WACA ± MIL Single-ring 
posterior box 
isolation ± MIL 
Lin,113 
2009 
Cohort 60 Persistent 100 WACA + lines WACA + lines + 
CFAE 
MacDonal
d,114 
2011 
RCT 22 Persistent 100 Rate-control CA 
Mansour,
115 2004 
Cohort 80 Mixed 19 Segmental PVI WACA 
Matiello,1
16 2008 
Cohort 221 Mixed 38 PVI with 8mm-
tip 
PVI with 4mm 
cooled-tip 
Matsuo,11
7 2011 
RCT 80 Persistent 100 MIL ablation 
with standard 
sheath (+PVI, 
roof, CTI) 
MIL ablation with 
steerable sheath 
(+PVI, roof, CTI) 
Mikhaylo RCT 34 Longstan 100 PVI, roof, line, As control + septal 
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Author, 
Year 
Study 
type 
N AF Type % 
PeAF 
Control group Treatment group 
v,94 2010 ding PeAF MIL + CS line  
Mont89, 
2014 
RCT 146 Persistent 100 AAD CA 
Narayan,2
3 2012 
Cohort 92 Mixed 72 Conventional 
ablation 
FIRM ablation then 
Conventional 
Nilsson,11
8 2006 
RCT 100 Mixed 49 Segmental 
ostial PVI 
Circumferential 
extra-ostial PVI 
Oral,119 
2005 
RCT 80 Persistent 100 Circumferentia
l PV ablation 
Non-encircling 
linear ablation 
Oral,120 
2006 
RCT 146 Persistent 100 Amiodarone 
and DCCV 
Amiodarone and 
DCCV + PVI 
Oral,93 
2008 
RCT 66 Longstan
ding PeAF 
100 LA ablation + 
DCCV 
Control + RA CFAEs 
Oral,92 
2009 
RCT 100 Longstan
ding PeAF 
100 Antral ablation 
+ DCCV 
Antral ablation + 
CFAE to sinus (or 2 
hrs) 
Pak,121 
2011 
Cohort 200 Persistent 100 LA ant wall 
line (from 
mitral isthmus 
to roof line) 
MIL 
Piorkows
ki,122 
2011 
RCT 130 Mixed 36 Non-steerable 
sheath 
Steerable sheath 
Rajappan,
123 2009 
RCT 56 Mixed 50 Non-steerable 
sheath 
Steerable sheath 
Rivard,124 
2012 
Case 
control 
80 Persistent 100 Stepwise 
ablation 
Stepwise ablation 
having restored SR 
1 month before 
Sairaku,12
5 2012 
RCT 30 Persistent 100 WACA WACA with HFS 
Stabile,81 
2006 
RCT 137 Mixed 33 AAD AAD + CA 
Stabile,126 
2009 
Cluster 
Cohort 
97 Persistent 100 Segmental PV 
ablation 
Control + 
confirmation of PV 
disconnection 
Tambore
ro,127 
2009 
RCT 120 Mixed 40 WACA + MIL + 
roof line 
WACA + MIL + roof 
and floor (post. wall 
isolation) 
Tambore
ro,128 
2010 
RCT 146 Mixed 47 WACA with 
only ablation 
catheter 
WACA  with circular 
mapping 
Verma,129 Case 200 Mixed 40 PVAI PVAI + CFAE 
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Author, 
Year 
Study 
type 
N AF Type % 
PeAF 
Control group Treatment group 
2007 control 
Verma,130 
2010 
RCT 100 Mixed 36 PVI or CFAE PVI + CFAE (3 arm) 
Willems,1
31 2006 
RCT 62 Persistent 100 PVI PVI + substrate 
modification 
Yamane,1
32 2007 
Cohort 187 Mixed 36 Ostial 
segmental PVI 
Antral segmental 
PVI 
Yokokaw
a,133 2011 
Cohort 66 Mixed 42 Point by point 
Ablation 
Ablation by catheter 
dragging 
Table 1-1: Studies included in the review. AAD: Anti-arrhythmic Drug, CA: Catheter Ablation, CFAE: Complex 
Fractionated Atrial Electrograms, DCCV: Direct Current Cardioversion, HFS: High Frequency Stimulation, L/RA: 
Left/Right Atrium, MIL: Mitral Isthmus Line, PeAF: Persistent Atrial Fibrillation, PV: Pulmonary vein, PV(A)I: 
Pulmonary Vein (Antral) Isolation, RCT: Randomised Controlled Trial, SVCI: Superior Vena Cava Isolation, WACA: 
Wide Area Circumferential Ablation, 
1.3.2.3. STUDY QUALITY 
In keeping with previous work we assessed study quality using a modified version of 
published quality assessment criteria for case series, combined with guidance from the 
Cochrane Handbook.95,134,135 Standard measures of quality such as randomisation method 
and blinding were of limited relevance due to the inclusion of non-randomised trials, but 
were variably reported in the included RCTs. No studies adjusted for multiple hypothesis 
testing when reporting outcomes at sequential time points or results of both single and 
multiple procedures. Indicators of potential bias, such as loss to follow-up, were variably 
reported and explained. Only four RCTs achieved all of the required quality 
criteria.109,127,128,131 Ignoring randomisation and blinding, only two NRCTs were assessed 
positively for all remaining criteria.23,129 Overall, therefore, the quality of included studies 
was generally poor.
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Author, 
Year 
Study 
type 
Randomisation 
Method 
Blinding Eligibility 
criteria 
reported 
Study Pop 
representative 
of normal 
practice 
Method of 
follow-up 
properly 
defined 
Equal 
follow-up 
between 
groups 
Was loss to 
follow-up 
reported or 
explained 
Prospective 
recruitment 
Consecutive 
recruitment 
Arentz,96 
2007 
RCT Not stated None Yes Yes Yes Unclear No loss to 
follow-up 
Yes Yes 
Bansch,97 
2013 
RCT Not stated Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Calo,98 
2006 
RCT Not stated Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Corrado,99 
2010 
RCT Computer Not 
stated 
Yes Yes Yes Unclear Yes Yes Yes 
Della 
Bella,100 
2009 
RCT Computer Not 
stated 
Yes Yes Yes Unclear No loss to 
follow-up 
Yes Yes 
Di Biase,101 
2009 
Cohort N/A N/A Yes No Yes Unclear No loss to 
follow-up 
Yes Yes 
Di Biase,102 
2010 
Cohort N/A N/A Yes Yes Yes Unclear No loss to 
follow-up 
Unclear Yes 
Dixit,103 
2012 
RCT Not stated Not 
stated 
Yes Yes Yes Yes Yes Yes Yes 
Elayi,91 
2008 
RCT Computer Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Estner,104 
2008 
Cohort N/A N/A Yes Yes Yes Unclear No loss to 
follow-up 
Yes Yes 
Estner,105 
2011 
RCT Envelopes Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Fassini,106 
2005 
RCT Not stated Not 
stated 
Yes Yes Yes Unclear No Yes Yes 
Gaita,107 
2008 
RCT Not stated Single 
blinde
d 
Yes Yes Yes Yes Yes Yes Yes 
Gu,108 RCT Computer Not Yes Yes Yes Yes No loss to Yes Yes 
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Author, 
Year 
Study 
type 
Randomisation 
Method 
Blinding Eligibility 
criteria 
reported 
Study Pop 
representative 
of normal 
practice 
Method of 
follow-up 
properly 
defined 
Equal 
follow-up 
between 
groups 
Was loss to 
follow-up 
reported or 
explained 
Prospective 
recruitment 
Consecutive 
recruitment 
2012 stated follow-up 
Hummel, 
201490 
RCT Not stated None Yes Yes Yes Yes Yes Yes Yes 
Jones,109 
2013 
RCT Computer Blinde
d 
endpoi
nts 
Yes Yes Yes Yes Yes Yes Yes 
Kistler,110 
2006 
Cohort Not 
Applicable 
N/A Yes Yes Yes Yes No loss to 
follow-up 
No Yes 
Kumagai,11
1 2013 
RCT Not stated None Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Lim,112 
2012 
RCT Not stated Not 
stated 
Yes Yes Yes Unclear Yes Yes Yes 
Lin,113 
2009 
Cohort Not 
Applicable 
N/A Yes Yes Yes No No loss to 
follow-up 
Yes Yes 
MacDonal
d,114 2011 
RCT Computer Single Yes Yes Yes Unclear Yes Yes Yes 
Mansour,11
5 2004 
Cohort N/A N/A Yes No No No No Unclear Yes 
Matiello,11
6 2008 
Cohort N/A N/A Yes Yes Yes No No Unclear Yes 
Matsuo,117 
2011 
RCT Not stated Not 
stated 
Yes Yes Yes Yes No Yes Yes 
Mikhaylov,
94 2010 
RCT Not stated Single Yes Yes Yes Yes No Yes Yes 
Mont89, 
2014 
RCT Block 
randomisati
on list 
None Yes Yes Yes Yes Yes Yes No 
Narayan,23 Cohort N/A N/A Yes Yes Yes Yes Yes Yes Yes 
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Author, 
Year 
Study 
type 
Randomisation 
Method 
Blinding Eligibility 
criteria 
reported 
Study Pop 
representative 
of normal 
practice 
Method of 
follow-up 
properly 
defined 
Equal 
follow-up 
between 
groups 
Was loss to 
follow-up 
reported or 
explained 
Prospective 
recruitment 
Consecutive 
recruitment 
2012 
Nilsson,118 
2006 
RCT Admin clerk Not 
stated 
Yes Yes Yes Yes No Yes Yes 
Oral,119 
2005 
RCT Envelopes Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Unclear 
Oral,120 
2006 
RCT Computer Not 
stated 
Yes Yes Yes Yes No Yes Unclear 
Oral,93 
2008 
RCT Not stated Not 
stated 
No Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Oral,92 
2009 
RCT Not stated Not 
stated 
Yes Yes Yes Unclear No Yes Yes 
Pak,121 
2011 
Cohort N/A N/A Yes Yes Yes Yes No Yes Yes 
Piorkowsk
i,122 2011 
RCT Computer Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Unclear 
Rajappan,1
23 2009 
RCT Envelopes Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Unclear Unclear 
Rivard,124 
2012 
Case 
control 
N/A N/A Yes Yes Yes Yes Yes No Yes 
Sairaku,125 
2012 
RCT Envelopes None Yes Yes Yes Unclear No Yes Yes 
Stabile,81 
2006 
RCT Computer None Yes Yes Yes Yes Yes Yes Yes 
Stabile,126 
2009 
Cohort N/A N/A No Yes Yes Yes No Yes Yes 
Tamborer
o,127 2009 
RCT Computer Double Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Tamborer
o,128 2010 
RCT Computer Single Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
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Author, 
Year 
Study 
type 
Randomisation 
Method 
Blinding Eligibility 
criteria 
reported 
Study Pop 
representative 
of normal 
practice 
Method of 
follow-up 
properly 
defined 
Equal 
follow-up 
between 
groups 
Was loss to 
follow-up 
reported or 
explained 
Prospective 
recruitment 
Consecutive 
recruitment 
Verma,129 
2007 
Case 
control 
N/A N/A Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Verma,130 
2010 
RCT Envelopes Single Yes Yes Yes Yes No loss to 
follow-up 
Yes Unclear 
Willems,13
1 2006 
RCT Computer Not 
stated 
Yes Yes Yes Yes No loss to 
follow-up 
Yes Yes 
Yamane,132 
2007 
Cohort N/A N/A Yes Yes Yes No No loss to 
follow-up 
Yes Yes 
Yokokawa,
133 2011 
Cohort N/A N/A Yes Yes Yes Yes No Yes Yes 
Table 1-2: Assessment of study quality. RCT: Randomised Controlled Trial
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1.3.2.4. DEFINITIONS OF SUCCESS 
For all studies, except for the two specifically assessing CA against medical therapy in 
patients with heart failure, the outcome measure used was recurrence of atrial 
fibrillation or other atrial tachyarrhythmia. The most frequent definition used was 
documented atrial arrhythmia lasting >30 seconds (22 studies). Other definitions used 
were arrhythmia lasting 3 seconds (one study), 32 seconds (one study), 60 seconds 
(four studies), 10 minutes (two studies) and 24 hours (one study). One study stated 
symptom-free status off anti-arrhythmic drugs and sinus rhythm on ECG. Fourteen 
studies didn’t state how they defined recurrence. Rhythm monitoring was performed 
using ambulatory ECG devices in 35 studies, trans-telephonic monitoring or daily ECGs 
in four and resting ECG in four. One study used implanted loop recorders. The means of 
monitoring heart rhythm was not clear in two studies. The two heart failure studies 
used left ventricular ejection fraction as a measure of success. In one it was the study’s 
primary endpoint and for the other it was a secondary endpoint with peak VO2 as the 
primary endpoint. Of all 45 eligible studies, only four reported the effect of the 
investigational technique on patients’ quality of life. 
1.3.2.5. COMPLICATIONS  
Four studies did not report procedural complication rates. Of the remaining 42 studies, 
four reported no complications although often failed to define what they considered a 
complication. Of those reporting complications, the definitions used were frequently 
unclear and varied greatly between studies. Overall, the median reported complication 
rate was 3% (range 0-15%). None of the studies with mixed populations provided a 
breakdown of complications by AF type. Of the total population (6085) there were 20 
reported arterial thromboembolic events and four deaths. 
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1.3.2.6. ANALYSIS 1: EFFICACY OF CATHETER ABLATION COMPARED TO MEDICAL THERAPY 
Four studies tested the efficacy of ablation against medical therapy in a general patient 
population.81,120 Oral et al. showed a borderline significant improvement in freedom 
from atrial fibrillation or flutter without the need for anti-arrhythmic drugs (AAD) (74% 
vs. 58%, p=0.05) after 12 months.120  The medical management strategy employed oral 
therapy with amiodarone for three months combined with either one or two electrical 
cardioversions. The authors stated the control group was designed to control for 
confounding variables rather than as a true comparison of CA and medical therapy.  In 
the CACAF study, Stabile achieved sinus rhythm with CA in 50% of the sub-group with 
PeAF but in none of those treated with AAD.81 Two recently published RCTs compared 
catheter ablation, each using a different technique, to AAD therapy in patients with 
PeAF.  The primary endpoint for Mont was 24 hours of AF which was significantly less 
common with CA than with AAD  (30% v 66%, p=0.002) as was a secondary endpoint of 
30 seconds of AF (40% v 70%, p<0.001).89 Similar results were  found in a second study, 
this time using phased RF ablation  (TTOP AF), that showed that a significantly higher 
proportion of patients undergoing CA achieved a >90% reduction in atrial 
tachyarrhythmia episodes at 6 months compared to treatment with Class I or III AAD 
(56% vs. 26%, p<0.001).90 Heterogeneity was low to moderate (32%). Overall, CA 
significantly reduced the risk of recurrent AF compared to medical therapy (OR 0.32, 
95%CI 0.20-0.53, p<0.001 (Figure 1-3)). 
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Figure 1-3: Forest plot showing ORs and 95%CIs for studies comparing catheter ablation with medical 
therapy 
1.3.2.6.1. PATIENTS WITH HEART FAILURE 
Two studies have assessed the efficacy of CA in patients with heart failure (MacDonald 
2011 and Jones 2013).109,114 Both studies defined heart failure as New York Heart 
Association Class II-IV symptoms with a left ventricular ejection fraction (LVEF) <35%. 
In both studies the medical therapy arm was treated according to a rate-control 
strategy, rather than with anti-arrhythmic drugs. Primary endpoints for these studies 
therefore assessed functional parameters such as change in LVEF and change in peak 
VO2 on cardiopulmonary exercise testing. Neither study assessed efficacy in terms of 
maintaining sinus rhythm. MacDonald studied 41 patients and found a non-significantly 
greater improvement in LVEF when measured by cardiac magnetic resonance (CMR) 
imaging (+4.6±11.1% with CA vs. +2.9±6.7%, p=0.06) but a more significant difference 
when measured by radionuclide ventriculography (+8.3±12.0% with CA vs. +1.4±5.9%, 
p=0.03). Of note, sinus rhythm was successfully maintained in only 50% of patients.114  
A post hoc analysis showed the improvement in LVEF was significantly greater for those 
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who remained in sinus rhythm by both CMR and radionuclide ventriculography 
(+10.5±10.4% vs. +1.6±7.7%, p=0.008 and +13.3±15.0% vs. +2.2±5.6%, p=0.045, 
respectively). Jones et al randomised 58 patients to either CA or pharmacological rate-
control. A greater proportion (88%) achieved sinus rhythm with CA by the end of the 
study (after a mean of 1.2 procedures, single procedure success rate 68%).109 
Nonetheless, the difference in LVEF improvement after 12 months, again measured by 
radionuclide ventriculography, was also non-significant between treatment arms 
(+10.9±11.5% with CA vs. +5.4±8.5%, p=0.06).  However, the primary endpoint of the 
study was change in peak VO2 after 12 months which showed a significantly greater 
improvement with CA than with rate-control therapy (mean difference between groups 
+3.07 ml/kg/min (95%CI 0.56-5.59), p=0.018).  
1.3.2.7. ANALYSIS 2: EFFECT ON EFFICACY OF ENCIRCLING ABLATION OF THE PVS 
Three studies provided data to assess the effect of ablation lesions that encircled the 
PVs.104,119,130 Oral tested encircling PV ablation against left atrial linear lesions (non-
encircling left atrial ablation).119 This study found the two strategies were equally 
efficacious (prevalence of AF after 9 months 28% vs. 25%, p=0.8). Two studies included 
an analysis of CFAE ablation with and without PVI.104,130 Both found the addition of PVI 
improved procedural success rates. Heterogeneity between studies was only moderate 
(I2=42%). Overall, adding ablation lesions that encircled the PVs significantly reduced 
recurrence rates (OR 0.26, 95%CI 0.09-0.74, p=0.01 (Figure 1-4)).  
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Figure 1-4: Forest plot showing ORs and 95%CIs for studies comparing encircling lesions of the pulmonary 
veins with other techniques in which the veins were not encircled 
1.3.2.8. IMPORTANCE OF ELECTRICAL ISOLATION 
Two studies looked specifically at the effect of electrical isolation of the PVs. Stabile 
performed a cluster-cohort study in patients treated at one of three centres, one of 
which (36 patients) performed an anatomical ablation with a procedural endpoint of 
loss of local electrograms. The other two centres (n=61) used a circular mapping 
catheter to assess electrical isolation of the PVs from the left atrium. After 15 months 
they found no difference in the rate of AF recurrence between the two groups (58% vs. 
56%, p=0.9).126 A subsequent randomised study allocated patients to a procedure in 
which a single catheter was used to both map and ablate (again using local electrogram 
attenuation as the acute endpoint) or to the additional use of a circular mapping 
catheter to assess isolation. The latter strategy was associated with a significantly lower 
rate of AF recurrence (29% vs. 55%, p=0.02).128 The reason for the discordance 
between these studies is not clear, but the design of the study by Stabile may have 
introduced considerable bias dependent on the skill and experience of the operators in 
the different centres. Two of the studies in the previous analysis also confirmed 
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electrical isolation of the PVs.104,130 Looking at these four studies together, in which one 
arm had confirmed electrical isolation and the other either had solely anatomical or no 
encircling PV ablation, electrical isolation of the PVs produced significantly lower 
recurrence rates (OR 0.33, 95%CI 0.13-0.86, p=0.02 (Figure 1-5)). Heterogeneity was 
moderately high (59%). Removal of the study by Stabile would have eliminated 
heterogeneity but not affected the direction or significance of the pooled analysis and 
therefore was included in the analysis. 
 
Figure 1-5: Forest plot showing ORs and 95%CIs for studies comparing electrical isolation of the pulmonary 
veins with techniques in which isolation was not a procedural goal or endpoint 
1.3.2.9. ANALYSIS 3: EFFICACY OF CIRCUMFERENTIAL VERSES SEGMENTAL PVI 
Originally, PVI was performed by isolating each vein individually (segmentally), usually 
at the level of the vein ostia. Subsequently a technique by which ipsilateral veins are 
isolated together in two pairs using a wide ring of ablation lesions performed in the PV 
antra (wide area circumferential ablation, WACA) has been used.  Three studies have 
assessed WACA against segmental ostial PVI techniques.96,115,118  One study was non-
randomised and this was the only study which permitted the use of anti-arrhythmic 
drugs. This study by Mansour followed-up patients who underwent segmental PVI for 
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considerably longer than patients treated with circumferential ablation (21 vs. 11 
months).115 There was no heterogeneity between studies. Considered together, these 
studies showed a non-significant trend towards improved outcomes with WACA (OR 
0.41, 95%CI 0.15-1.10, p=0.08 (Figure 1-6)). Only a single study (Nilsson) reported 
outcomes from multiple procedures.118 This study reported better outcomes with 
WACA from both a single and multiple procedures, although the difference was only 
significant for the latter (OR 0.16, 95%CI 0.04-0.63, p<0.01). 
 
Figure 1- 6: Forest plot showing ORs and 95%CIs for studies comparing circumferential pulmonary vein 
isolation with a segmental technique 
One further study (Elayi 2008) was considered but was not included as all three 
treatment arms involved a form of wide area antral PV isolation (typical circumferential 
PVI in one arm and a novel lesion set named PV antral isolation in the other two).91 Its 
inclusion would have created considerable heterogeneity ((I2=77.5) and a marked shift 
in the funnel plot. Sensitivity analysis showed that its inclusion would not have altered 
the overall significance (OR 0.80, 95%CI 0.14-4.51, p=0.80).   The study contained three 
arms and the main finding was the additional effect of CFAE ablation over PV antral 
ablation and so was included in Outcome 5. 
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1.3.2.9.1. OTHER PVI TECHNIQUES 
A single non-randomised study of patients with paroxysmal or PeAF assessed whether 
antral or ostial ablation was better for segmental PVI. After a mean of 1.4 procedures, 
AF recurrence in  patients with PeAF was less common with antral ablation (22% vs. 
52%, p=0.03), although follow-up in that group was also markedly shorter (647±197 vs. 
1,015±257 days) making the results difficult to interpret.132   
1.3.2.10. ANALYSIS 4: EFFICACY OF LINEAR ABLATION LESIONS  
Three eligible studies looked at the impact of adding additional linear ablation to 
PVI.106,107,131 One study tested the effect of an ablation line between the mitral annulus 
and left inferior PV (“mitral line”).106 Two studies tested a combination of a mitral line 
and a left atrial roof line connecting contralateral superior PVs.107,131 One further study, 
containing patients with both paroxysmal and PeAF, had a 2x2 factorial design including 
a comparison with and without mitral isthmus ablation.112 However, the study authors 
did not provide results split by AF type for this comparison, although they did for the 
other (included in the analysis of more or less extensive ablation, below). Heterogeneity 
was acceptable (moderate) between eligible studies (I2=36%). Pooled single procedure 
success rates were significantly higher in patients receiving additional linear ablation 
(OR 0.22, 95%CI 0.10-0.49, p<0.001 (Figure 1- 7)). Only the study by Gaita reported 
multiple procedure success rates and the outcomes were again significantly better in 
the linear ablation group (OR 0.22 95%CI 0.08-0.64, p=0.005).24 
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Figure 1-7: Forest plot showing ORs and 95%CIs for studies comparing ablation strategies using linear 
ablation lesions against strategies of pulmonary vein isolation without linear ablation 
1.3.2.10.1. MORE OR LESS EXTENSIVE LINEAR ABLATION 
Three studies looked at the effect of fewer or extensive linear lesions, in addition to PVI. 
Mikhaylov added a septal line and Tamborero added a left atrial floor line, both to left 
atrial roof and mitral lines.94,127 Lim added box isolation of the posterior wall to a mitral 
line.112   Despite the slight differences in lesions deployed and the fact that Mikhaylov 
enrolled patients only with longstanding PeAF, there was no statistical heterogeneity 
between studies and no evidence of publication bias from visual analysis of the funnel 
plot. Overall there was no benefit seen from more extensive linear ablation (OR 0.77, 
95%CI 0.41-1.43, p=0.40 (Figure 1-8)).  
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Figure 1-8: Forest plot showing ORs and 95%CIs for studies in which a comparison was made between one 
strategy using less extensive linear ablation against a strategy of more extensive lesions 
Pak studied outcomes for a group with a mitral line against a group who had a more 
extensive anterior wall line.121 Because the number of linear lesions in both groups was 
the same, although one was longer than the other, it was not included in the previous 
analysis. This showed a significantly higher success rate with a line across the anterior 
wall of the left atrium compared to a standard lateral mitral line. Of note, bidirectional 
conduction block across the anterior wall line was significantly more common than for 
the mitral line (69% vs. 32%, p<0.001). It may have been this, rather than the line itself, 
that accounted for the difference between study arms, as failure to achieve bidirectional 
block across an ablation line increases the risk of iatrogenic macro re-entrant left atrial 
tachycardia. The authors did not undertake a regression analysis to look at this 
possibility. 
1.3.2.11. ANALYSIS 5: EFFICACY OF COMPLEX FRACTIONATED ATRIAL ELECTROGRAM (CFAE) 
ABLATION 
Seven studies looked at the effect of additional CFAE ablation.91-93,103,113,129,130 There was 
substantial heterogeneity between studies when looking at single procedure success 
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rates (I2=61%) mainly due to the inclusion of the most recent RCT (the RASTA study) by 
Dixit103 However, heterogeneity was low when looking at AF recurrence after multiple 
procedures, even with the RASTA study included, and the study was within the expected 
funnel plot. In addition, we did not consider there to be any valid clinical reason for 
exclusion. Four studies showed no benefit of CFAE ablation, including one by Oral 
(2008) in which right atrial CFAE ablation was added, in a randomised manner, to a 
cohort who remained in AF after left atrial ablation including left atrial CFAEs.93 
Although slightly different in this regard to the other studies in this analysis, the clinical 
effect being measured in each is that of adding CFAE ablation. Exclusion of this study 
would have actually increased heterogeneity (I2=68% from 61%) and sensitivity 
analysis showed no effect on the significance of the pooled analysis. We therefore 
included both the RASTA study and the study by Oral in our analysis. Two studies 
showed a statistically significant benefit and one, the RASTA study discussed above, 
showed worse outcomes with CFAE ablation. One study, by Lin, reported results both on 
and off anti-arrhythmic drugs but this had only a negligible effect on the overall study 
findings.113 We therefore used the results off drugs for the analysis as all the other 
eligible studies required the patients to be off medication. The study found in favour of 
CFAE ablation but with shorter follow-up in that group. The study by Elayi had three 
arms (CPVI, PVAI, and PVAI+CFAE). For this analysis we compared the latter two (PVAI 
vs. PVAI + CFAE) due to the consistent form of PVI used in both arms. Overall, CFAE 
ablation showed no additional benefit over other ablation techniques after a single 
procedure (OR 0.64, 95%CI 0.35-1.18, p=0.15) or multiple procedures (OR 0.67, 95%CI 
0.42-1.08, p=0.10 (Figure 1-9)).  
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Figure 1- 9: Forest plot showing ORs and 95%CIs for studies reporting the effect of adding complex 
fractionated atrial electrogram ablation to other techniques 
Three of the included studies in this analysis enrolled only patients with longstanding 
PeAF.91-93 Sensitivity analysis showed that results for these studies in isolation did not 
differ from the overall result (OR 0.64, 95%CI 0.38-1.07, p=0.09) and removal of the 
studies would not have altered the direction or significance level of the overall pooled 
result (OR 0.57, 95%CI 0.18-1.88, p=0.36).  
 
1.3.2.11.1. COMPARISON OF CFAE ABLATION AND LINEAR LESIONS 
Only a single study has compared CFAE ablation against linear lesions. Estner 
randomised 116 patients to one or other treatment in addition to PVI. The proportion of 
patients in each group with a recurrence of AF during 12 months’ follow-up without 
antiarrhythmic drugs was the same in both groups (39% vs. 37%, p=0.88).105 
  
  Page 62 of 266 
1.3.2.12. ANALYSIS 6: EFFICACY OF OTHER PERI-ABLATION MANAGEMENT AND STRATEGIES   
1.3.2.12.1. PERI-ABLATION MANAGEMENT  
Two studies looked at aspects surrounding the CA procedure, not directly related to the 
actual ablation itself. Gu randomised 123 patients with PeAF to either a single AAD or a 
combination of Propafenone and amiodarone for 2 months post-CA but showed no 
significant difference in AF recurrence over 1 year (36% vs. 33.9%, p=0.78).108 Rivard 
looked at the effect of restoring sinus rhythm prior to ablation in 40 patients against 40 
case-matched controls, all with PeAF. They found this strategy decreased the extent of 
ablation performed but did not alter either single (55% vs. 45%, p=0.28) or multiple 
procedure (90% vs. 70%, p=0.28) success rates.124 
1.3.2.12.2. LEFT ATRIAL OR BI-ATRIAL ABLATION 
Three randomised studies looked at the effect of adding right atrial ablation in addition 
to left atrial ablation and reported conflicting results. Corrado tested the addition of 
superior vena cava isolation (n=73) to PVI alone (n=87) and found no difference in 
recurrence rates (27% vs. 29%, p=0.9).99 Calo used a more extensive lesion set and 
found a 39% (n=41) recurrence rate in a group treated with PVI plus cavotricuspid and 
mitral isthmus ablation compared to 15% (n=39) when intercaval posterior line, 
intercaval septal line, and electrical disconnection of the superior vena cava was also 
performed (p=0.02).98 Notably, completeness of these linear lesions, rather than block 
across them, was determined as the lesion endpoint, which may have adversely affected 
outcomes. Oral evaluated the addition of right atrial CFAEs (or nothing) to patients still 
in AF after left atrial ablation that included left atrial CFAEs. They found no difference in 
the proportion of patients remaining free from recurrent AF after a single (30% vs. 
24%, p=0.8) or multiple procedures (58% vs. 52%, p=0.6) over 17 months’ follow-up.93 
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Combining the three studies showed no significant benefit of performing bi-atrial, 
rather than isolated left atrial ablation (OR 0.62, 95%CI 0.31-1.24, p=0.17 (Figure 1-
10)). Heterogeneity was only moderate (I2=40%). 
 
Figure 1-10: Forest plot showing ORs and 95%CIs for studies comparing a left atrial ablation strategy against 
a strategy using bi-atrial ablation 
1.3.2.12.3. MAPPING TECHNIQUES  
A recent non-randomised study looked at the effect of adding a newly developed 
mapping and ablation technique, Focal Impulse and Rotor Modulation (FIRM), to a 
conventional WACA.23 Of 107 procedures performed in the complete study, 76 had 
PeAF, although three were lost to follow-up. Of those remaining, the addition of FIRM 
significantly increased the proportion of patients free of AF after a mean follow-up of 9 
months (82% vs. 38%, p<0.001). 
 
Two studies looked at the effect of integrating computed tomography imaging data into 
an electroanatomical mapping system (CartoMerge, Biosense Webster, Diamond Bar, 
California, USA). One RCT with 83 patients with PeAF (from a total cohort of 290) 
showed that an ablation guided by image-integration was more effective at maintaining 
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sinus rhythm than  an ablation guided by conventional fluoroscopy  (75% vs. 52%, 
p<0.01).100 A second non-randomised study found a similar magnitude of  improvement 
but, with only 48 patients with PeAF, appears to have been underpowered for the 
difference to reach statistical significance (62% vs. 42%, p=0.2).110 A single quasi-
randomised cohort study assessed freedom from AF off AAD or with previously 
ineffective AAD after either ablation using the Hansen Robotic Medical System or 
conventional manual ablation. One hundred and twenty seven patients out of 390 
studied had PeAF and statistically similar rates were found with both treatment 
strategies (76% vs. 72%, p=0.64).101  
 
1.3.2.12.4. STEERABLE VS NON-STEERABLE SHEATH 
Three randomised studies looked at the effect of using a steerable sheath. As each study 
assessed the effect on a different and non-comparable lesion set (PVI alone, PVI with 
extensive linear lesions and mitral isthmus line alone), a meta-analysis was not 
performed. Matsuo  achieved bidirectional conduction block across the mitral isthmus 
line more often with a steerable sheath (98% vs. 78%, p=0.02) but, interestingly, this 
did not affect freedom from recurrent AF (53% vs. 43%, p=0.41).117 A standardised 
additional left atrial ablation protocol, including segmental PVI, was performed in both 
groups.  A second study, in which patients underwent extensive left atrial ablation, 
contained 44 patients with PeAF from a total sample size of 130. Although freedom 
from atrial tachyarrhythmias during 6 months’ follow-up of a single procedure was 
significantly higher with the use of a steerable sheath in the group as a whole, the 
difference failed to reach statistical significance in patients with PeAF (67% vs. 39%, 
p=0.07).122 It is likely that a large type II error was present due to the small number of 
patients with PeAF. Although this was also true of the third study by Rajappan, there 
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was no trend seen when the lesion set was PVI alone (with additional CFAE ablation if 
required); with success rates after 6 months of 40% (4/10) with a non-steerable and 
41% (7/17) with a steerable sheath.123  
 
1.3.2.12.4. OTHER STRATEGIES 
One study looked at the difference between isolating the veins by making a series of 
spot ablations (point-by-point) and continuously dragging the ablation catheter along 
the ablation lines. Although usually considered of limited clinical importance, the 
primary endpoint was recurrence of AF within the first 3 months post-ablation.  A high 
proportion of patients had an early recurrence and although the recurrence rate for the 
group overall was lower for continuous dragging, the difference was not significant for 
the subgroup of patients with PeAF (58% (n=12) vs. 81% (n=16), p=0.2).133 By 12 
months, the difference seen in the overall cohort was no longer significant but 12 month 
data by AF type was not provided.  
 
One non-randomised study looked at the effect of catheter design and RF power on 
clinical outcomes. In a mixed cohort they found that, compared to a catheter with an 
8mm non-irrigated ablation tip (Group 1, 55W 50°C), arrhythmia-free survival after 12 
months was lower with a cooled 4mm tip at low power (Group 2, 30W 45°C) but not for 
a cooled 4mm tip at high power (Group 3, 40W 45°C). The authors communicated that a 
similar trend was seen for patients with PeAF between the first two groups (72% vs. 
25%, p<0.01) despite a longer follow-up time for the first group that would normally be 
expected to be associated with lower success rates (20±10 vs. 14±6 months). 
Unfortunately the authors did not provide data for the subgroup of patients with PeAF 
in Group 3.116 
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One small RCT (30 patients) found no significant difference in medium term (15 
months) freedom from recurrent AF with the use of high-frequency stimulation of the 
atria in addition to WACA (33% vs. 27%, p=0.73).125  
 
A waiting period at the end of the procedure before checking for persisting isolation is 
generally recommended after PVI but this was questioned by a study that randomised 
patients to a wait of an hour after vein isolation versus immediate check and 
termination of the procedure. In 47 patients with PeAF out of a total of 107 they found 
no difference in the clinical success rates over 10 months between the two groups (52% 
vs. 55%, p=0.77) which mirrored the result of the larger, mixed cohort.13 
One further study randomised 100 patients still in AF after PVI and left atrial linear 
ablation to receive either an intravenous does of the antiarrhythmic drug nifekalant or 
nothing before CFAE ablation. They found nifekalant shortened the procedure and 
reduced the amount of ablation performed without affecting success rates over 12 
months after a single procedure (74% vs. 76%, p=0.82).111  
 
Finally, in 217 patients with PeAF from a cohort of 266 undergoing a repeat CA with 
frequent premature atrial contractions or an atrial tachyarrhythmia originating from 
the left atrial appendage (LAA), electrically isolating the LAA in addition to a standard 
ablation procedure appeared to produce considerably greater freedom from AF (83%) 
in the 12 months following ablation than either performing focal LAA ablation (15%) or 
not performing any LAA ablation (6.5%) (P<0.001).102  
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1.3.3.  DISCUSSION  
Each of the analysis areas has produced results worthy of further discussion. Most 
importantly, in a general population of patients with PeAF, our analysis has shown a 
clear benefit in terms of freedom from recurrent AF with CA when compared to medical 
therapy. However, for patients with heart failure the picture is less clear. Unlike all 
other studies in this review, neither heart failure study assessed freedom from 
recurrent AF as an endpoint as both used rate-control in their medical therapy group. 
Whilst peak VO2 is improved with CA compared to rate control medication, the effect on 
LVEF is uncertain and may depend on the ability to maintain sinus rhythm and/or the 
imaging modality used.  
 
In terms of ablation technique, PVI has long been considered the cornerstone of AF 
ablation and our analysis confirms that encircling and electrically isolating the PVs both 
appear to improve procedural success rates. WACA showed a non-significant trend 
toward better results than segmental PVI but further study is needed to clarify this. The 
addition of linear ablation lesions within the left atrium significantly reduces the risk of 
AF recurrence, although there appears to be a limit to the extent of linear ablation that 
provides incremental improvement. The lack of benefit for more extensive linear lesion 
sets may be due to the cumulative risk of deploying an incomplete linear lesion, 
potentially creating a zone of slow conduction and pivot point which then allows macro-
reentrant atrial tachycardia to occur. It is worth noting that two of the three studies 
testing more extensive lesion sets added non-anchored lesions. Lines, such as LA roof or 
mitral isthmus lines, that are deployed between two sites of anatomical or functional 
block can be tested and confirmed as having bidirectional block across them. In 
contrast, non-anchored lines (such as septal or inferior left atrial lines) cannot be tested 
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for continuity in the same way and bidirectional conduction block is not relevant in this 
situation. Counter intuitively, Matsuo found that higher rates of mitral line block 
achieved with a steerable sheath did not translate into better clinical results.117 In our 
opinion, the optimum left atrial linear lesion set is not clear from this analysis. Adding 
linear ablation within the right atrium produces variable results.  
 
From our analysis of Analysis 5, CFAE ablation does not appear to significantly improve 
procedural success rates when added to other ablation strategies and is inadequate as a 
solo strategy.  An important problem to consider when comparing CFAE studies is the 
variability in how CFAE ablation was performed. Although there was a degree of 
similarity between how the included studies defined CFAEs there was not complete 
uniformity and mapping techniques also varied. Crucially the definition of successful 
CFAE ablation was not described in three studies and different in each of the remaining 
four. Before publication of the most recently published study (Dixit 2012),103 the pooled 
odds would have favoured CFAE ablation as an adjunctive strategy (OR 0.52, 95%CI 
0.35-0.79). It is possible that the end point used for CFAE ablation (CFAE abolishment 
using a power of ≥20 W for at least 20 seconds with a concomitant 5- to 10- Ω decrease 
in impedance) in the RASTA study was less robust than that used in other trials. In 
addition, the lack of significant difference in a study comparing CFAE ablation to linear 
lesions suggests it may be an effective strategy in some patients. For Analysis 6 the 
included studies were highly variable and it was only possible to produce a single 
pooled analysis showing that bi-atrial ablation appeared to offer no benefit over sole left 
atrial ablation. In addition, there is a weak message that steerable sheaths may produce 
better outcomes for linear ablation but not for PVI. The role of rotor ablation and the 
FIRM technique is attracting considerable interest but so far has only been 
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demonstrated in a single non-randomised study. Should the results of the CONFIRM 
trial be replicated in other studies this will add considerably to the debate as to what 
ablation in addition, or possibly even instead of, PVI should be performed for patients 
with PeAF. One final point of note is that for none of the outcomes of interest did it make 
any statistical difference whether clinical results were analysed after a single or 
multiple procedure(s). 
1.3.3.2. COMPARISON TO OTHER META ANALYSES 
We are aware of few other studies that have looked at the efficacy of CA and CA 
techniques in patients with PeAF. As mentioned earlier, the Cochrane review found few 
eligible studies and by failing to either treat chronic and PeAF uniformly or to extract 
results for the sub-group of patients with PeAF from mixed trials (apart from in one 
case where the results were explicitly presented in that format) they were unable to 
reach a conclusion either about overall efficacy or which ablation strategy may be most 
effective.136 Parkash attempted to perform a more comprehensive analysis than the 
Cochrane review though they too limited themselves to RCTs.137 Predominantly because 
of this, their study covered fewer areas of analysis than ours. Where we and they 
analysed similar questions, the two reviews agreed on the comparison between CA and 
medical therapy and the effect of linear ablation lesions. However the results were 
different in other areas. In part this is because a number of recent studies were not 
included in their analysis as they have only been published subsequently. Additionally, 
some of their analyses appear to have inadvertently mixed patients with paroxysmal 
and PeAF and these and other discrepancies explain much of the difference in our 
findings. Like us, Piccini showed a considerably higher rate of freedom from AF after CA 
compared to a non-ablation strategy but combined 6 studies with both paroxysmal and 
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PeAF. Of note, removal of the single study containing only patients with PeAF increased 
the odds ratio dramatically (9.74 to 15.78).138 The same group also looked at the effect 
of CFAE ablation, which they found improved single procedure success (OR 2.0, 95%CI 
1.04-3.8, p=0.04) but again this was in a mixed AF population and they found no 
evidence in patients with PeAF and no treatment effect in long-standing PeAF (OR 2.1, 
95%CI 0.42-10.3).139 One meta-analysis found favourably for CA in heart failure but also 
combined paroxysmal and PeAF.140 Therefore, this study adds considerably to the 
evidence base available to clinicians and health policymakers.  
1.3.3.3 . LIMITATIONS 
Although we have managed to assess several areas of potential interest, most analyses 
contained few studies, most studies were relatively small and study quality was 
variable. As previously stated very few studies met all of our quality criteria. Universal 
standards have been published for the reporting AF ablation trials, including minimum 
follow-up period, but these are rarely strictly adhered to.14 Until this becomes the norm 
uncertainty will remain as to how to best interpret study results. Results will have been 
influenced by the variable definitions of success and length of follow-up. By including 
both RCTs and NRCTs, we increased the available evidence for analysis. However, the 
meta-analysis technique was originally intended for use with RCT data and, whilst 
inclusion of observational data is now well accepted, additional bias may be introduced. 
Whilst we followed published guidance for performing such analysis, there is more 
chance of potential confounding in observational studies which is not necessarily 
detectable.86 However, we were mindful of this and a sensitivity analysis (Table 1-3) 
showed that the strategy we employed (including RCTs and NRCTs) increased power 
without introducing significant bias.  Finally, we deliberately pooled both persistent and 
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longstanding PeAF. It is conceivable that treating these as separate entities may have 
produced different results in some analyses, however few studies made this distinction 
when presenting their findings.   
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Analysis RCTs/ 
NRCTs 
Main 
analysis 
RCTs only Comment 
1 4/0 OR 0.32, 95% 
CI 0.20-0.53 
N/A N/A 
2.1 3/0 OR 0.26, 95% 
CI 0.09-0.74 
N/A N/A 
2.2 2/2 OR 0.33, 95% 
CI 0.13-0.86 
OR 0.27, 95% 
CI 0.11-0.64 
Inclusion of two NRCTs increased 
the sample size and resulting 
power of the meta-analysis but had 
very little effect on the overall 
effect size* 
3 2/1 OR 0.41, 95% 
CI 0.15-1.10 
OR 0.34, 95% 
CI 0.11-1.05 
Inclusion of one NRCTs increased 
the sample size and resulting 
power of the meta-analysis but had 
very little effect on the overall 
effect size* 
4 3/0 OR 0.22, 95% 
CI 0.10-0.49 
N/A N/A 
4 3/0 OR 0.77, 95% 
CI 0.41-1.43 
N/A N/A 
5 5/2 OR 0.64, 95% 
CI 0.35-1.18 
OR 0.76, 95% 
CI 0.35-1.63  
As there were 5 RCTs analysis 
could have been performed 
without NRCTs. However, inclusion 
of two NRCTs increased the sample 
size and resulting power of the 
meta-analysis but did not affect the 
effect size 
6 3/3 OR 0.62, 95% 
CI 0.31-1.24 
N/A N/A 
Table 1-3: Sensitivity analysis examining the effect of inclusion of non-randomised trials in meta-analyses 
*My pre-specified criteria required at least 3 studies for meta-analysis to be performed so quantitative 
analysis would not have been performed using RCTs 
1.3.3.4. CLINICAL IMPLICATIONS 
Despite the current restrictions on funding and regulatory approval, for patients with 
PeAF, catheter ablation significantly reduces AF recurrence when compared with 
medical therapy. For those undergoing ablation, the pulmonary veins should be 
encircled by ablation lesions and electrical isolation confirmed. Additional limited linear 
ablation is likely to improve procedural success. Ablation of CFAEs may be of benefit in 
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some patients but the overall impact is unclear.  Very extensive ablation strategies and 
those involving right atrial ablation appear to offer little, if any, additional benefit. In our 
analyses, where data were available we found the relative benefits seen held true both 
after a single or multiple procedure(s). Future research should be in sufficiently large 
studies to minimise risk of type II error and should seek to distinguish patients with 
persistent from longstanding PeAF as duration of AF has an important bearing on 
success rates with ablation.14 If researchers do decide to recruit mixed populations they 
should also report results stratified by AF duration. This would provide greater clarity 
when attempting to apply study findings to routine clinical practice. The international 
AF expert consensus document, published in 2012, provides clear standards for 
reporting outcomes in clinical trials.14 It is important that investigators strive to adhere 
to these standards in future studies to improve the quality of available evidence. We 
found a surprising dearth of procedural safety and complication data in the published 
studies, and these should be given greater prominence as endpoints in future studies. As 
CA is primarily indicated to improve symptoms of AF it is essential that future studies 
measure and report the effect of interventions on patients’ quality of life, something that 
occurred very rarely in studies included in this review. 
1.3.4. CONCLUSIONS  
For patients with PeAF, CA achieves significantly greater freedom from recurrent AF 
than medical therapy. The most efficacious ablation strategy is likely to be one 
combining isolation of the PVs with a limited number of additional linear lesions within 
the left atrium. Neither biatrial ablation nor CFAE ablation appear to provide any 
additional advantage. However, the ideal lesion set remains unclear and may not be the 
same for all patients.   
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2 .  I M P R O V I N G  P A T I E N T  O U T C O M E S  B Y  
B E T T E R  U N D E R S T A N D I N G  C U R R E N T  
P R A C T I C E :   
R E A L  L I F E  L O N G  T E R M  O U T C O M E S  A F T E R  
P E R S I S T E N T  A F  A B L A T I O N ;  S I X  Y E A R  D A T A  
F R O M  A  H I G H  V O L U M E  U K  C E N T R E  
2.1. BACKGROUND  
Although, as we have seen, recent randomised controlled trials have shown superior 
efficacy of CA compared to medical therapy for patients with PeAF the follow-up for 
these trials is short.89,141 In Chapter One, my systematic review of randomised and non-
randomised controlled trials of CA in PeAF found the mean follow-up was only 13.5±6 
months.142 One issue for both forms of the disease is that early CA success does not 
always translate into long-term freedom from AF.143 Whilst short-term success is 
obviously vital, if this is not maintained longer term than the benefit to the patient is 
blunted. If we are seeking optimum outcomes for our patients then early improvements 
must be maintained long term. Whilst some long term data exist for ablation of PAF, late 
recurrence after CA is considered to be a particular concern when the patient was 
initially treated for PeAF.14,144,145  To investigate this further, I reviewed consecutive CA 
procedures performed for PeAF over a three-year period at a single, high-volume, 
centre in the United Kingdom and followed-up patients for a further three years in 
order to provide up to six years of outcome data. 
 
2.2. METHODS  
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2.2.1. PATIENTS  
Consecutive patients who underwent a first-time CA for PeAF at Liverpool Heart and 
Chest Hospital (LHCH) during a three-year period (01/01/2008 – 31/12/2010) were 
identified retrospectively and clinical notes reviewed for procedural data. Patients were 
classified as having PeAF if they had AF present continuously or had episodes of AF 
lasting for longer than 7 days at a time or requiring cardioversion, as specified by the 
published guidelines at the time the study was initiated.49 Comprehensive demographic, 
medical history and procedural details were collected from the hospital notes and 
electronic data storage systems Data verification was performed for all outlying data 
points. 
2.2.2. FOLLOW-UP  
Clinical follow-up data was collected prospectively until January 2014. Two clinicians, 
both of whom were independent of the original procedure, reviewed the follow-up data. 
Missing follow-up data were obtained by contacting the patient’s base hospital and/or 
General Practitioner. Recurrence of AF was deemed to have occurred whenever AF or 
atrial tachycardia was documented on resting ECG or during a period of monitoring, or 
– in keeping with the real world nature of this study – if the responsible clinician treated 
the patient for recurrence of AF without definitive proof, for example by performing 
repeat CA or starting new antiarrhythmic medication because of the return of the 
patient’s typical symptoms.  Mortality data was obtained from the UK’s central 
healthcare database (NHS Spine). For any patient who died during follow-up their 
General Practitioner was contacted for cause of death and further details. At the end of 
the study all patients were contacted by phone to invite them to provide final follow-up 
data. Telephone interviews were carried out using a standardised interview template. 
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To avoid loss of follow-up due to working patterns or holidays, initial unsuccessful 
daytime contact was followed up by repeated attempts in the evening and at the 
weekend, spread out over a several week period.  The study was approved by both the 
hospital and regional research ethics committees. 
2.2.3. ELECTROPHYSIOLOGICAL STUDY  
CA was performed under conscious sedation or general anesthesia. Antiarrhythmic 
drugs were stopped at least five half-lives prior to the procedure, except for amiodarone 
which was generally continued. Post procedural anticoagulation was with warfarin with 
bridging low molecular weight heparin (LMWH) used until the patient’s INR was ≥2. 
Pre-procedural transoesophageal echocardiography was carried for patients in AF 
without at least four preceding weeks of therapeutic anticoagulation. In general, 
vascular access was exclusively via the right femoral vein, with other routes only used 
as required. A deflectable decapolar catheter was positioned within the coronary sinus. 
Transseptal access was gained using a Brockenbrough or Endrys needle under 
fluoroscopic guidance with either a single or double puncture. A variety of long sheaths 
were used. Unfractionated heparin was used to maintain an activated clotting time 
above 250-300 seconds. In all cases, pulmonary vein isolation (PVI) was first 
performed, predominantly using a 3.5-4mm irrigated tip radiofrequency catheter with 
flow rates between 12-30mls/minute, using a segmental ostial or wide area 
circumferential ablation (WACA) pattern. A 20-pole circular mapping catheter was used 
to measure electrical activity within the pulmonary veins. The addition of linear lesions 
and complex fractionated atrial electrogram (CFAE) ablation was according to operator 
preference. Temperature limits were set to 50° Celsius and ablation power was limited 
to 25-30 watts on the posterior left atrial (LA) wall, 30-35 watts on the anterior wall, 
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roof and the intervenous carina, 25 watts in the coronary sinus and 50 watts for cavo-
tricuspid isthmus ablation. Ablation was carried out either using a continuous dragging 
technique or individual point-by-point lesions of 20-40 seconds duration to achieve 
>75% attenuation of the local electrogram. In three cases PVI was performed using the 
HD Mesh Ablator (C.R. Bard Inc. Murray Hill, New Jersey, USA) and in one case with the 
Arctic Front cryoablation system (Medtronic Inc, Minneapolis, Minnesota, USA). In 
keeping with published guidance, PVI was defined as proven entrance block. For linear 
lesions, excluding non-anchored lesions, the desired end point was bidirectional 
conduction block, as verified with appropriate pacing maneuvers.14  The overall 
procedural end-point was completion of the attempted lesion sets rather than 
termination of AF. Patients were monitored overnight and routinely discharged the 
following day.   
2.2.4. STATISTICAL ANALYSIS  
Discrete variables are described in terms of the frequency and proportion and 
compared using the χ2 or Fisher’s exact test. Continuous variable are described as mean 
± standard deviation, and compared using unpaired t-tests, or median (interquartile 
range, IQR) and compared using Mann-Whitney U test, dependent on the distribution. 
Analyses were performed using IBM SPSS Statistics software version 21. Survival data 
was plotted using the Kaplan-Meier estimator. The log-rank test was used to compare 
survival between groups. Univariable and multivariable predictors of AF recurrence 
were examined using logistic regression using forward conditional modelling.   We pre-
specified that variables with a p value ≤0.1 would be included in the multivariable 
model, and if necessary to maintain a minimum of 10 events per variables, selected on a 
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hierarchical basis146.  Where applicable, two-tailed tests were used in all analyses. A P 
value ≤0.05 was considered significant for all tests. 
2.3. RESULTS  
2.3.1.PATIENTS AND BASELINE CHARACTERISTICS  
We identified 189 patients in whom first-time percutaneous CA for PeAF was attempted 
during the study period. Baseline characteristics are provided in Table 2-1. The mean 
duration of the current episode at the time of CA was 7±14 months. 37 (20%) of 
patients had longstanding PeAF, defined as 12 months’ continuous AF with no period of 
sinus rhythm (SR) lasting >24 hours.  143 patients (76%) had at least one attempt at 
electrical cardioversion prior to their CA, although only 70 (46%) maintained SR for >1 
month. The mean CHA2DS2-VASc score was 1.45±1.46 (median=1).  One patient did not 
undergo ablation as LA access was not possible, leaving 188 patients who were eligible 
for follow-up.  
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Characteristic  
Male gender, n(%) 157 (83%) 
Age (years) 57.3±9.7 
Time since first AF diagnosis (months) 48±52 
Longstanding PeAF, n(%) 37 (20%) 
Left atrial anteroposterior diameter (mm) 44±6 
Left ventricular systolic function, n(%) 
Good (Ejection fraction (EF) >50%) 
Mildly impaired (EF 40-49%) 
Moderately impaired (EF 30-39%) 
Severely impaired (EF <30%) 
 
156 (83%) 
12 (6%) 
9 (5%) 
4 (2%) 
Hypertension, n(%) 85(45%)  
Diabetes, n(%) 12 (6%) 
Obstructive sleep apnoea, n(%) 11 (6%) 
Previous stroke/ transient ischaemic attack, 
n(%) 
8 (4%) 
Ischaemic heart disease, n(%) 15 (8%) 
Table 2-1: Baseline characteristics of patients undergoing catheter ablation for PeAF 
2.3.2. PATIENT JOURNEY  
In total 332 CA procedures were performed or attempted. Four procedures were 
abandoned before any ablation was performed due to complications of transseptal 
puncture. Of these, three had no sequelae and one resulted in a small pericardial 
effusion that was managed conservatively. These procedures were included in 
complication data but excluded when calculating arrhythmic outcome data. Excluding 
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abandoned procedures, 105 (56%) patients underwent more than one CA for AF.  The 
“patient journey” experienced in our patient cohort is illustrated in Figure 2-1. Eight 
patients (4%) were eventually treated by implantation of a permanent pacemaker and 
atrioventricular node ablation. 
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Figure 2-1: The procedural journey for our cohort of patients with persistent atrial fibrillation. Patients 
underwent a maximum of 4 ablations and these are detailed in the centre of the diagram as well as the 
number with post-procedural recurrence. To the left are the patients without recurrence and to the right are 
those with recurrence who did not have further ablation. 
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2.3.3. FOLLOW-UP  
Clinical follow-up data was available for 186 of 188 eligible patients (98.5%). Mean 
follow-up time was of 46±16 months and ranged between 4-72 months. Follow-up of 
greater than one year was available for >95% of patients. Eight patients died during 
follow-up.  All deaths were remote from the CA, with the earliest occurring after 121 
days. Five deaths were non-cardiovascular (two from malignancy, one each from 
pulmonary fibrosis, pneumonia, and renal failure) and three were cardiovascular in 
aetiology (one each of aortic dissection, heart failure, and myocardial infarction). Three 
patients suffered a stroke or transient ischaemic attack (TIA) during follow-up, of whom 
two had complete neurological recovery.  All three had had warfarin stopped prior to 
their event, in one because of intolerable side effects, one because of low risk profile 
(CHA2DS2-VASc=0) and one by the original referring physician despite a previous 
history of TIA. Data on antithrombotic medication was available for 139 patients (75%), 
of whom 75 (54%) were taking oral anticoagulation (warfarin in 69, direct thrombin/ 
Factor Xa inhibitor in 6), 27 (19%) an antiplatelet agent, and 37 (27%) no anti-
thrombotic therapy. Mean CHA2DS2-VASc was significantly lower for those on no 
therapy or an antiplatelet agent (no therapy 0.65±0.75, antiplatelet 1.07±1.00, 
combined 0.83±0.88) compared to those or an oral anticoagulant (1.52±1.12, P<0.001).  
2.3.4. PROCEDURAL COMPLICATIONS  
Seven patients experienced major complications. There were three pericardial effusions 
requiring percutaneous (n=2) or surgical (n=1) drainage, two inadvertent aortic 
punctures, one phrenic nerve paralysis and one femoral arterial pseudo aneurysm. 
Overall, this represents an incidence of major complications of 2.1% per procedure and 
3.7% per patient. There were eighteen minor complications of which eleven related to 
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vascular access and four were pericardial effusions managed conservatively. One 
patient developed constrictive pericarditis four years after his CA, which had been felt 
at the time to be uncomplicated. He was found to have a calcified pericardial 
haematoma on pericardiectomy that may have been an unrecognised consequence of 
his CA procedure.  
2.3.5. ABLATION PROCEDURES  
Of 188 index procedures, 91% were performed under conscious sedation and 9% under 
general anaesthesia. Conventional radiofrequency energy was used in 98% of 
procedures. 90%, of cases utilised 3-dimensional mapping systems: CARTO (Biosense 
Webster, Diamond Bar, California, USA) in 60% and Ensite NavX (St. Jude Medical, St. 
Paul, Minnesota, USA) in 30%. In 96 (51%) cases, the 3-dimensional map of the LA was 
integrated with a pre-operative computed tomography (CT) scan. Mean procedure 
duration was 200±41 minutes, and mean ablation and fluoroscopy times were 57±22 
minutes and 40+31 minutes respectively. Average radiation dose, in terms of Dose-
Area-Product, was 5796±7634 mGycm2.  
 
PVI was performed in all cases, with additional linear lesions deployed in 146 cases 
(78%) and CFAE ablation in 62 (33%). PVI was by means of WACA in 109 cases, 
segmental isolation in 75, and a mixed approach in three. The most common LA linear 
lesion was a roof line (117, 62%) followed by a floor line (72, 38%). A mitral isthmus 
line was created in 37 (20%) cases. A right atrial flutter line was performed in 97 (52%) 
patients. CFAE ablation was performed in the LA in 56 (30%) cases and in the right 
atrium in 9 (5%). 
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At the start of the procedure 112 (60%) patients were in AF or flutter and a further 23 
patients developed sustained AF intra-operatively. Of these 135, 28 (21%) were ablated 
to SR but the majority (104, 77%) were cardioverted either electrically or 
pharmacologically. Three patients remained in AF. 
2.3.6. OUTCOMES AFTER A SINGLE PROCEDURE  
Antiarrhythmic medication was continued until the first follow-up appointment 
(median 3 (IQR 2-3) months after CA (IQR 2-3)) for 75% of patients (47% Amiodarone, 
17% flecainide 8% sotalol and 3% others). Allowing for a 3-month blanking period, 139 
(75%) patients experienced recurrence of AF after a single procedure during extended 
follow-up. The initial recurrence mechanism was paroxysmal in 55 patients (39%), 
persistent in 81 (58%) and unclear in four. AF was the recurrence arrhythmia in 104 
(74%) patients with atrial tachycardia or flutter seen in 29 (21%). The recurrence 
arrhythmia was unknown for 7 patients. The median time to first recurrence was 210 
days (range 91-1850). A graphical representation of recurrence over time is shown in 
Figure 2-2. Although first recurrence was seen to occur as late as 5 years after a hitherto 
successful procedure, 71% of AF recurrences occurred within the first year following CA 
and 91% within two years. 
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Figure 2-2: Recurrence curve showing number of patients remaining free from documented recurrence over 
time after a single procedure 
Regression analysis identified AF as initial rhythm at the time of CA (OR 2.05, 95%CI 
1.05-4.03, P=0.037) as the only univariable predictor of AF recurrence after a single 
procedure, while integration of CT imaging into 3-dimensional mapping reduced the 
risk of recurrence (OR 0.39, 95%CI 0.19-0.78, P=0.008). Female sex (P=0.092) met the 
pre-specified criteria for inclusion in multi-variable modelling, but was not 
conventionally significant. After multivariable analysis, only AF as initial in-lab rhythm 
(OR 2.59, 95%CI 1.27-5.31, P=0.009) remained a statistically significant predictor of 
recurrence, and CT integration (OR 0.33, 95%CI 0.16-0.69, P=0.003) remained an 
  Page 86 of 266 
independent predictor of success. Details of single procedure univariable and 
multivariable analyses are given in Table 2-2. 
Variable Univariable Multivariable 
P value OR (95% CI) P value OR (95% CI) 
Age 0.374 1.02 (0.98-1.05)    
Female sex 0.092 2.59 (0.86-7.84) 0.063  
Hypertension 0.559 1.22 (0.62-2.39)    
Body Mass Index  0.671 0.98 (0.91-1.06)    
Diabetes 0.388 0.57 (0.16-2.04)    
LA Diameter (mm) 0.564 1.02 (0.95-1.09)    
Time since diagnosis* 0.985 1.00 (0.99-1.01)    
Current episode 
length* 
0.406 1.02 (0.98-1.06)    
Longstanding PeAF 0.776 0.88 (0.37-2.10)    
General anaesthesia 0.195 2.72 (0.60-12.37)    
3D mapping 0.989 0.99 (0.30-3.24)    
CT integration 0.008 0.39 (0.19-0.78) 0.003 0.33 (0.16-0.69) 
WACA 0.349 0.72 (0.36-1.44)    
Linear ablation 0.775 1.10 (0.56-2.19)    
CFAE ablation 0.192 1.64 (0.78-3.44)    
AF as initial rhythm 0.037 2.05 (1.05-4.03) 0.009 2.59 (1.27-5.31) 
Ablate to SR† 0.163 0.52 (0.20-1.31)    
Table 2-2: Logistic regression analysis for freedom from recurrent AF after a single procedure. OR – Odds 
ratio, CI – Confidence interval, WACA – Wide area circumferential ablation, CFAE – Complex fractionated 
atrial electrogram * Time in months, †compared to those cardioverted to SR. 
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2.3.7. OUTCOMES AFTER MULTIPLE PROCEDURES  
In our cohort, patients underwent a mean of 1.75±0.79 procedures (range 1-4). Median 
follow-up time after patients’ last CA was 35 months (IQR 15-45). 90 (48%) had a 
further recurrence of AF following their final procedure. Median time to recurrence 
after last procedure was 301 days (range 91-1850). A graphical representation of 
recurrence over time is shown in Figure 2-3. Of those who remained free of recurrence, 
31 (32%) remained on Class I or III antiarrhythmic drugs. 
 
Figure 2-3: Recurrence curve showing number of patients remaining free from documented recurrence over 
time after their last procedure 
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As shown in Table 2-3, the only univariable predictor of AF recurrence after the final 
procedure was age (OR 1.05, 95% CI 1.01-1.08, P=0.006). Female sex (P=0.08) and time 
(in months) since first diagnosis of AF (P=0.07) also both met the criteria for inclusion 
in multi-variable modelling. CT integration (OR 0.33, 95% CI 0.18-0.61, P<0.001) and 
isolation of the pulmonary veins using a WACA technique (OR 0.49, 95% CI 0.27-0.88, 
P=0.018) were associated with a lower risk of recurrence. After controlling for 
confounding with multivariable modelling, only age (OR 1.05, 95% CI 1.01-1.09, 
P=0.018) and (lack of) CT integration (OR 0.30, 95% CI 0.15-0.60, P=0.001) remained 
statistically significant in terms of predicting recurrence.   
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Variable Univariable Multivariable 
P value OR (95%CI) P value OR (95%CI) 
Age 0.006 1.05 (1.01-1.08) 0.018 1.05 (1.01-1.09) 
Female sex 0.080 2.03 (0.92-4.46) 0.424  
Hypertension 0.434 1.26 (0.71-2.25)     
BMI  0.645 0.98 (0.92-1.05)     
Diabetes 0.479 0.63 (0.18-2.24)     
LA Diameter (mm) 0.800 1.01 (0.95-1.06)     
Time since diagnosis* 0.071 1.01 (1.00-1.01) 0.211  
Current episode length* 0.900 1.00 (0.98-1.02)     
Longstanding PeAF 0.353 0.68 (0.30-1.53)     
General anaesthesia 0.594 1.31  (0.48-3.56)     
3D mapping 0.801 0.88 (0.31-2.44)     
CT integration <0.001 0.33 (0.18-0.61) 0.001 0.30 (0.15-0.60) 
WACA 0.018 0.48 (0.27-0.88) 0.370  
Linear ablation 0.202 0.68 (0.37-1.23)     
CFAE ablation 0.755 1.10 (0.60-2.03)     
AF as initial rhythm 0.938 0.98 (0.54-1.76)     
Ablate to SR† 0.138 0.51 (0.21-1.24)     
Time to first 
recurrence# 
0.767 1.00 (1.00-1.00)     
Table 2-3: Logistic regression analysis for freedom from recurrent AF after multiple (mean 1.7) procedures. 
OR – Odds ratio, CI – Confidence interval, WACA – Wide area circumferential ablation, CFAE – Complex 
fractionated atrial electrogram. *Time in months, #for those patients who had a recurrence of AF after their 
first procedure, †compared to those cardioverted to sinus. 
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2.3.8. LONGSTANDING PEAF 
The presence of longstanding (>1 year) PeAF has traditionally been associated with 
poorer outcomes after CA but was not a predictor of recurrence after single or multiple 
procedures in our cohort. To investigate this further we performed a subgroup analysis 
and found that AF recurrence was no more likely for patients with longstanding PeAF 
than for those with shorter duration PeAF after either a single (73% v 74%, P=0.9) or 
final (41% v 48%, P=0.4) procedure. 
2.3.9.  EFFECT OF CT  INTEGRATION ON FREEDOM FROM RECURRENT AF 
As shown in Tables 2-2 and 2-3, integration of CT imaging into 3-dimensional mapping 
was the only significant predictor of outcome after multivariate modelling after both 
single and multiple procedure(s). We therefore undertook subgroup survival analysis 
grouping patients according to use of CT integration during their initial procedure. AF-
free survival was significantly increased with CT integration after both initial (P=0.026) 
and final procedure (P=0.001) compared to patients whose ablation was performed 
without image integration, as shown in Figure 2-4 and 2-5. 
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Figure 2-4: Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped 
according to use of CT integration 
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Figure 2-5: Kaplan-Meier curve showing AF-free survival after the final procedure for patients grouped 
according to use of CT integration  
2.3.10. QUALITY OF LIFE (QOL)  AFTER CA  OF PEAF 
As a surrogate for formal QoL measurement, patients’ health status was assessed by the 
independent investigators for each follow-up clinic visit. We also asked patients to rate 
their own health state at the final telephone follow-up. Overall, 82% of patients felt 
better in terms of their arrhythmia with 62% of patients having considerable clinical 
improvement or arrhythmia cure and a further 20% gaining at least some improvement. 
These proportions did not differ between those cases adjudicated by the investigators 
and those reported directly by the patient. Although three-quarters of patients with 
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ongoing episodes of AF still gained a benefit in terms of their health status, patients who 
remained free from recurrent AF were significantly more likely to gain symptomatic 
improvement (75% v 93%, P <0.001).  
2.4. DISCUSSION  
There are a number of conclusions to be drawn from the data presented.  Firstly, CA of 
PeAF is safe with a low rate of complications. Our 2.1% incidence of major 
complications, with no thromboembolic events, compares favourably with that reported 
in worldwide registries and other studies147-151. Secondly, recurrence after the initial CA 
is the norm, rather than the exception. Although two years’ follow-up is sufficient to 
observe approximately 90% of AF recurrence, recurrences can occur even after five 
years of remission. After multiple procedures (in our cohort the mean number was 1.7 
which is lower than reported in many other series151) over half of patients can be 
rendered free of AF. Importantly, although many patients continue to experience 
episodes of AF, the vast majority gain clear symptomatic benefit, especially if persisting 
SR is achieved. The improvement in those with recurrent AF presumably relates, in part, 
either to conversion of continuous persistent to paroxysmal AF or to the previously 
demonstrated increase in asymptomatic AF after ablation.152 Finally, there are few 
predictors of successful outcome. In our series, although being in AF was associated 
with a higher recurrence risk after the initial procedure and increased age predicted 
poorer long-term success, only integration of CT imaging into 3-dimensional mapping 
predicted both single and multiple procedure success. 
Few other groups have reported long-term CA outcomes for large series of patients 
undergoing CA for PeAF. The largest reported study contained 676 patients with non-
paroxysmal AF.153 Success rates of 67% after a single procedure and 84% after multiple 
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procedures were reported. However, in contrast to our study they appear to have found 
very few recurrences occurring between 24-84 months after either single or multiple 
procedures, and none later than 32 months. Intensity of follow-up after the initial 12 
months was unclear.  Another leading European centre reported slightly lower single 
(20%) and multiple procedure (45%) success rates compared to our study, but that was 
in a population with longstanding PeAF over a slightly longer follow-up period (56 
months).154 They found that only total AF duration, which was significant on univariate 
but not multivariate analysis in our study, predicted freedom from AF.   
Other studies have generally been of short duration and/or contained small numbers of 
patients. In the largest previously published study from the UK, Hunter reported on 125 
patients with PeAF as part of a larger mixed cohort. Single and multi-procedure success 
rates for PeAF off antiarrhythmic drugs were 20% and 60% respectively over a follow 
up period of 2.7 years.151 An important study by Bertaglia highlighted the importance of 
long-term follow-up in this group of patients. In patients who had already remained in 
SR for 12 months after their initial CA, they found an actuarial recurrence rate of 55% at 
6 years.143 A recent meta-analysis of long-term CA outcomes for PeAF has reported 42% 
(95% CI, 25-61%) success after a single procedure and 78% (95% CI, 69-85%) after 
multiple procedures but with substantial heterogeneity between studies.135  
One of the most striking findings from our study is the value of CT-integration into a 3-
dimensional mapping system in predicting procedural success. Since its introduction, 
there has been much interest in image-integration due to the potential benefits of 
accurate anatomical visualisation, particularly of anomalous PV arrangements, leading 
to improved ablation delivery.155 A few small randomised controlled trials (RCTs) and 
observational studies yielded mixed results.110,156-160 Detailed review of these studies 
highlights several important limitations. In two of the RCTs in which no difference in 
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outcome was found, CT imaging was performed in all patients and was available for 
review by operators, thereby negating part of the benefit of CT-integration in 
recognising variant anatomy.110,157 A meta-analysis showed a non-significant reduction 
in risk of AF recurrence with image-integration (RR=0.76 95% CI 0.55-1.04, P=0.09).161 
Crucially, the five studies included in the meta-analysis had follow-up durations of only 
6-12 months. The only previous study with longer follow-up (283 patients with median 
37 months follow-up), which was not included in the meta-analysis, showed a 
significant improvement in single procedure success with CT-integration compared 
with 3-dimensional mapping alone (P=0.018), in keeping with our findings.160 
2.4.1. IMPLICATIONS FOR CLI NICAL PRACTICE  
The term curative AF ablation is often used but, from our results, would appear to be 
misleading for PeAF. Patients must be aware that recurrence is the norm, rather than 
the exception. Operators may consider using 3-dimensional mapping techniques that 
combine integration of computed tomography images, as our results suggest this has a 
significant impact on long term success. That notwithstanding, the indication for CA is 
the relief of AF symptoms rather than freedom from recurrent AF and our results show 
this is achievable for the majority of patients. Although previously discouraged as a 
primary endpoint for clinical trials, 162 formal assessment of QoL will help us to better 
inform patients and make more meaningful cost-effectiveness analyses than those 
based purely on arrhythmic outcome.  
2.4.2. LIMITATIONS  
Because the study was observational, follow-up and management was decided on 
clinical grounds by the responsible physician. As a result there was some inevitable 
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variation in the intensity of follow-up and monitoring and treatment strategies 
employed. ECGs were performed for all patients attending follow-up clinics, but more 
intense monitoring tended to be dependent on symptoms and therefore it is possible 
that some patients with asymptomatic paroxysms of AF were missed. However, the long 
duration of follow-up and broad definition of recurrence goes some way towards 
mitigating this risk. Our final follow-up was by telephone which may have reduced the 
accuracy of reports of recurrence. However, by asking if patients had had an episode of 
AF confirmed by a doctor, we attempted to achieve a similar degree of diagnostic 
certainty as required at other follow-up points. We based our QoL assessment on 
patients’ reported clinical state rather than a formal questionnaire that would have 
provided more objective information. Whilst other long-term studies have employed 
similar techniques, it is clearly sub-optimal.151 We have since changed our practice to 
collect validated generic and AF-specific QoL data from all patients at each clinic visit. 
Finally, the CA procedures in our study pre-dated the advent of contact force sensing 
technology that may result in more durable lesions and thus higher success rates for AF 
ablation than those found in our study. However this is an inevitable limitation while 
reporting long-term results of a rapidly evolving procedure such as CA for AF. 
2.4.3. CONCLUSION  
CA of PeAF is safe, with a low incidence of major complications. During long-term 
follow-up, recurrence of AF is common, particularly after a single procedure but 
considerable improvements in patient wellbeing can be achieved, especially in those 
who remain free of recurrent AF. Use of 3D-mapping with CT image integration is 
associated with improved procedural success rates. 
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3 .  M E T H O D S  O F  T H E  S U B S T R A T E  
M O D I F I C A T I O N  W I T H  A B L A T I O N  A N D  
A N T I A R R H Y T H M I C  D R U G S  I N  N O N -
P E R M A N E N T  A T R I A L  F I B R I L L A T I O N  
( S M A N - P AF )  R A N D O M I S E D  C O N T R O L L E D  
T R I A L  
 
The following methods detail the study protocol for the central study for this thesis. The 
main results are presented in Chapter 4 and a substudy in Chapter 5. 
3.1 INTRODUCTION  
Atrial fibrillation (AF) is a continuum of disease.47 At one extreme are patients with a 
single paroxysm without accompanying comorbidity. At the other end are patients with 
continuous, permanent AF in whom sinus rhythm cannot be restored. These latter 
patients would be expected to have adversely remodelled left atria and may well have 
additional comorbidities, such as hypertension, known to increase susceptibility to 
AF.163 For convenience, AF is classified as either paroxysmal or persistent but, as 
discussed in Chapter 1, the boundary between these categories is fairly arbitrary and 
can be indistinct.  The term permanent AF is sometimes used to describe persistent AF 
present continuously for longer than one year but more correctly applies to those 
patients in whom persistent AF has been accepted by physician and patient, irrespective 
of duration. Not only have there been subtle changes to the internationally accepted 
definitions but both AF types may be present in the same patient and it is technically 
possible for a patient with paroxysmal AF to have a higher burden of AF than a different 
patient classified as having persistent AF.14 Where AF is truly paroxysmal, its 
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occurrence may be predominantly due to “triggers”, such as pulmonary vein ectopy, 
which both initiate and sustain AF in an otherwise relatively normal heart.24 Removal of 
the trigger might be expected to prevent further recurrences. As AF progresses to more 
advanced, sustained disease triggers may still be important for initiation of AF but its 
sustained nature probably relies on a remodelled atrium that provides a substrate that 
favours maintenance of AF. In these patients modification of the substrate may be at 
least as important as removal of the trigger. 
 
3.2. ORIGINAL HYPOTHESES/  RESEARCH QUESTION  
I hypothesised that modification of the AF substrate by radiofrequency ablation would 
improve single procedure success rates for catheter ablation (CA) for substrate-based 
non-permanent AF when compared to that achieved with short-term peri-procedural 
anti-arrhythmic drug therapy alone.  
3.3. DESIGN  
The study was designed as a prospective, two-way, multicentre randomised, controlled 
single-blinded trial. Eligible consenting patients were randomised, via a computerised 
randomisation procedure, in equal proportions into one of two groups. 
 Pulmonary venous isolation only (PVI group), or  
 PVI and linear ablation (PVI + lines group). 
All patients received peri-procedural AADs as described below. 
3.4. STUDY DURATION  
Current recommendations for trials of interventions in AF are that follow up should be 
for a minimum 12 month duration.162,164 However, it was necessary for the study to be 
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performed within the time restraints of an MD (Res) research project, completed within 
allowed Out Of Programme (Research) Time granted from my national cardiology 
training programme by my employing Deanery. Therefore, a pragmatic decision was 
made a priori to report six month follow up data for the purpose of this thesis.  In 
keeping with the abovementioned recommendations, study follow up was continued for 
a further six months to provide a total follow up period of 12 months for the purpose of 
reporting the study in the medical literature.  
3.5. END POINTS  
3.5.1. PRIMARY ENDPOINT  
The primary endpoint for this thesis was defined as documented atrial fibrillation or 
other atrial tachyarrhythmia (including right or left atrial flutter and both focal and 
macro re-entrant atrial tachycardia) at six months following a single procedure.  
In accordance with published guidelines, to qualify as a primary endpoint an episode of 
AF must have met at least one of the following criteria162,165: 
 30 seconds or more of symptomatic or asymptomatic atrial tachyarrhythmia 
captured on continuous ambulatory (Holter) ECG monitoring (Burdick Vision, 
Cardiac Science Holdings (UK) limited) or in situ cardiac rhythm management 
device (e.g. pacemaker). 
 30 seconds or more of symptomatic atrial tachyarrhythmia captured on 
symptom-activated ambulatory ECG monitoring (R.Test Evolution 3, Novacor UK 
Ltd). 
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 Any symptomatic episode of tachycardia lasting longer than 30 seconds with 
contemporaneous documentation of atrial tachyarrhythmia on resting 12 lead 
ECG. 
3.5.2.  SECONDARY ENDPOINTS :   
The following secondary endpoints were pre-specified for analysis 
 Adverse events (death, stroke, procedural complications, cardiovascular 
hospitalisation). 
 Mean QoL score six months after the index procedure. 
 Per protocol analysis of the primary outcome 
 Analysis of the primary endpoint according to AF type  
 Freedom from atrial tachyarrhythmia after 12 months, following a single 
procedure 
o This endpoint will not be reported in this thesis for reasons given above. 
o For the purpose of reporting the study in the medical literature this was 
pre-defined as the primary endpoint. 
 Freedom from AF/ atrial tachycardia at 12 months following up to two 
procedures 
o This endpoint will not be reported in this thesis for reasons given above. 
 Mean QoL score 12 months after the index procedure. 
o This endpoint will not be reported in this thesis for reasons given above. 
 
3.5.2.1  ADVERSE EVENTS 
The following definitions were used for adverse events: 
  Page 101 of 266 
 Death. 
o All-cause mortality (with no adjudication). 
 Stroke (ischaemic or haemorrhagic)  
o A clinical syndrome consisting of rapidly developing clinical signs of 
focal (at times global) disturbance of cerebral function, lasting more 
than 24 hours or leading to death within 24 hours with no apparent 
cause other than that of vascular origin.166  
 Procedural Complications 
o Any of the following discharge diagnoses were classified as procedural 
complications 
 Pericardial effusion requiring percutaneous or surgical 
drainage. 
 Bleeding requiring transfusion and/or radiological or surgical 
intervention. 
 Transient Ischaemic Attack (with stroke counted 
independently). 
 Symptomatic pulmonary vein stenosis (>50% reduction 
compared with pre-operative imaging). 
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3.6. SAFETY  
3.6.1. EXPECTED COMPLICATION RATES  
A local audit of 150 AF ablation procedures performed shortly before initiation of the 
study revealed the following complications and rates: significant (delaying discharge) 
groin haematoma (1.3%), Stroke (0.7%), pericardial effusion requiring drainage (0.7%). 
Total/ combined incidence of significant complications was 2.7%. This was in keeping 
with other leading centres.144 A recent worldwide survey of 20 825 catheter ablation 
procedures for AF on 16 309 patients revealed an overall major complication rate of 
4.5% including: cardiac tamponade 1.31%; stroke 0.23% (transient ischaemic attack 
0.71%); major vascular complication 1.5% and death 0.15%. All other complications 
were reported in less than 0.3% of cases.167 These data made up the basis of the risks 
quoted in the Patient Information Sheet and in the (clinical) informed consent process 
on the day of ablation. 
3.6.2. REPORTING OF ADVERSE EVENTS  
The standard definition of a serious complication is an event which a) results in death, 
b) is life-threatening, c) requires hospitalisation or prolongation of existing 
hospitalisation, d) results in persistent or significant disability or incapacity, or e) 
consists of a congenital anomaly or birth defect.  
  As detailed above, CA is associated with a known risk of serious complications. Given 
the intended sample size, it is to be expected that those complications known to occur in 
greater than 1% of cases will be encountered during the course of the study. These were 
therefore considered Expected Serious Adverse Events (SAE). There was no additional 
requirement to report serious adverse events above the standard local adverse event 
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reporting procedure. SAEs with a known occurrence rate of less than 1% (Stroke or 
Death) would not be expected to be seen during the study.  If these occurred in the peri-
procedural period, i.e. at a time when their occurrence may have been linked to their 
procedure, or if any SAE was associated with peri-procedural AAD therapy (as 
mandated by protocol) they were regarded as Suspected Unexpected Serious Adverse 
Events (SUSARs). In addition to standard local reporting period, SUSARs were to be 
reported to the Research Ethics Committee and the Study Sponsor 
3.7 BLANKING PERIOD  
Episodes of atrial tachyarrhythmia occurring entirely and solely within three months 
(90 consecutive days) of the index ablation period were not counted as recurrence of AF 
for the purpose of either the primary or secondary study endpoints.162,165 
3.8. PATIENTS  
Patients were recruited though the heart rhythm service at three NHS hospitals that 
make up the clinical partnership of the Institute of Cardiovascular Medicine and Science. 
Patients eligible for CA and felt to be suitable for inclusion by their cardiologist were 
initially contacted either by letter or in person at the time of their outpatient 
appointment. All patients were provided with the Participant Information Sheet (PIS) at 
the time of first contact  
 Patients initially contacted by letter received a follow up telephone call at least 1 
week later to allow for discussion of the study. Patients provisionally agreeing to 
participate were interviewed in person when they next attended the department 
(usually for an outpatient appointment or booked investigation) at which point 
the consent forms were completed and signed.  
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 Patients initially seen in person were encouraged to take time to read the PIS and 
discuss it with relevant relatives and friends.  It was made explicitly clear that 
they were free to either complete and return the consent form before they left 
the hospital or to return it by post at a later date if they wished to take more time 
to consider whether or not to participate.  
3.9. INCLUSION CRITERIA  
Patients listed for CA at were assessed for inclusion against the following criteria 
 Age over 18 years. 
 Able and willing to give written, informed consent. 
 Non-paroxysmal atrial fibrillation, as pre-classified as  
o Persistent AF:  AF requiring Electrical/ Chemical cardioversion or that 
lasting >7 days.  
o Sustained Paroxysmal AF with underlying substrate: Patients with 
Individual AF episode(s) lasting >12 hours but less than 7 days plus 
one or more of the following: 
 Age >65 years. 168 
 Hypertension with left ventricular hypertrophy.169  
 Significant left atrial dilatation of >45 mm on Echo (PLAX 
view). 
 Obesity (BMI >30), and/ or confirmed diagnosis of sleep 
apnoea.170 
 Diabetes Mellitus requiring hypoglycaemic drugs and/or 
Insulin.171 
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 On-going symptoms (EHRA Class 2 or above) in spite of treatment with rate 
control/ antiarrhythmic medication or intolerance of these medications. 
3.10. EXCLUSION CRITERIA  
Presence of any of the following attributes or characteristics at the time of potential 
recruitment were excluded from the study 
 Inability or unwillingness to receive oral anticoagulation.  
 Previous ablation procedure for AF. 
 Unwillingness or inability to complete the required follow up arrangements. 
 Presence of long standing persistent AF with continuous AF longer than 12 
months. This included patients in whom sinus rhythm may have been 
maintained following electrical cardioversion for a period of less than 1 week at 
a stretch. 
 Documented typical atrial flutter (proven on 12 lead ECG) 
o Patients whose first documented episode of atrial flutter occurred after 
randomisation were not excluded from the study but, if randomised to the 
PVI only arm, also received linear ablation of the cavo-tricuspid isthmus 
(flutter line). For the purposes of Intention to Treat analysis this patients 
were analysed in accordance with their initial randomisation 
 Prior prosthetic mitral valve replacement or severe structural cardiac 
abnormality172 
 Contraindications and/ or prior intolerance to both amiodarone and flecainide 
 Reversible cause for atrial fibrillation 
 Known hypertrophic or infiltrative cardiomyopathy 
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3.11. RANDOMISATION  
Randomisation was performed using freely available computerised randomisation 
software (Minim, www.sghms.ac.uk/depts/phs/guide/randser.htm) incorporating a 
partial minimisation procedure to adjust the randomisation probabilities between 
groups to balance for AF type (persistent or sustained paroxysmal) and was stratified 
according to NHS Trust.173,174 
3.12. STUDY VISITS AND INVESTIGATIONS  
The schedule of visits and investigations is given in the table below 
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Inclusion/ Exclusion 
criteria 
X - - - - - - - 
Baseline Characteristics X - - - - - - - 
Consent X - - - - - - - 
Clinical Review X - - - - X X X 
Liver/ Thyroid function X - - - - - - - 
Start study medication - X1 - - - - - - 
EHRA Symptom Score X - - - - X X X 
QoL Questionnaire X - - - - - X X 
Electrocardiogram X X2 X2 X2  X X X 
CT/ MRI scan - X3 - - - - - - 
24 Holter ECG - X - - - X4 X4 X4 
Echocardiogram - X - X5 - - X - 
AF Ablation - - X - - - - - 
Troponin T - - - X5 - - - - 
Stop study medication - - - - X - - - 
Table 3-1: Study visit schedule.  1At least 6 weeks pre-procedure for all patients unless already prescribed at 
time of recruitment. 2Electrograms recorded at these points as part of standard clinical care but not 
specifically required for the study protocol. 3Choice of modality made according to clinical requirements and 
availability. 4Holter monitoring not necessarily required if recurrence of AF, meeting the definitions of a trial 
endpoint, confirmed by alternative modality. 5Only performed on a subset of patients. 
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3.13. FOLLOW UP  
Study follow up visits were performed at 3, 6 and 12 months post-ablation as detailed 
above. Additional clinical visits were permitted as required. A 12 lead resting ECG was 
performed at all visits. 24 hour ambulatory ECG (Holter) monitoring was performed at 
all study visits barring the exceptions detailed above.  Ad hoc Holter monitoring was 
also performed as required for patients with intercurrent symptoms suggestive of atrial 
tachyarrhythmia. Prolonged (7-14 day) symptom activated ambulatory monitoring was 
performed for patients with on-going symptoms where symptom-arrhythmia 
correlation was not achieved from the resting ECG or Holter recordings. 
Warfarin/ other oral anticoagulant agents were continued for at least three months post 
ablation. At that point the decision whether or not to continue was made individually, 
based on CHADS2/ CHA2DS2 VASc score, freedom from AF and patient preference.  
3.14. BASELINE DATA  
The following data were collected prior to randomisation, either at the initial 
consultation or during the time the patient was on the waiting list for AFA. 
 Inclusion and exclusion criteria. 
 AF history 
o AF Categorisation (SusPAF or PeAF)  
o Substrate marker for patients categorised as SusPAF. 
o Number of previous cardioversions, duration of sinus rhythm after most 
recent DCCV and AAD used at time of cardioversion. 
 Comorbid conditions 
o Hypertension, previous myocardial infarction, previous stroke and/ or 
TIA, Peripheral vascular disease, valvular heart disease, heart failure, 
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tachycardia induce cardiomyopathy (current or previous), diabetes 
mellitus (type 1 or 2), obstructive sleep apnoea (OSA), smoking history, 
and CHA2DS2 VASc score.175  
o Possible undiagnosed OSA was also screened for using a simple screening 
questionnaire (with 2 or more answers suggestive of OSA) 
 Do you snore? 
 Are you excessively tired during the day? 
  Do you have a history of hypertension? 
 Is your neck size > 17in (male) or > 16in (female)? 
 Have you been told you stop breathing during sleep? 
 Other Clinical data 
o Height, weight, BMI and gender. 
o Heart rhythm at time of recruitment (based on 12 lead ECG findings). 
o Prescribed medications and previously failed AADs.  
 Symptom evaluation (EHRA class).162  
 12 lead electrocardiogram (ECG). 
 24 hour ambulatory ECG (Holter) , to assess mean baseline heart rate and 
establish the presence of persistent/ non-paroxysmal AF and overall AF 
burden.176   
 Quality of Life Assessment using the Atrial Fibrillation Effect on QualiTy of life 
questionnaire (AFEQT). 177 
 Thyroid function and liver function tests 
o Any significant abnormalities in these tests were discussed with the 
clinical team.  For patients receiving, or due to receive, amiodarone 
consideration was given to the use of flecainide as an alternative agent. 
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3.15. QUALITY OF LIFE ASSES SMENT  
Quality of life was assessed objectively at the time of recruitment and at 6 and 12 
months after ablation. A subjective assessment was also made by the reviewing clinician 
at all study visits using the EHRA score.162 
3.15.1. AFEQT  QUESTIONNAIRE  
The Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire is a validated, 
disease-specific, self-administered QoL instrument.178 It has 20 questions with four 
conceptual domains and published algorithms allow calculation of domain and global 
scores. Each of the 20 questions is marked on a seven point Likert scale. The 
questionnaire specifies a recall period of the preceding four weeks. The questionnaire 
was used under licence from St. Jude Medical Inc, (Minnesota, USA).  The raw scores are 
used to generate the AFEQT overall score and the component sub-scores (symptoms, 
activities and concerns) using algorithms supplied by the company. 
3.15.2. ANTI-ARRHYTHMIC DRUG PROT OCOL  
A study published shortly before the commencement of this trial suggested that pre-
procedural AAD therapy may improve the success rates for ablation in substrate-based 
AF.179 Subgroup analysis from that study suggested that the improved clinical outcome 
could not be predicted simply by the restoration of sinus rhythm and that the key 
element appeared to be reversal of the adverse remodelling that occurs in the atria of 
patients with AF.  All patients were prescribed an AAD for a minimum of six weeks pre-
procedure and exactly six weeks post procedure. Deviation from this was only 
permitted if mandated by clinical need. 
The choice of AAD was decided according to the following algorithm: 
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A two week loading regime was used for patients commenced on amiodarone as part of 
the study. This consisted of a dose of 200mg of amiodarone three times a day for seven 
days followed by the same dose twice a day for a further seven days. 
3.16. ANTICOAGULATION  
All patients not already receiving oral anticoagulation therapy were commenced on 
either warfarin or dabigatran. For patients on warfarin the aim target INR level was 
between 2 and 3 but management of warfarin dosing was not managed as part of the 
study protocol.180  The standard dose of dabigatran was 150mg twice daily.54   
  
Patient established on a 
clinically effective regime of 
either amiodarone or 
flecainide at the time of 
recruitment? 
Yes 
Continue current regime 
 
NO 
Amiodarone 
contraindicated? 
Yes 
Flecainide 50mg twice daily, 
titrated to 100mg if 
tolerated 
No 
Amiodarone 200mg daily  
(after oral loading regime) 
Figure 3-1: Antiarrhythmic treatment algorithm 
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3.17. ABLATION PROCEDURE  
 All patients continued oral anticoagulation peri-procedurally with an INR on the day of 
procedure between 2.0 and 3.5 considered acceptable for those taking warfarin.181,182 
Periprocedural use of Dabigatran was allowed according to local guidelines for patients 
taking these agents. Transoesophageal echocardiography (TOE) was permitted to 
exclude left atrial thrombus prior to CA at the discretion of the operator according to 
their normal practice. As a guide, TOE was recommended for patients in AF at the time 
of their ablation if the INR readings in the previous 4 weeks are <2.0 for those taking 
warfarin, or if anticoagulation had been inadequate (e.g. missed doses) for those taking 
Dabigatran. 
 After successful transseptal puncture patients were anticoagulated with intravenous 
unfractionated heparin to maintain an Activated Clotting Time (ACT) of >250-300 
seconds.  
Atrial fibrillation ablation was performed under conscious sedation or general 
anaesthesia  in a standard fashion in a similar manner to that which has been described 
previously.183 Single or double transseptal punctures were made using fluoroscopic 
guidance with additional pressure monitoring. If patients were in AF at that point, they 
underwent DCCV to restore sinus rhythm.  An electroanatomical map of the left atrium 
was then created and, whenever possible, then integrated with the MR or CT 
reconstruction of the atrium using a 3D navigation system (CartoMerge; Biosense 
Webster, Diamond Bar, California, USA).110,159   
Group 1: Using a 3.5-4mm irrigated tip radiofrequency ablation catheter a series 
of lesions >2 mm outside PV ostia were made to encircle and electrically isolate 
the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, 
WACA).184  A 20-pole PV mapping catheter was used to confirm electrical 
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isolation. If the patient was in atrial fibrillation at this stage, sinus rhythm was 
restored with electrical cardioversion and PVI isolation of the pulmonary veins 
confirmed in sinus rhythm. 
Group 2: Initially, isolation of the pulmonary veins was undertaken in an 
identical manner to Group 1.  Once PVI had been achieved, patients received a 
pre-specified additional linear ablation lesion set. This consisted of a left atrial 
roof line, mitral isthmus line, (including ablation inside the coronary sinus if 
necessary), and ablation on the cavotricuspid isthmus (CTI). If the patient was in 
atrial fibrillation at this stage, the acute end-point would be signal obliteration at 
the ablated area. Once sinus rhythm was restored with electrical cardioversion, 
PVI was confirmed in sinus rhythm and conduction block across the LA roof line, 
Mitral line and CTI was then verified with appropriate pacing manoeuvres as 
detailed below. 
In both groups a minimum waiting time of 30 minutes was allowed to elapse between 
complete isolation of the pulmonary veins and verification of conduction block and 
pulmonary vein isolation.   
In either of the 2 groups, if AF became organised to a regular atrial tachycardia or 
sustained atrial flutter at any stage, attempts were made to map and ablate this to sinus 
rhythm according to the protocol described by Jais et al.185 That notwithstanding, these 
patients still received the pre-specified ablation lesion set according to their 
randomisation group.  Patients who were randomised to PVI only but required a cavo-
tricuspid isthmus line to treat induced flutter were still considered to have been treated 
as per their randomisation for intention to treat analysis but had this deviation from 
protocol recorded. 
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At the end of the procedure and at the discretion of the operator, administration of 
intravenous protamine to reverse the effects of heparin was permitted but not 
mandated. 
3.18. LESION DESCRIPTION AN D DEFINITION OF SUCCESS  
The follow descriptions were used to define the ablation lesions performed as part of 
the study protocol and the criteria for judging those lesions as completely or partially 
successful when checked after the compulsory waiting period  
Lesion Description Complete success Partial success 
Left sided 
WACA 
Creation of a 
contiguous series of 
lesions >2 mm outside 
PV ostia which 
encircles* and 
electrically isolate the 
pulmonary veins in 
two ipsilateral pairs. 
Ablation within the 
WACA is also 
permitted, especially 
across the intervenous 
carina. 
* If isolation of both 
veins is demonstrated 
before complete 
encirclement (e.g. by 
ablation of all active 
fascicles)  then it is not 
mandatory to 
complete the entire 
lesion 
Success checked with 
Spiral catheter within each 
pulmonary vein in turn, 
demonstrating by either  
(a) Elimination of all 
PV potentials, or 
(b) Entrance block into 
the PV with 
dissociated PV 
potentials 
Failure of complete 
isolation of 1 or 
more veins  
Right sided 
WACA 
Roof Line Creation of a 
contiguous 
line of ablation lesions 
along the LA roof, 
joining the superior 
PVs  
Demonstration of 
caudocranial activation of 
the posterior wall and/ or 
online corridor of double 
potentials along the 
entire length of the roof 
during sinus rhythm 
and/or during pacing of 
the anterior LA 
Significant slowing 
of conduction  but 
without 
demonstrable 
conduction block 
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Mitral 
isthmus 
line 
Creation of a 
contiguous line of 
ablation between the 
lateral mitral annulus 
and the inferior aspect 
of the left-sided 
WACA. 
 
Where necessary this 
may include ablation 
within the coronary 
sinus. 
 
Pacing lateral to the line 
through the ablation 
catheter placed 
endocardially 
demonstrating a proximal-
to-distal activation 
sequence 
along the CS septal of the 
line 
Slowing of 
conduction across 
the line but 
without meeting 
the criteria for 
complete success 
Cavo-
tricuspid 
isthmus 
Line 
Creation of a 
contiguous line of 
ablation lesions from 
the ventricular aspect 
of the tricuspid 
annulus (where the 
atrioventricular 
electrogram shows a 
1:1 to 2:1 ratio) 
and the rim of the IVC 
(the point at which no 
local electrogram can 
be recorded) 
At least one of:  
Demonstration of bi-
directional block across 
the line by means of 
differential pacing so that: 
When pacing from CS or 
MAP catheter (placed 
lateral to CTI) the 
conduction time to the 
other catheter DECREASES 
when MAP is moved to a 
more lateral position. The 
manoeuvre is then 
repeated whilst pacing 
from the other catheter. 
 
Demonstration widely 
split (>90ms) double 
potentials  with an 
intervening isoelectric 
interval along the entire 
course of the ablation line 
Significant slowing 
of conduction 
across the line but 
without 
demonstrable 
block 
Table 3-2: Ablation lesions (and definitions of success) used as part of study protocol  
3.19. RECURRENCE OF AF   
Recurrence of AF, or other atrial tachyarrhythmia following ablation was managed 
according to clinical need with repeat ablation offered to all with enduring symptoms 
(EHRA Class 2 or greater). Patients who developed continuous persistent AF after their 
ablation were offered electrical cardioversion as the first line treatment option. Patients 
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whose symptoms were mild and/ or who declined a repeat ablation procedure were 
maintained on AAD as required. 
3.20. REPEAT ABLATION  
Patients with symptomatic PAF occurring or continuing after the pre-defined blanking 
period or who reverted back to PeAF following electrical cardioversion were offered 
repeat ablation. This was performed using the lesion set allocated at randomisation. 
Additional ablation was only permitted if:  
 The original lesion set was found to be intact (all veins still isolated and 
persisting conduction block across all linear lesions), in which case additional 
ablation was permitted according to the operator’s standard practice. And/ or 
 A de novo focal or macro-reentrant atrial tachycardia or flutter was seen, in 
which case this was mapped and ablated as described for the index ablation 
procedure. 
Only the initial and first repeat procedure were limited by study protocol.  If a third 
ablation was required for any patient during the study period the choice of ablation 
lesions was left to the discretion of the operator. 
 
 
3.21. SAMPLE SIZE C ALCULATION  
A formal sample size calculation was performed, using StatsDirect software version 
2.7.8, according to the following equation  
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Zp is the standard normal deviate for probability p. We accepted the more conservative 
continuity corrected sample size (nc) having specified the number of control subjects 
per experimental subject (m) to be 1. 
Based on local audit data we assumed a 6 month single procedure success rate of 55% 
in Group 1 and 80% in Group 2. Allowing for an α error of 0.05 and a β of 20% (80% 
power) the number of patients required was calculated as 124.  Allowing for an 
anticipated 5% attrition rate gave a target sample size of 130. 
3.22. STATISTICAL ANALYSIS  
All end points, apart from the pre-specified per-protocol analysis, were examined by 
means of a modified intention-to-treat analysis. In this, patients who underwent 
ablation were analysed according to the allocated treatment arm, irrespective of the 
actual lesion set delivered. Patients who withdrew or were withdrawn after 
randomisation but before their procedure were excluded from analysis. Categorical 
variables were compared with χ2 or Fisher’s exact test where appropriate. The 
dependent variables were checked for normal distribution by the ShapiroWilk statistic 
and appropriate descriptive statistics generated. Continuous variables were expressed 
as means (±SD) and be compared with the use of the student’s t-test (if normally 
distributed) or Wilcoxon rank-sum and signed-rank tests (if not). All reported p values 
were two-sided and a value of 0.05 or lower was considered significant for all tests. 
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Statistical tests were performed either with either StatsDirect software version 2.7.8. or 
IBM SPSS Statistics software version 21. 
3.23. ASSESSMENT OF PRIMARY  ENDPOINT  
Monitoring ECG traces were assessed initially by an experienced cardiac physiologist 
and then reviewed by a clinician who categorised each recording as either showing an 
atrial tachyarrhythmia lasting 30 seconds or longer (primary endpoint achieved) or not. 
If the primary reviewing clinician was uncertain, an expert secondary review was 
performed by an experienced electrophysiologist.  
Any cases in which there was uncertainty about classification of outcome (mainly due to 
difficulties clarifying the exact timing of an event) the decision was passed to an 
independent adjudication committee who were provided with al available clinical and 
trial data. All assessors were blinded to treatment allocation. 
3.24. RECRUITMENT  
Recruitment commenced at Liverpool Heart and Chest Hospital in October 2011. The 
study was initially conducted as a single site study to allow testing and verification of 
the protocol. With the establishment of the Institute of Cardiovascular Medicine and 
Science, permission was granted for multi-centre involvement, and recruitment at 
Harefield Hospital and The Royal Brompton Hospital began in June 2012. The study 
closed to recruitment in June 2013 having achieved the intended recruitment target. A 
CONSORT diagram for the study is shown below. 
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3.24.1. CONSORT  DIAGRAM  
 
Figure 3-2: Study CONSORT diagram 
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3.24.2. PROGRESS  
Overall the study was well received by patients with a high proportion of eligible 
patients agreeing to participate. However, fewer than expected patients met the study’s 
inclusion criteria. In addition the unexpected delay in moving the study from single 
centre to multi-centre status also slowed recruitment.  Our original intention was that 
all patients would have been recruited and all index ablations performed by May 2013 
but it became clear during the course of the study that this was not likely to be achieved. 
Although recruitment was completed in June 2013, due to the demands on the NHS 
waiting lists, the final ablation was not performed until November 2013. 
3.25. ETHICAL CONSIDERATIONS  
3.25.1. GOOD CLINICAL PRACTICE  
The study was conducted in accordance with the requirements of the Declaration of 
Helsinki and International Conference on Harmonisation Good Clinical Practice 
guidelines. Institutional review and approval was provided by the Research and 
Development Committees at Liverpool Heart and Chest Hospital NHS Foundation Trust 
and The Royal Brompton and Harefield Hospitals NHS Foundation Trust. All documents 
intended to be made available to patients were reviewed and approved by the Service 
Users Research Endeavour (SURE) group at LHCH to ensure clarity and readability for 
patients. 
3.25.2. NATIONAL RESEARCH ETHICS SERVICE (NRES) 
The study was reviewed by the NRES Committee North West – Greater Manchester 
Central, on 13 June 2011 and a Favourable Opinion was granted on 1st July. The 
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Research Ethics Committee reference was 11/NW/0354. In accordance with the 
standard requirements for monitoring of a favourable ethical opinion, a progress report 
was submitted annually to the Committee.  
According to the NHS Health Research Authority guidance document, “After Ethical 
Review”, a substantial amendment is defined as an amendment to the terms of the 
application, or to the protocol or any other supporting documentation, that is likely to 
affect to a significant degree:    
1. The safety or physical or mental integrity of the subjects of the trial;   
2. The scientific value of the trial;   
3. The conduct or management of the trial; or   
4. The quality or safety of any investigational medicinal product used in the trial. 
A single Notification of Substantial Amendment was submitted on 5th July 2012 and 
approved on 6th August. 
3.25.3. CONFIDENTIALITY  
Participants were assigned a unique code which was used to identify them though out 
the trial and on all study documents. Electronic records were stored securely either on a 
password protected laptop or on secure Trust servers with controlled access 
permissions. 
3.26. FLOW CHART  
The following flowchart was provided to all potential participants to illustrate 
graphically the requirements of involvement in the trial. 
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Figure 3-3: Study flow diagram 
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3.27. TRIAL REGISTRATION  
Clinical trials should be registered on a publically accessible database. The study was 
prospectively registered at www.clinicaltrials.gov with the registration number 
NCT01445925. 
3.28. CASE RECORD FORM  
Data were recorded on a paper Case Record Form (CRF), a copy of the final version of 
which is included in the appendices. This was then transferred to a purpose-built 
Microsoft Access 2007 database which acted as the electronic CRF (eCRF). The database 
is fully relational allowing for one-to-one and one-to-many relationships between 
tables. The design allows collection of all trial data to be performed through a single 
user-friendly portal. By coding elements using Visual Basic for Applications 6 (VBA6) 
scripting language the database was able to make simple calculations such as the 
patient’s age based on their date of birth and procedure date, the CHA2DS2 VASc score 
based on documented comorbidities and the required dates of follow up. Microsoft 
Access supports Structured Query Language (SQL) which allowed me to write queries 
which could then be used to check data integrity and perform initial analyses. In turn, 
some of these queries provided the basis for Microsoft Word 2007 mail merge 
documents which provided a semi-automated means of communication with 
participants and their GPs. By combining queries with the inbuilt report function, it was 
possible to maintain a rolling schedule of required appointments and investigations for 
all participants. A screenshot of the eCRF is shown below. 
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Figure 3-4: Screen shot of eCRF database  
3.29. SPONSOR  
Liverpool Heart and Chest Hospital NHS Foundation Trust acted as the study sponsor. 
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4 .  I M P R O V I N G  P A T I E N T  O U T C O M E S  T H O U G H  
B E T T E R  A B L A T I O N  S T R A T E G I E S :  R E S U L T S  
O F  T H E  S U B S T R A T E  M O D I F I C A T I O N  W I T H  
A B L A T I O N  A N D  A N T I A R R H Y T H M I C  D R U G S  
I N  N O N - P E R M A N E N T  A T R I A L  
F I B R I L L A T I O N  ( S M A N - P A F )  
R A N D O M I S E D  C O N T R O L L E D  T R I A L  
4.1.INTRODUCTION  
Initial attempts at ablation of AF targeted triggers by attempting to ablate individual 
ectopic foci within the pulmonary veins.186  Modern techniques have evolved to 
encirclement of ipsilateral vein pairs by creating contiguous rings of ablation lesions in 
the antral area between the vein ostia and the body of the left atrium (Wide Area 
Circumferential Ablation, WACA).115,187-189 Whilst the key purpose of these WACA 
lesions is to electrically isolate the pulmonary veins, thereby removing the most potent 
triggers, a relatively large area of tissue needs to be ablated to achieve this aim. This 
ablation may additionally modify the left atrial substrate by creating physical barriers to 
re-entry, interrupting potential sites of rotor activation and by modification of the 
autonomic innervation of the heart due to indirect ablation of ganglionic plexi which 
tend to be concentrated in the antral regions. Further modification of the left atrial 
substrate can be achieved by the use of antiarrhythmic drugs, by performing more 
extensive ablation within the atria or by combining both approaches.  
In this study, I set out to assess whether very extensive modification of the left atrial 
substrate by addition of bi-atrial linear ablation lesions to a strategy combining WACA 
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and periprocedural antiarrhythmic drug therapy provides greater freedom from AF 
recurrence in the medium term.   
4.2. METHODS  
The trial methodology is described in detail in an earlier Chapter. In brief, I set out to 
randomise 130 patients with persistent or sustained paroxysmal episodes of AF to one 
of two ablation strategies. Treatment allocation was in a 1:1 ratio. For the purpose of 
the study I defined persistent atrial fibrillation as an episode of AF lasting longer than 7 
days and sustained paroxysmal AF as episodes of AF lasting ≥12 hour (but less than 7 
days) in patients with an additional comorbid condition previously shown to be 
associated with abnormal left atrial substrate. Ablation was performed at three sites 
(two NHS trusts) within the UK, all tertiary AF referral centres. Recruitment was 
stratified according to AF type and NHS trust. For the purpose if this study, patients 
were followed up for six months during which time they were seen clinically and had 
periodic ECG monitoring. The primary endpoint of the study was recurrence of AF 
within the follow up period after an initial blanking window.  
4.3. RESULTS  
4.3.1. PATIENT CHARACTERISTICS  
Of 130 enrolled patients, 64 (49%) were randomised to PVI with peri-procedural 
pharmacological substrate modification (PVI group) and 66 (51%) to a strategy of 
additional substrate modification with linear lesions (PVI + lines group). Characteristics 
of enrolled patients are shown in the table below. 
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Table 4-1: Baseline characteristics of patients enrolled in the SMAN-PAF randomised controlled trial 
4.3.2. FOLLOW UP  
All bar two patients who underwent ablation completed follow up as planned and 
thereby provided data for analysis. Of those who did not complete follow up, one patient 
reported freedom from symptomatic AF episodes but repeatedly failed to attend any 
follow up appointment after his ablation and did not undergo any ECG monitoring. A 
second patient, with pre-existing Crohn’s disease had a relapse shortly after his 
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ablation. He was hospitalised for this and later underwent extensive surgery.  
Unfortunately, he died from complications of his Crohn’s disease approximately eight 
months after his ablation. Both patients had been randomised to the PVI only ablation 
strategy. 
Six patients, three in each arm, withdrew or were withdrawn from the study after 
randomisation but before ablation had been performed. Of these, in three patients a 
decision was made to switch to medical therapy rather than undergo ablation. In two 
this was because their symptoms were sufficiently controlled on their periprocedural 
antiarrhythmic drug regime and in the other because of presence of left atrial thrombus. 
One patient underwent an alternative intervention. In two patients a new diagnosis of 
hypertrophic cardiomyopathy, an exclusion criteria, was made based on pre-procedural 
imaging. These patients were not included in subsequent analyses. 
4.3.3.  ABLATION PROCEDURES  
The allocated lesion set was attempted in all but one patient according to 
randomisation. One protocol violation occurred where a patient randomised to PVI+ 
lines did not have the additional linear ablation because of a clinical decision by the 
operating consultant.  One further patient had no linear ablation because inability to 
cannulate the coronary sinus meant that it would have not been possible to check line 
integrity using standard pacing manoeuvres, as required by protocol. Two further 
patients, who had there procedure under conscious sedation, had only a partial lesion 
set due to ongoing pain which limited the ability to deliver radiofrequency energy. In 
eight patients allocated to PVI only an additional cavo-tricuspid isthmus line was 
performed because of sustained atrial flutter induced during the procedure.  All patients 
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described above were included in an intention to treat analysis according to their initial 
randomisation. 
Successful isolation of all four pulmonary veins was achieved in 122 (98%) of patients. 
In one patient it was not possible to cannulate the lower veins to check isolation. In two 
patients it was not possible isolate one of the four pulmonary veins (right upper in one, 
and right lower in the other). For those who had additional linear ablation performed, 
bidirectional block was demonstrated for all attempted lines in 50 (82%). In terms of 
individual linear lesions, proven bidirectional block was achieved for 90% (55/61), of 
roof lines 83% (49/59) of mitral isthmus lines, and 96%(65/68) of cavotricuspid 
isthmus lines.  
 
Details of the index procedure for all patients who underwent ablation are given in 
Table 4-2. No repeat procedures were performed within the six month follow up period. 
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Total 
n = 124 
PVI 
n = 61 
PVI + linear 
lesions 
n = 63 
P value 
Procedure 
Time (mins) 
191 ±51 172 ± 44 209 ± 52 <0.001 
Ablation Time 
(secs) 
3435 ±1415 2503 ± 1061 4352 ± 1084 <0.001 
DAP (Gycm2) 3065 ± 4853 2106 ± 1679 3992 ± 6496 0.03 
Fluoro Time 
(secs) 
1356 ± 764 1079 ± 527 1610 ± 858 <0.001 
Wait Time 
(mins) 
62 ± 33 43 ± 16 80 ± 35 <0.001 
General 
Anaesthetic 
49 (40%) 16 (26%) 33 (52%) 0.003 
CT/ MR Merge 84 (68%) 39 (64%) 45 (71%) 0.37 
Sinus Rhythm 
at start 
89 (72%) 43 (71%) 46 (73%) 0.75 
Incomplete 
lesions 
16 (13%) 2 (3%) 14 (22%) 0.002 
Table 4-2: SMAN-PAF Procedural details 
4.3.4. PRIMARY ENDPOINT  
Within the first six months after ablation, excluding events occurring solely within the 
pre-specified blanking period, recurrence of atrial tachyarrhythmia occurred in 11 
patients (18.6%)  in the PVI group and 16 patients (25.4%) in the PVI + lines group 
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following a single ablation procedure. The difference between the groups was not 
statistically significant (p=0.37). 
4.3.4.1. PREDICTORS OF AF RECURRENCE 
Univariable predictors of occurrence of the primary endpoint were sought using binary 
logistic regression analysis. Details of the analysis are given in Table 4-3. Only 
procedural duration and ablation time met the pre-specified inclusion criteria for 
inclusion in the multivariable model. However, neither remained significant on 
multivariable analysis.      
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Variable Univariable analysis Multivariable analysis 
Odds 
Ratio 
95% CI P value Odds 
Ratio 
95% CI P 
value 
Ablation time (mins) 1.02 1.00-
1.04 
0.09 1.01 0.99-
1.03 
0.49 
CHA2DS2 VASc Score 1.14 0.83-
1.58 
0.42    
Current/ Ex smoker 1.72 0.94-
3.14 
0.08    
Diabetes 0.70 0.24-
2.03 
0.51    
Ejection fraction (%) 1.00 0.96-
1.04 
0.86    
Female sex 1.08 0.44-
2.69 
0.86    
General anaesthetic 0.85 0.35-
2.04 
0.71    
Hypertension 0.97 0.41-
2.32 
0.95    
Incomplete lesions 1.32 0.43-
4.05 
0.63    
Left atrial diameter 
(mm) 
1.02 0.94-
1.10 
0.69    
Myocardial infarction 0.29 0.04-
2.38 
0.25    
Persistent AF 1.09 0.45-
2.62 
0.86    
Procedure time (mins) 1.01 1.00-
1.02 
0.03 1.01 1.00-
1.02 
0.13 
Treatment allocation 1.49 0.62-
3.53 
0.37    
Wait time (mins) 1.00 0.99-
1.01 
0.99    
Table 4-3: Binary logistic regression analysis of SMAN-PAF results 
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4.3.5.  SECONDARY ENDPOINTS  
4.3.5.1. COMPARISON OF PERSISTENT AND SUSTAINED PAROXYSMAL ATRIAL FIBRILLATION 
Of the 122 patients who completed follow up, the primary endpoint was observed in 17 
of 75 patients with PeAF and 9 of 47 with SusPAF (22.7% v 19.1%, p=0.64) after a single 
procedure. Although underpowered for subgroup analysis, there was no signal that 
occurrence of the primary endpoint differed between treatment arms according to AF 
type (PeAF (PVI 19.4%, PVI + linear lesions 25.6%, p=0.52) SusPAF (PVI 17.4%, PVI + 
linear lesions 20.8%, p=0.76)). 
4.3.5.2.  PER PROTOCOL ANALYSIS  
As described in Section 0, eight patients randomised to PVI only, also had ablation of the 
cavotricuspid isthmus because of induced typical right atrial flutter. Two patients 
randomised to PVI + linear lesions had only two of the three prescribed linear lesions 
and two had none (effectively treated with a PVI only strategy). To evaluate whether 
this may have affected the primary endpoint, I performed a per protocol analysis of 
patients who received PVI alone against those who received a complete linear lesion set.  
The primary outcome occurred in 14/59 (24%) patients treated with PVI + linear 
lesions and 9 of 53 (17%) patients treated with PVI alone. As with the main intention to 
treat analysis, there was no significant difference between the groups (P=0.38) with 
similar proportions in both analyses. 
4.3.5.3. QUALITY OF LIFE 
The overall AFQT score for the cohort at baseline was 50.7±22.3 which improved 
significantly to 80.9±19.1 six months after ablation (P<0.0001). The improvement after 
ablation was seen in both treatment groups. No significant difference was seen between 
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the study groups, either at baseline (p=0.72), or at the six month follow up visit 
(P=0.54). These results are shown in Table 4-4. 
 Baseline 
Six months’  
follow up 
P value 
(Baseline – 6 months) 
Overall cohort 50.7±22.3 80.9±19.1 P<0.0001 
PVI only 49.8±22.9 82.3±18.0 P<0.0001 
PVI + linear 
lesions 
51.6±22.0 79.4±20.3 P<0.0001 
P value 
(PVI v. PVI + lines) 
0.72 0.54 N/A 
Table 4-4: Overall AFEQT score at baseline and at the six month follow up visit 
Improvement in QoL after ablation was seen both in those who remained free from the 
primary endpoint (50.9±21.9 - 83.1±16.6, P<0.0001) and those patients who suffered 
recurrence of AF (49.8±24.2 – 71.8±25.7, P=0.015). Although the magnitude of 
improvement was greater in those who did not have recurrence, the difference at the six 
month follow up period was not statistically different (71.8±25.7 v. 83.1±16.6, P=0.14). 
4.3.6. SAFETY ENDPOINT  
4.3.6.1. MAJOR COMPLICATIONS 
There were no peri-procedural deaths and no thromboembolic events occurred in the 
peri-procedural period or during follow up. One patient suffered a pericardial effusion 
which was successfully drained percutaneous without persisting sequala. Two femoral 
pseudo aneurysms occurred, both which were successfully treated with direct injection 
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of thrombin. The overall rate of major complications was 2.4% with no difference 
between treatment groups (P=0.62).  
There was one non-cardiovascular death, details of which are given above in Section 0. 
Including this in our pre-specified safety analysis gave an incidence of major 
complications and all cause death of 4.9% (n=3) in the PVI only group and 1.6% (n=1) in 
the PVI + linear lesions group. This difference was not statistically significant (P=0.36) 
4.3.6.2. OTHER COMPLICATIONS 
One procedure was abandoned due to complications of transseptal access but had no 
clinical sequelae and the patient went on to have a subsequent successful procedure. 
Five patients developed haematomas relating to femoral venous access which were 
managed conservatively but which either delayed discharge or prompted subsequent 
readmission. Two patients were admitted with symptoms of heart failure follow their 
procedure both of whom were successfully managed medically. Including major 
complications, all cause death and minor complications gave an incidence of 9.7%, with 
no difference between the treatment groups (PVI 8.2%, PVI + linear lesions 11.1%, 
P=0.76). 
4.4. DISCUSSION  
Our study was powered based on an assumption of freedom from the primary endpoint 
after a single procedure being achieved in 80% of patients in the PVI + linear lesions 
group and 55% of the PVI group at 6 months. Overall, 78.7% of patients remained free 
of AF - very close to the upper limit of what we believed possible with either strategy 
with a non-significant 5.2% difference in favour of the less extensive strategy (the 
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opposite direction to that which we had predicted). This finding was not affected by 
whether patients had PeAF or SusPAF. 
 
When a study produces an unexpected non-significant result there are several 
important questions to ask. Firstly, was the original expectation on which the sample 
size was calculated reasonable and, secondly, was the study underpowered. If the 
answers to these questions confirm that the trial methodology was robust then we need 
to look back at differences with previously published studies which may explain the 
findings. 
 
We designed the trial expecting that additional linear lesions would reduce recurrence 
of AF compared to PVI alone in patients treated with peri-procedural antiarrhythmic 
drugs. This assumption was derived from local audit data but was in keeping with 
published literature. Our trial population was patients with PeAF and those with an 
advanced form of PAF causing sustained episodes of PAF, likely to be associated to an 
abnormal left atrial substrate and therefore more akin to PeAF than purely trigger-
based PAF. This specific patient group has never been studied previously. Three studies 
have previously trialled a pulmonary vein isolation technique with against one 
involving additional linear ablation in patients with PeAF.106,107,131 I performed meta-
analysis of the patients with PeAF included in these studies in my introductory Chapter 
and found that addition of linear lesions significantly and substantially reduced the risk 
of recurrence (OR 0.22, 95%CI 0.10-0.49, p<0.001).142   In two of these studies which 
included both patients with PAF and PeAF a significant difference between treatment 
arms was seen in both subgroups. My initial assumption would therefore appear to have 
been a reasonable one.  
  Page 136 of 266 
The sample size calculation, and thus the trial’s “power” to detect a difference between 
groups, was made using conventional values for α and β error (5% and 20% 
respectively) and an expected between-group difference of 25%.  Of the three studies 
discussed above the mean difference between treatment arms was 33%, similar to the 
value we used in our calculation. Looking solely at patients with PeAF, the mean 
difference between groups was 36%. Therefore, whilst the effect size we anticipated 
was large, it was entirely in keeping with the available evidence.  When one talks of a 
trial’s power, one is referring to its ability to avoid incorrectly failing to reject the null 
hypothesis when, in fact, a true difference exists between the groups being studied (a 
type II error). From our results, if the null hypothesis is false it would appear to be 
because PVI alone is superior to performing additional linear lesions. Therefore, I 
believe our study did not find a beneficial effect of additional linear lesions because one 
does not exist rather than because our sample was too small.  
 
From our study we cannot say whether the slightly lower recurrence rate seen in the 
PVI group (18.6% v 25.4%) represents a true difference between groups. However, the 
magnitude of the difference seen (7%) is sufficiently small that, if true, a study design 
containing over 2000 patients would be required to prove it. Given that a PVI only 
strategy entails shorter procedure times, ablation times, and lower radiation doses, I do 
not believe it is necessary to prove that the strategy is superior. If the two are 
equivalent then these ancillary benefits are sufficient for it to be the strategy of choice 
for clinicians.  
 
Why then, do our results differ so markedly from those I reviewed in the introductory 
Chapter? The answer may be due to the means of pulmonary vein isolation. As 
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discussed in the introduction to this Chapter, isolating the veins using WACA – as we did 
for all patients – involves ablation of a significant amount of antral atrial, rather than 
venous, tissue.118 This may well have an additional substrate modification effect over 
and above pure venous isolation. In my earlier meta-analysis I found that studies 
looking at WACA compared to segmental isolation showed a non-significant trend 
towards  lower incidence of AF recurrence with the former (OR 0.41, 95%CI 0.15-1.10, 
p=0.08). Previous studies of linear lesions in addition to PVI did not use a WACA 
technique. Gaita et al. performed ablation of ostial vein potentials, with encircling, 
segmental ablation only performed if electrical isolation not achieved.107 Similarly 
Fassini performed electrical disconnection of the veins with non-encircling lesions, 
guided by electrogram mapping.106 Willems did isolate the veins anatomically, as well as 
electrically, but used segmental isolation of individual vein ostia meaning that 
considerably less, potentially important, antral atrial tissue was ablated.131 It may be 
that modifying atrial substrate with linear lesions is of benefit only when the ablation 
around the pulmonary veins is limited. Performing WACA of ipsilateral vein pairs may 
sufficiently alter the atrial substrate, nullifying any potential effect of linear lesions.  
One aspect of this study, which is unique from other such studies mentioned above, is 
the universal use of peri-procedural AAD use. Although this strategy is common in 
clinical practice, AADs have been stopped at or before the time of CA in previous clinical 
trials of linear ablation. A benefit of continuing AAD was suggested by a number of 
observational studies, which contributed to our trial design.124,179 However, the recently 
published AMIO-CAT RCT found no benefit of 8 weeks’ amiodarone in 212 patients with 
either PAF or PeAF, followed up for 6 months, as in our study.190  Although the AMIO-
CAT study suggests no absolute benefit from peri-procedural AAD, I cannot say whether 
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our use of this strategy reduced the benefit that would have been seen of one study 
group of the other in this trial. 
 
Another unique aspect of my study is the inclusion of patients with SusPAF. The 
decision to include this group was based partly on our belief that the distinction 
between PAF and PeAF is not clear cut, rather that it is a continuum between 
predominantly trigger-based and predominantly substrate-based atrial disease. As 
described in Chapter 3, patients required both prolonged (>12 hours) episodes of PAF – 
longer than would necessarily be expected if AF is simply driven by automatic 
pulmonary vein ectopy, and an additional comorbid condition that has previously been 
shown to be associated with abnormal atrial remodelling (substrate). The Substrate and 
Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF) trial similarly included 
both patients with PeAF and “advanced” PAF.130 Our subanalyses, presented in Section 
0, did not suggest that inclusion of the SusPAF group altered the overall primary finding 
of our trial and the similarity of results between the groups would seem to back our 
assertion that patients with SusPAF have a similar disease process to those with PeAF. 
 
The concept of time-lag bias may also apply, whereby early studies of a new 
intervention tend to be positive, with negative results only emerging later.191 This 
concept is well established and has been demonstrated in a number of areas of medical 
research.192 Although my results differ from those included in my earlier analysis, they 
tally more closely with a trial not published yet in full but recently presented at the 
European Society of Cardiology in September 2014, The STAR AF 2 trial is a large multi-
centre study of patients with PeAF.193 Like us they tested PVI alone against PVI + linear 
lesions and, in a third arm, PVI + complex electrogram ablation. Like us they found that 
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freedom from AF was slightly more common in the PVI only group than in the more 
extensive ablation groups (59% for PVI v 44% for linear ablation and 48% for PVI plus 
electrograms, p=0.15). Taken together, these two trials reopen the question as to 
whether additional ablation is of benefit in PeAF and whether any possible benefit 
outweighs the additional procedure time and radiation exposure.   
4.4.1.  LIMITATIONS  
Undoubtedly a limitation of the results we present is the short duration of follow up.  
This is very likely to overestimate the overall long-term benefits of ablation. Gaita et al. 
included in their paper, study outcomes at both one and three years.107 They found that 
the between group effect size in patients with PeAF did not differ greatly with extended 
follow up (18% at one year compared to 22% at three years). Although a greater change 
was seen in patients with PAF (11% to 24%), the direction of the effect was unchanged, 
suggesting it is unlikely that longer follow up would have allowed us to reject the null 
hypothesis in favour of PVI plus linear lesions.  
It is important to bear in mind that our results should not be extrapolated to other 
groups. Brooks et al. performed a comprehensive review of studies of patients with long 
standing PeAF.194 They found low success rates in, mainly non-randomised, studies 
using a PVI only strategy.  Based on this review, the current international consensus 
document recommends the use of more extensive lesion sets than PVI alone. It was on 
this basis that patients with longstanding PeAF were excluded from our study. 
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4.5. CONCLUSION  
Over six months’ follow up, in patients with non-permanent substrate-based AF treated 
with peri-procedural AADs, significant QoL benefits can be achieved with approximately 
80% of patients rendered free of recurrent atrial tachyarrhythmia. The addition of 
linear ablation lesions, to a strategy of pulmonary vein isolation with wide area 
circumferential ablation, requires significantly more ablation; increasing procedure 
duration and prolonging fluoroscopy time, but provides no clinical benefit. 
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5 .  I M P R O V I N G  P A T I E N T  O U T C O M E S  B Y  
B E T T E R  U N D E R S T A N D I N G  A B L A T I O N  
L E S I O N  Q U A L I T Y :   
A  N O V E L  M A R K E R  T O  P R E D I C T  E A R L Y  
R E C U R R E N C E  A F T E R  A T R I A L  F I B R I L L A T I O N  
A B L A T I O N ;  T H E  A B L A T I O N  
E F F E C T I V E N E S S  Q U O T I E N T  
5.1. INTRODUCTION  
In earlier Chapters of this thesis I have examined the efficacy of catheter ablation (CA) 
of persistent atrial fibrillation (AF), both in the published literature and from our local 
experience. In Chapter 2 we found that, aside from CT image integration, there were no 
consistent predictors of clinical success. This is in keeping with previously published 
literature.195 The inability to either reliably identify those patients who are likely to do 
well after ablation, or to predict when acute success will be maintained in the longer 
term remains the procedure’s Achilles’ Heel.  When patients with recurrence return to 
the catheter laboratory for a repeat procedure they are almost invariably found to have 
electrical conduction across an ablation lesion initially thought to be intact at the 
original procedure.196 Recent data have shown that ablation lesions in any given 
segment are only as effective as the ‘worst’ ablation performed in that segment.197  
Cardiac Troponin T (cTnT) is released when myocardial cell death occurs and the level 
detectable in the bloodstream correlates with the mass of necrotic cardiac 
myocytes.198,199 Serum cTnT is the most reliable marker of myocardial damage after AF 
ablation.200,201 The high sensitivity assay (HScTnT) is an order of magnitude more 
sensitive than previously-available commercial assays.202 Theoretically it might be 
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expected that there would be a strong linear relationship between the amount of 
ablation performed and the post-procedural release of HScTnT and other cardiac 
specific biomarkers. However this is not always the case and studies have produced 
contradictory findings in terms of the relationship between cardiac Troponin levels 
post-PVI and clinical outcome.203,204 We postulated that this may be because some of the 
ablation lesions are ineffective due to poor tissue contact or ablation of previously 
ablated areas, and that the ratio of post-ablation HScTnT levels to the total ablation time 
would be a better indicator of the ‘quality’ of radiofrequency (RF) ablation delivered 
during the PVI procedure. We termed this novel ratio the Ablation Effectiveness 
Quotient (AEQ). We hypothesized that a high AEQ would correlate directly with 
freedom from early (<6 months) recurrence of AT. 
5.2. METHODS  
5.2.1. PATIENTS  
The study population consisted of a subset of 60 patients undergoing first-time AF 
ablation at one of the contributory centers (Liverpool Heart and Chest Hospital) of the 
SMAN-PAF randomized controlled trial, presented in Chapter 4. Briefly, this is a 
prospective, two-way, multicenter randomized controlled single-blinded trial for 
patients with either persistent AF (PeAF) or sustained episodes of paroxysmal AF (PAF). 
Patients received either PVI alone (PVI), or PVI plus additional linear ablation (PVI+). 
Exclusion criteria included a reversible cause for AF, prior ablation for AF, prosthetic 
mitral valve replacement and hypertrophic or infiltrative cardiomyopathy. Patients with 
documented typical right atrial flutter were excluded as it was felt to be potentially 
unethical to randomize them to a PVI only strategy. Although included in the main trial, 
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patients with moderate or severe left ventricular systolic dysfunction on 
echocardiography were excluded from this study because of the possible effect on 
troponin levels.205 
5.2.2. ABLATION PROCEDURE  
CA was performed under conscious sedation or general anesthesia in a standard 
manner.183 Following transseptal access, an electroanatomical map of the left atrium 
was created and, where available, integrated with a magnetic resonance (MR) or 
computed tomography (CT) reconstruction of the atrium using a 3D navigation system 
(CartoMerge; Biosense Webster, Diamond Bar, California). Using a 3.5 mm irrigated-tip 
radiofrequency ablation catheter (Thermocool or Thermocool Smarttouch; Biosense 
Webster, Diamond Bar, California)  a series of lesions  at least 2 mm outside the 
pulmonary vein (PV) ostia were made to encircle and electrically isolate the PVs in two 
ipsilateral pairs (wide area circumferential ablation (WACA))184 using a catheter drag 
technique with the end-point of individual lesions being >75% signal attenuation. A 20-
pole PV mapping catheter was used to confirm electrical isolation. In keeping with 
published guidance, pulmonary vein isolation was defined as proven entrance block 
with testing for exit block permitted but not mandated.14 Testing with adenosine was 
not routinely performed. If the patient was in AF at this stage, sinus rhythm was 
restored with intra-procedural electrical cardioversion and isolation of the PVs was 
confirmed in sinus rhythm. For those patients randomized to receive additional linear 
ablation lesions, these were delivered once PVI had been achieved. These consisted of a 
left atrial roof line, mitral isthmus line (including ablation inside the coronary sinus if 
necessary), and cavotricuspid isthmus ablation. The end point was conduction block 
across all three lines as verified with appropriate pacing manoeuvres.206 For all patients, 
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a minimum waiting time of 30 minutes from last PV isolation was mandated following 
complete isolation of the PVs before verification of PVI could be made. Acute procedural 
success was defined as electrical isolation of all PVs and bidirectional block 
demonstrated across any linear lesions. All patients were monitored overnight and 
discharged the following day.  
5.2.3. ABLATION EFFECTIVENESS QUOTIENT (AEQ) 
HScTnT was measured in all patients between 12 and 18 hours following the ablation 
procedure during which time period HScTnT levels have been described as having 
reached a stable peak.207,208 Baseline HScTnT measurements were performed in a 
random selection of patients at the time of recruitment. Blood samples were analyzed 
using the Elecsys electrochemiluminescence immunoassay (Cobas, Roche Diagnostics 
GmbH, Mannheim, Germany) in an accredited on-site diagnostic laboratory. The assay 
employs two monoclonal antibodies specifically directed against human cTnT and 
provides a precise and reliable measure of cardiac myocyte necrosis.209,210 Ablation time 
was recorded automatically by the electrophysiology recording system (LabSystem Pro, 
BARD Electrophysiology, MA). AEQ was defined as the ratio of HScTnT, measured in 
ng/L, to total ablation time, measured in seconds.  
5.2.4. FOLLOW-UP AND ARRHYTHMIA MONITORIN G  
All patients received anti-arrhythmic drug therapy with either amiodarone or flecainide 
for at least 6 weeks before their ablation and this was continued for six weeks after, at 
which point it was stopped. Mandatory study follow-up visits were performed at three 
and six months post-ablation and additional clinical visits were permitted as required. A 
12-lead resting ECG and 24 hour ambulatory ECG (Holter) monitoring were performed 
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at all study visits. Additional 7-14 day symptom-activated ambulatory ECG monitoring 
was performed as required for patients with intercurrent symptoms suggestive of AT. 
Monitoring ECG traces were assessed initially by an experienced cardiac physiologist 
and then reviewed by a clinician. In case of uncertainty, a second review was performed 
by an experienced electrophysiologist. All assessors were blinded to treatment 
allocation. 
5.2.5. STUDY ENDPOINT  
The primary endpoint was defined as documented AT (AF or other atrial 
tachyarrhythmia) at six months following a single procedure. In accordance with 
published guidance, an episode of AT had to last more than 30 seconds and be 
documented on resting or ambulatory ECG to qualify as a primary endpoint.162,206 
Episodes of AT occurring entirely and solely within three months of the index ablation 
procedure were not counted as recurrence of AF.162,206 
5.2.6. STATISTICAL ANALYSIS  
Analyses were performed using IBM SPSS Statistics software version 21 (IBM Corp., 
Armonk, New York). Continuous data are presented as mean ± standard deviation and 
compared using unpaired t-tests or median (interquartile range) and compared using 
Mann-Whitney U test. Categorical data are presented as number and proportions and 
were compared using the χ2 statistic or Fisher’s exact test if expected frequencies were 
too small for χ2 (less than 5 for any individual cell).  Linear regression was used to 
compare the relationship between HScTnT and ablation time and logistic regression 
was used to compare the relationship between each of these variables and the primary 
outcome.  Correlation was assessed using Pearson’s correlation coefficient. The 
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Receiver Operating Characteristic (ROC) was used to assess the potential for AEQ to 
predict clinical outcome.  Where applicable, two-tailed tests were used in all analyses. A 
P value of 0.05 or lower was considered significant for all tests. 
5.3.RESULTS  
5.3.1. PATIENT CHARACTERISTICS  
Sixty patients were included in the study. Their baseline characteristics are shown in 
Table 5-1. Forty-two patients (70%) were male and 22 (37%) had PAF. The mean age 
was 62.5 years (range 40-87). All patients were white Caucasian. All 240 pulmonary 
veins were successfully isolated at the time of the index ablation. It was not possible to 
achieve bidirectional block across the mitral isthmus line in four patients (three without 
recurrence, one with) nor across the left atrial roof line in two patients (neither of 
whom had arrhythmia recurrence). Overall the rate of acute procedural success, defined 
as isolation of all veins and bidirectional block across any attempted linear lesion was 
90%. Within the follow up period of the study, 20 patients (33%) had a documented 
arrhythmia recurrence and 40 patients (67%) did not. Mean creatinine was equal in 
both groups (0.99±0.17 v. 0.99±0.22, P=0.97) and no patient had an estimated 
glomerular filtration rate (eGFR) less than 30 mL/min/1.73m2. The mean baseline 
HScTnT level was 6±2.1ng/L and none had a level above the upper reference limit (99th 
percentile) for the high sensitivity assay (14 ng/L). Performance of intraprocedural DC 
cardioversion had no significant effect on the mean post-ablation HScTnT level 
(1388±788 ng/L vs. 1251±594 ng/L, P=0.45).  
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Characteristic Total 
(n=60) 
Recurrence 
(n=20) 
No 
Recurrence 
(n=40) 
P value 
Age (years) 62.5±10.6 63.1±11.7 62.3±10.1 0.79 
Male Sex   42 (70.0%) 14 (70%) 28 (70%) >0.99 
Paroxysmal Atrial 
Fibrillation 
22 (36.7%) 9 (45%) 13(32.5%) 0.34 
Left Atrial size (mm) 42.3±6.2 43.9±5.8 41.5±6.3 0.17 
Body Mass Index (Kg/m2) 29.5±4.6 29.8±6.0 29.4±3.4 0.76 
Serum Creatinine 
(mg/dL)  
0.99±0.21 0.99±0.17 0.99±0.22 0.97 
Hypertension  35 (58.3%) 9 (45%) 26 (65%) 0.14 
Diabetes  3 (5.0%) 1 (5.0%) 2 (5.0%) >0.99 
CHA2DS2-VASc  1 (1-2.5) 1.5 (0.5-2) 1 (1-3) 0.87 
HScTnT (ng/L ) 1307±675 1175±706 1372±658 0.29 
Ablation time (secs)  3237±1245 3428±1336 3171±1205 0.46 
PVI only  29 (48.3%) 9 (45.0%) 20(50.0%) 0.72 
Waiting time (minutes)  58.3±25.2 53.0±20.6 60.0±27.4 0.27 
Intraprocedural DCCV  24 (40.0%) 11 (55.0%) 13 (32.5%) 0.09 
General anaesthesia 16 (26.7%) 6 (30%) 10 (25.0) 0.68 
Table 5-1: Baseline characteristics for AEQ analysis. Continuous variables are presented as mean ± standard 
deviation or median (interquartile range); discrete variables as n (%).PVI: Pulmonary Vein Isolation, 
HScTnT: High sensitivity Cardiac Troponin T, AEQ: Ablation Effectiveness Quotient, DCCV: Direct current 
cardioversion 
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5.3.2. PRIMARY OUTCOME  
Mean AEQ was significantly lower in those with recurrence (0.35±0.14 ng/L/s) than 
those with clinical success (0.45±0.18 ng/L/s, P=0.02). Although there was a positive 
linear relationship between HScTnT and ablation time as assessed by Pearson 
correlation, the correlation coefficient was only moderate (r= 0.512). There were no 
significant differences in the mean HScTnT levels and mean ablation times in patients 
who had AT recurrence compared to those who did not (Table 5-1). Univariate logistic 
regression showed that AEQ was the only significant predictor of AT recurrence 
(P=0.03) (Table 5-2).   
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Variable Odds Ratio (95% Confidence 
Interval) 
P value 
Age (years) 1.01 (0.96-1.06) 0.78 
Body Mass Index 
(Kg/m2) 
1.02 (0.89-1.18) 0.76 
Serum Creatinine 
(mg/dL) 
1.06 (0.72-15.49) 0.97 
Paroxysmal atrial 
fibrillation 
1.70 (0.57-5.11) 0.35 
Left Atrial Size (mm) 1.07 (0.97-1.17) 0.17 
CHA2DS2-VASc Score 0.94 (0.61-1.44) 0.94 
PVI only 0.82 (0.28-2.40) 0.72 
Waiting time (mins) 0.99 (0.96-1.01) 0.26 
Ablation Time (per 100 
secs) 
1.02 (0.97-1.06) 0.31 
HScTnT (per 100 ng/L) 0.95 (0.87-1.04) 0.29 
AEQ (per 0.01 ng/L/s) 0.96 (0.92-0.99) 0.03 
Table 5-2: Univariate logistic regression analysis for predictors of recurrence of atrial tachyarrhythmia after 
atrial fibrillation ablation. PVI: Pulmonary Vein Isolation, HScTnT: High sensitivity Cardiac Troponin T, AEQ: 
Ablation Effectiveness Quotient 
5.3.3. COMPARISON OF ABLATION STRATEGIES  
Patients who underwent PVI plus linear ablation (PVI+) had both higher mean ablation 
times (4135±980 vs. 2361±839 secs, P<0.001) and HScTnT levels (1619±733 vs. 
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954±394 ng/L, P<0.001) than those who underwent PVI alone.  There was no difference 
in mean AEQ for patients having PVI alone compared to PVI+; either overall (0.43±0.16 
(PVI) vs. 0.40±0.19 (PVI+), P=0.6), or grouped by whether they had recurrence 
(0.36±0.11 (PVI) vs. 0.34±0.17 (PVI+), P=0.7) or clinical success (0.46±0.18 (PVI) vs. 
0.45±0.19 (PVI+), P=0.9). 
5.3.4. COMPARISON WITH CONTACT FORCE READINGS  
For the 20 patients for whom contact force data was available the mean contact force 
during ablation was 11.2±4.3g. There was no significant correlation between average 
contact force and AEQ (P=0.14). In addition the mean contact force was not statistically 
different for those patients in the success group from those with recurrence (11.0 ± 5.2g 
vs. 11.8 ±2.8g, P=0.69). 
5.3.5. REPEAT PROCEDURES  
Twelve patients with recurrence underwent repeat ablation. Of these, eleven had 
reconnection of at least one pulmonary vein and only one patient, who had a history of 
PeAF and had received PVI only, had persisting isolation of all four pulmonary veins. 
This patient had an AEQ of 0.47, compared to a mean AEQ of 0.36±0.16 for the 11 
patients with PV reconnection. 
5.3.6. SUB-GROUP ANALYSIS  
Sub-group analysis was performed by AF type. In patients with PeAF, there was no 
difference in mean AEQ between those with and without recurrence (0.39±0.17 vs. 
0.44±0.18 ng/L/s, P=0.44). However, in PAF patients, mean AEQ was significantly lower 
for those with recurrence compared to those without (0.30±0.07 vs. 0.49±0.18 ng/L/s, 
P=0.003, Figure 5-1). Logistic regression was performed for the sub-group with PAF, 
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using the same range of covariates as for the full cohort. As in the full cohort, AEQ (OR 
[per 0.01 ng/L/s] 0.87 (95% CI 0.78-0.98) p=0.02) was the only significant univariate 
predicator, with all other covariates failing to show significance. 
 
Figure 5-1: Box and Whisker chart of AEQ and early recurrence of atrial tachyarrhythmia in patients with 
paroxysmal atrial fibrillation. Thick line represents the median value, the box represents the interquartile 
range and whiskers represent inner fences (1.5x box height). Cases outlying the inner fences are marked 
with open circles. 
5.3.7. EXTENDED FOLLOW UP  
Having established that AEQ appears of value in PAF, but not in PeAF, we extended the 
follow up of patients with PAF to twelve months post ablation. During this medium term 
follow up period one additional patient had AT recurrence. Mean AEQ was significantly 
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lower in those with recurrence at 12 months (0.33±0.12 ng/L/s) than those with 
clinical success (0.48±0.18 ng/L/s, P=0.035). 
5.3.8. AEQ  TO PREDICT CLINICAL OUTCOME IN THE MEDIUM TERM IN PAROXYSMAL AF 
For the cohort with PAF, the ability of AEQ to predict AT recurrence was assessed using 
ROC analysis. The area under the curve (AUC) was very high both at six months (0.88) 
and with extended follow up to twelve months (0.80, Figure 5-2) suggesting good 
discriminative ability at both time points. Nine of twelve patients with an AEQ below 0.4 
ng/L/s had recurrence. In contrast, AT occurred in only one of the 10 patients with a 
higher AEQ.  An AEQ cut-off value of >0.4 ng/L/s had a sensitivity of 75% (95% CI 0.43-
0.93) and a specificity of 90% (95%CI 0.54-0.99)  in predicting freedom from 
recurrence in PAF (positive predictive value 90% (95%CI 0.54-0.99)  negative 
predictive value 75% (95% CI 0.43-0.93)) although the small sample size means these 
figures should be treated with caution.  
  Page 153 of 266 
 
Figure 5-2: Receiver Operating Characteristic (ROC) curve for AEQ as a predictor of freedom from recurrence 
of atrial tachyarrhythmia over 12 month follow up in patients with paroxysmal atrial fibrillation. 
5.4. DISCUSSION  
Achieving durable electrical isolation of the PVs is the goal of most AF ablation 
procedures.206 Although acute PV isolation can be achieved in almost all cases, it is 
unusual to ﬁnd no evidence of return of PV conduction at the time of repeat procedure 
for patients with AT recurrence.206 The major contributory factor to PV recovery is 
thought to be ineffective ablation producing extracellular oedema that mimics tissue 
necrosis but produces only temporary electrical changes. In contrast, cTnT is only 
released following irreversible cell death.198  The concept of AEQ stems from the idea 
that effective ablation lesions are likely to be those where rapid cell death occurs before 
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the formation of significant edema. Such lesions would be expected to have a higher 
chance of being transmural and observed electrical endpoints more likely to be 
permanent. Our results do appear to support this novel hypothesis.     
 
Our results strike accord with recent findings from the EFFICAS 1 study which 
suggested that an initial non-transmural ablation lesion may make it difficult to achieve 
transmurality with further ablation at the same site.197  At present our results can be 
considered only proof-of-concept and require validation in larger populations. However 
AEQ is a novel, simple measure which provides new insight into why AF ablation 
succeeds or fails and may, eventually, be a useful clinical tool. 
At the time of the procedure, the integrity of any linear or encircling ablation lesion is 
based on the extent to which it is possible to demonstrate that electrical conduction 
across the lesion no longer occurs. The limitation is that it is not truly possible to test 
the integrity of an ablation lesion until the entire lesion set is complete. By that point 
edema is already likely to have developed at points of ineffective ablation and repeated 
attempts to re-ablate these areas may not result in true long-lasting transmurality. 
Indeed, the EFFICAS 1 study found that the average number of ablations per segment 
was inversely correlated with isolation.197  If the initial lesion is not transmural, edema 
occurs that not only mimics tissue necrosis in terms of acute electrical isolation but also 
increases wall thickness by up to 100%.211,212 This tissue swelling reduces the effect of 
tissue heating and makes it difficult to achieve full transmurality with subsequent 
ablations.197 Neuzil and colleagues recently stated that the goal of any RF ablation 
should be to achieve transmurality with the first attempt but as yet there is no means of 
ensuring or measuring this.197 Whilst AEQ cannot be used to ensure the quality of 
ablation in real time it may be a way of assessing it subsequently.  
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Our study shows that AEQ correlates very well with early clinical success in patients 
with PAF, but not in patients with PeAF. The reason for this discrepancy most probably 
relates to the abnormal atrial substrate that is more prevalent in the latter.18  In PAF, 
isolating the PVs effectively eliminates arrhythmia triggers.213   However, in PeAF even 
effectively delivered ablation lesions around PVs will not target the variety of extra-
pulmonary triggers, re-entrant wavelet circuits and rotors that may be important in this 
population.23,214 Only one of our patients was observed to have persisting isolation of all 
PVs at the time of his repeat procedure for recurrence. It is a notable observation that 
this patient had PeAF and a relatively high AEQ of 0.47, illustrating that even effective 
ablation, both in terms of AEQ and enduring lesions, in this group of patients may not 
guarantee freedom from recurrence. 
 
The ablation time is a fairly crude measure of amount of RF energy delivered. The 
development of catheter contact force technology and software developments within 
electroanatomical mapping systems allow measurement of the force-power-time 
integral which may provide further refinement to the AEQ concept.  In our study we 
found no relationship between average contact force and either AEQ or clinical success. 
This is likely to be due, at least in part, to the manner in which contact force data was 
recorded. Ablation markers were placed onto the electroanatomical map manually and 
these recorded only the contact force at the moment the marker was created. They 
therefore capture only a very limited snapshot of the true lesion being delivered. A 
more accurate mean of recording lesion contact force may well have yielded different 
results. Our ongoing study using a new facet of the Carto 3 mapping system, Visitag, will 
allow further exploration of the relationship between AEQ and both the total energy 
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delivered (cumulative force-power-time) as well as the quality of lesions at repeat 
electrophysiology study for both those with and without clinical recurrence of AF 
(http://clinicaltrials.gov/show/NCT01942408). In addition only a small number of 
patients were included in this post-hoc subanalysis which substantially reduces its 
power to detect a significant result. Our abovementioned prospective validation study 
should provide much greater clarity of this issue. 
5.4.1. POTENTIAL CLINICAL IMPLICATIONS  
The lack of durability of PVI continues to be an important issue that impacts on single-
procedure success rates.215 At present there is no way to identify those patients acutely 
following ablation whose PVI is likely to endure and thus who are likely to remain 
arrhythmia-free on follow up. Our study provides a preliminary investigation into the 
potential of AEQ in this regard.  However, it appears that patients with PAF with high 
AEQ are at considerably lower risk of AF recurrence. If our findings are confirmed in 
future studies, it may be that patients with high AEQs can be discharged after only 
limited follow-up. This would be both economically beneficial and reassuring to patient 
and physician alike. Conversely, it may be that patients with a low AEQ should be 
monitored more intensively and have a low threshold for further interventional 
therapy. It may be preferable to maintain anti-arrhythmic and/or anticoagulant therapy 
in the long-term in these patients.  
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5.4.2. LIMITATIONS  
This was an exploratory study of a novel hypothesis regarding how we define an 
effective ablation lesion, in the setting of a procedure that has almost universal acute 
success but considerable rates of late failure in terms of arrhythmia recurrence. As such, 
at this stage it has to be considered as hypothesis generating until verified in larger, 
more uniform cohorts. That notwithstanding, the fact that such a simple measure can 
produce significant results seems, to us, worthy of further study and discussion. The 
simplicity of AEQ is also a potential weakness. If all but one of the RF lesions along the 
WACA are effective and transmural, the AEQ would be expected to be high even if the 
one suboptimal RF application subsequently resulted in vein reconnection and 
recurrent arrhythmia. Conversely, even if the entire WACA lesion set has been 
completed effectively in the ‘first-pass’, considerable unnecessary ablation could still be 
delivered subsequently, thereby lowering the AEQ. This might happen if there is initial 
failure to recognize a far-field signal as such in an isolated vein, or while performing 
extra-PV ablation in a patient with purely PV-trigger driven AF. This limitation may 
partially explain the inconsistent outcomes for patients with moderate to low AEQ 
levels in our study. Assessment of myocardial scar within the left atrium and of ablation 
lesion quality by cardiac magnetic resonance scanning may have provided additional 
useful information. However, at present these techniques have not been shown to be 
reliable or reproducible.216 A significant proportion of our study patients underwent 
electrical cardioversion during their PVI procedure. Although this may have had a minor 
influence on troponin levels we did not find evidence of this, in keeping with previous 
work.204 Although we measured baseline HScTnT in only a small sample of our patients, 
the magnitude of the levels seen after ablation compared to the low levels found in a 
normal population (<14ng/L) and the levels we found at baseline (6±2.1ng/L) means 
  Page 158 of 266 
that variations in baseline levels are likely to have had negligible impact on post-
procedural HScTnT level and therefore on AEQ.  Our findings show that the relationship 
between AEQ and clinical success is much stronger in PAF than PeAF. Future work, such 
as the ongoing study mentioned above, which minimizes patient heterogeneity, may 
allow clearer understanding of the relevance of the AEQ.  
5.5. CONCLUSION  
The AEQ is a simple, novel means of assessing lesion quality after AF ablation. In 
patients with PAF, a high AEQ appears to correlate well with freedom from early AF 
recurrence. Short term results appear to be maintained to at least one year post 
ablation. 
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6 .  I M P R O V I N G  P A T I E N T  O U T C O M E S  B Y  
I M P R O V I N G  S A F E T Y :   
A  P R O S P E C T I V E  S T U D Y  O F  T H E  U S E  O F  
U L T R A S O U N D  T O  G U I D E  V A S C U L A R  A C C E S S  
F O R  C A T H E T E R  A B L A T I O N  F O R  A T R I A L  
F I B R I L L A T I O N  
6.1. INTRODUCTION  
In earlier Chapters of this thesis I have concentrated on the outcome of freedom from 
recurrent AF. However, as discussed in the thesis introduction, this is not the only 
outcome of relevance to patients.  In 2012 the European Society of Cardiology clearly 
stated in their updated guidelines on the management of AF that, “improving safety of 
catheter ablation should be a primary goal in the further development of this therapy”51. 
As mentioned previously, two large worldwide surveys of the methods, efficacy, and 
safety of catheter ablation (CA)147,148 published in 2005 and 2010 showed a dramatic 
increase in the number of CA procedures being performed over this period. This 
increase in operator experience, accompanied by improved techniques and technology, 
led to a reduction in the overall procedural complication rate from 5.9% to 4.5%. 
However, complications relating to vascular access actually increased from 0.9% to 
1.5% of procedures. Vascular complications were also the most frequently observed in 
the SMAN-PAF trial, presented in Chapter 4. Furthermore published surveys/registries 
reported only the most serious of vascular complications, unavoidably leading to an 
underreporting of the true incidence. A previous study found that physicians 
significantly underreported procedural complications when compared to what patients 
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themselves perceived (4.5% v. 24%) and that patient reported complication rate rose 
even further (32%) if post-discharge reporting was encouraged217 .   
The use of two-dimensional ultrasound has become standard practice within fields such 
as anaesthesia and nephrology to improve the safety and success rates of venous 
cannulation 218. Three prospective studies using ultrasound compared to an anatomical 
approach have all showed reduced complications and improved success rates in a 
diverse spectrum of patients 219-221. A number of retrospective studies showed 
improved procedural outcomes, such as time to cannulation or successful cannulation 
and non-significant trends towards reduced complications 222-224.  None showed any 
detrimental effect of ultrasound guidance.  A summary of published studies is provided 
in Table 6-1. Vascular ultrasound has not, however, been widely adopted in 
interventional electrophysiology and consequently there are no studies investigating its 
potential safety benefits for CA.  
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Reference  Study type Population  N  Outcome  Finding  
(US v 
Anatomical)  
Farrell 
1997222   
Retrospective Dialysis (IJV)  69  First attempt  83% v 36% 
P<0.0001  
  Dialysis (FV)  30  First attempt  86% v 56% 
P=NS  
Iwashima 
2008 221   
Prospective, 
non-
randomised 
Paeds (FV)  87  Art puncture  7%  v 32% 
p<0.01  
Kwon 
1997 223   
Prospective 
with historical 
controls 
Dialysis (FV)  66  First attempt  93% v 55% 
P<0.05  
Hilty 1997 
219   
Prospective 
RCT 
CPR (FV)  20*  Success  90% v 65%, P 
= 0.06 
     Art puncture  0% v 20% 
p=0.03  
Prabhu 
2010 220  
Prospective 
RCT 
Dialysis (FV)  110  Complication  6% v 18% 
p=0.04  
Dudeck 
2004 225  
Prospective 
RCT 
Angiography 
(FA)  
112  Complications  NS difference  
  Weak pulse  42  Attempts  1.8 v 3.1 p < 
0.05 NNT = 2  
  Leg >60cm  23  Attempts  1.0 v 2.3 p < 
0.001 NNT = 2  
Zollo 
2001224  
Retrospective Dialysis (FV) 230 
(anat) 
v 38 
(US) 
Art Puncture 2.6% v 
11.2%**  
    Haematoma 0% v 3.9% 
NICE TAG 
49226  
Review/ 
Guideline 
Pooled (IJV)   Complications  57% RRR, 
95% CI 13% -
78%, p = 0.02  
Table 6-1: Studies of the use of vascular ultrasound to assist cannulation of the Femoral (FV) or Internal 
Jugular Vein (IJV). Where specific p values are stated as NS (not significant) this reflects manuscripts that did 
not report numeric values. RCT = Randomised controlled trial. * Patients had bilateral line insertion and 
acted as their own controls 
We hypothesized that the conventional definition of vascular complications 
underestimates the true incidence of patient-reported significant vascular access events 
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following CA, and that the routine use of ultrasound to guide venous access would 
decrease the incidence of these events.  
6.2. METHODS  
We prospectively studied consecutive patients undergoing CA at our centre over a 10-
month period. In the first phase of the study performed from May 2012 to Sept 2012, 
vascular access was performed as per standard technique (Group S). The second phase 
of the study was performed from Oct 2012 to Feb 2013 and mandated the use of 
ultrasound for vascular access for all patients (Group U). In every other way the CA 
technique and peri-procedural patient management was identical in the two phases. 
The ablation procedures were performed under general anaesthesia or intravenous 
conscious sedation (fentanyl and midazolam). After transseptal access had been 
successfully achieved intravenous unfractionated heparin was administered to target an 
Activated clotting time (ACT) of greater than 300 seconds. Patients with persistent AF 
were routinely anticoagulated with warfarin for a period of at least four weeks pre-
procedure to ensure a stable International Normalized Ratio (INR) of between 2.0 and 
3.5. Patients with a sub therapeutic INR at the time of the procedure were treated with 
subcutaneous enoxaparin post procedurally using a standardized protocol (1 mg/Kg on 
the day of the procedure, then 1.5mg/Kg OD) until their INR levels reached 2.0. Patients 
with paroxysmal AF were either anticoagulated with warfarin peri-procedurally or 
administered dabigatran postoperatively having been left anticoagulant naïve pre-
procedurally. 
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6.2.1. VASCULAR ACCESS  
Vascular access was via the right femoral vein unless this route was inaccessible or 
unachievable. Three sheaths were inserted for catheters in the coronary sinus, and for 
ablation and circular mapping catheters in the left atrium.  In a small proportion of 
patients, a fourth sheath was inserted to allow placement of a diagnostic catheter in the 
right atrium. In patients in Group S, the default method for locating the femoral vein was 
based on conventional surface anatomical landmarks and palpation of the femoral 
arterial pulse. Vascular ultrasound was not routinely used, but was permitted without 
restriction by protocol if considered necessary by the operator because of predicted or 
unexpectedly encountered difficulties using the anatomical approach. The use of 
multiple guide wires via a single sheath was permitted but not used for any study 
patient. The femoral artery was not used for invasive blood pressure monitoring. This 
represents standard practice at our institution. 
 
Patients in Group U received routine ultrasound-guided vascular access. It was 
mandated that operators used real-time 2-dimensional vascular ultrasound (SonoSite S-
ICU™, Fujifilm SonoSite Inc, Washington, USA) to guide cannulation of the femoral vein. 
The ultrasound probe (10-5MHz) was covered in a sterile sheath and sterile ultrasound 
gel was placed both between the probe and the sheath, and the sheath and the patient's 
skin. The probe was held in the operator's non-dominant hand with the ultrasound 
beam orientated perpendicular to the femoral vessels allowing them to be seen in cross 
section (Figure 6-1).  Initial cannulation was performed under direct visualisation, so 
that the path of the modified-Seldinger needle was observed passing into the vein, 
accompanied by aspiration of venous blood into the syringe. Once a guide wire had been 
placed in the vein using ultrasound guidance, it was left to the operator's own 
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preference whether to use it for subsequent punctures. The reasons for this were 
twofold. Firstly, the guide wire produces acoustic shadowing and, on occasion, makes it 
difficult to avoid trapping air between the skin and the probe. Both of these issues 
reduce the quality of the obtainable ultrasound image. Secondly, the guide wire 
provides the operator with a direct, physical marker of the location of the vein that can 
be used to guide subsequent punctures.  
 
In both groups, at the end of the procedure the sheaths were removed with the patient 
still on the operating table and manual pressure applied to the puncture site until 
haemostasis was achieved. Reversal of anticoagulation with intravenous protamine was 
permitted at the operator’s discretion.   
 
Figure 6-1: Left Panel: Two-handed technique for gaining venous access under ultrasound guidance. Right 
panel: Representative image of the femoral vasculature. The femoral artery (FA) is non-compressible and has 
a circular cross-sectional appearance. The shape of the femoral vein (FV) is variable and can be altered by 
compression. The echo-bright needle tip (arrows) can be seen entering the vein at the 2 o’clock position, 
distorting the vessel wall as it enters. 
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Before commencing the second phase of the study operators were trained in the use of 
vascular ultrasound using prosthetic phantoms (simulation) and over a two-week 
period during live cases.  Training cases were excluded from analysis. All operators 
were competent and experienced at gaining femoral access using an anatomical 
approach before the initiation of the study, with each having performed greater than 
100 prior procedures. 
Data on vascular complications were collected at three time points; immediately 
following the procedure, at the time of hospital discharge and at one month post-
procedure by means of a bespoke postal questionnaire. The pre-specified primary 
outcome measure evaluated was overt (BARC 2 or greater) bleeding complications 227. 
Secondary measures, as assessed by the follow up patient questionnaires, were 
prolonged groin pain and prolonged (>2 weeks) bruising.  
 
The BARC (Bleeding Academic Research Consortium) Criteria are standardised bleeding 
definitions for cardiovascular clinical trials, developed by consensus amongst an expert 
group and adopted by the European Society of Cardiology as an appropriate means by 
which to quantify bleeding complications in conditions such as acute coronary 
syndrome and percutaneous coronary intervention227,228. There are 6 (0-5) BARC levels. 
Neither BARC 4 (Coronary Artery Bypass related) nor BARC 5 (fatal) bleeding was 
encountered during the study. BARC 0 indicates no bleeding, BARC 1 is bleeding that is 
not actionable and does not cause the patient to seek additional attention while BARC 2 
bleeding is clinically overt bleeding that is actionable (requiring intervention by a health 
care professional, leading to or prolonging hospitalization or increased level of care, or 
prompting testing or treatment) but does not meet criteria for a higher category. BARC 
  Page 166 of 266 
3 bleeding for the purpose of this study represented bleeding requiring transfusion. We 
classified an overt bleeding complication as one meeting the criteria for either BARC 2 
or greater. Patients due to have combined venous and arterial access, for example for 
concomitant coronary angiography were prospectively excluded. 
 
The study received prospective institutional approval as a Quality Improvement Project, 
in accordance with published guidance229. All patients gave written informed consent.  
6.2.2. STATISTICAL ANALYSIS  
 All data were analysed on an Intention to Treat basis.  Analyses were performed using 
IBM SPSS Statistics software version 20. Continuous data are presented as mean ± 
Standard Deviation and compared using unpaired t-tests. Binary categorical data were 
compared using the χ2 statistic and the Mann-Whitney U test was used to compare the 
number of sheaths used.  Univariate and multivariable predictors of bleed were 
examined using logistic regression.   Variables with a p-value of less than or equal to 0.1 
were included in the multivariable model, and if necessary to maintain a minimum of 10 
events per variables, were selected on a hierarchical basis146.  Where applicable, two-
tailed tests were used in all analyses. A p value of 0.05 or lower was considered 
significant for all tests. 
6.3.RESULTS  
6.3.1. PATIENTS   
We studied 146 consecutive patients in Group S and 163 consecutive patients in Group 
U. Two procedures in Group U were performed without ultrasound guidance due to 
protocol deviation and in one case ultrasound use was abandoned in favour of an 
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anatomical approach. All three were included in the intention to treat analyses. Follow 
up questionnaires were received from 92.6% of patients (n =138 (Group S) v. 148 
(Group U), p=0.1). 
6.3.2. BASELINE CHARACTERISTICS  
The two groups were well matched at baseline. Characteristics for each group are given 
in Table 6-2. The majority of patients were male (72.5%) with a mean age of 58.9±10.2 
years. A regime of uninterrupted warfarin therapy was used for 70.2% of patients 
(Group S 109 (74.7%), Group U 108 (66.3%), p=0.11) with a mean INR of 2.2 and was 
not either statistically or clinically different between the study groups (Δ 0.15, p=0.07). 
Bridging therapy for Enoxaparin was used for only two patients and all other patients 
were anticoagulated only post-procedure (Group S 37 (25.3%), Group U 53 (32.5%), 
p=0.17). Patients with persistent AF accounted for 29.8% of the study population.  
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Variable  Group S (n=146) Group U (n=163) P value 
Sex (n, % male)  100 (68.5%) 121 (74.2%) 0.26 
Age, years (mean, SD) 58.7 (±11.0) 59.1 (±9.6) 0.78 
BMI (Mean, SD) 28.9 (±5.5) 29.1 (±4.3) 0.76 
Redo Procedure (n, % yes) 49 (33.3%) 50 (30.9%) 0.64 
Number of sheaths 
(median, range)  
3 (2-4) 3 (2-4) 0.35 
Uninterrupted warfarin (n, 
% yes)  
109 (74.7%) 108 (66.3%) 0.11 
Protamine Use (n, % yes)  126 (85.7%) 147 (90.7%) 0.17 
Pre-procedure INR (Mean, 
SD)  
2.15 (±0.44) 2.28 (±0.61) 0.07 
Periprocedural LMWH use 
(n, % yes) 
24 (16.4%) 28 (17.2%) 0.86 
Peak ACT  (mean, SD) 367 (±83) 382 (±114) 0.21 
Table 6-2: Baseline Characteristics for the two groups in the study of ultrasound use 
6.3.3. PRIMARY OUTCOME MEASURE  
A BARC 2+ bleed was significantly less common in Group U (n=17, 10.5%) as compared 
to Group S (n=29, 19.7%) p=0.023. This absolute risk reduction (ARR) of 9.2% equated 
to a relative risk reduction (RRR) of 47.0%, and a number needed to treat (NNT) of 11 
to prevent one bleeding event. There were no fatal (BARC 5) bleeds. BARC 3 
complications occurred in two patients in Group S and in one patient in Group U.  
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 Ultrasound use was permitted in Group S when access was either expected or found to 
be more difficult. Despite the fact that this was a selected high-risk group, none of the 
Primary Outcomes in Group S occurred whilst using ultrasound. 
Of the 46 BARC 2+ bleeding complications seen in the study, 3 patients required blood 
transfusion (one retroperitoneal haemorrhage, two large localized haematomas within 
the adductor muscle group), 4 patients required hospital re-admission, 2 had 
unscheduled medical care following discharge but were not admitted to hospital and 36 
patients required additional, unplanned and unanticipated intervention to achieve 
haemostasis after leaving the catheter laboratory. Of these, 13 required a mechanical 
adjunct (e.g. Femostop device) and 23 required manual compression to suppress 
hematoma.  One had a significant hematoma but no additional intervention. Where 
patients had more than one qualifying event they were categorized according to the 
above hierarchy. Non access site related bleeding complications were not included in 
any analysis. 
6.3.4. SECONDARY OUTCOME MEASURES  
Group U patients were significantly less likely to suffer groin pain after discharge (n=39, 
27.1%) as compared to patients in Group S (n=59, 42.8%), p=0.006. This ARR of 15.7% 
and RRR of 36.7% translated to a NNT of 7. Patients in Group U were also less likely to 
require the use of analgesic medications after they had left hospital (n=14, 9.7%) as 
compared to Group S (n=34, 24.6%), p=0.001.  The incidence of prolonged local 
bruising, lasting longer than two weeks, was also significantly lower in Group U (n=31, 
20.5%) than in Group S (n=55, 40.4%) p=0.001.  
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Inadvertent arterial puncture, as recognised by the operator, was less common in Group 
U than Group S (10 (6.1%) v. 19 (13.0%)), p=0.04. Patients with inadvertent arterial 
puncture were significantly more likely to experience a BARC 2+ bleed (p=0.002). 
We did not specifically measure the time taken to gain vascular access but did 
retrospectively assess procedure duration using the hospital’s electronic database, 
supplemented by paper case notes when required. Procedures in Group U were 
significantly shorter than those in Group S, suggesting a potential indirect benefit of 
ultrasound use (184 ±53 min v. 167 ± 4 min, p=0.04). 
6.3.5. EFFECT OF LEARNING CURVE  
All clinicians received simulation and clinical training in the use of vascular ultrasound 
prior to the second phase of the study. For each procedure performed during the 
Ultrasound phase of the study, operators were asked their experience level with the 
technique (fewer than 5 cases, 5 to10 cases, or greater than 10 cases).  Nine cases in 
Group U were performed by operators with prior experience of fewer than 5 
ultrasound-guided procedures. When compared to cases performed by operators with 
experience of 10 or more prior cases, there was a significant higher incidence of a BARC 
2+ bleed (22.9% v. 8.0% p=0.03). 
6.3.6. PREDICTORS OF BARC  2+  BLEED  
The results of univariate binary logistic regression to estimate the magnitude of risk of 
BARC 2+ bleeding associated with various patient and procedural variables are given in 
Table 6-3.  Significant predictors of bleeding were increasing age (OR 1.05, 95%CI 1.01 
– 1.09 p=0.008), inadvertent arterial puncture (OR 4.29, 95% CI 1.93 – 9.55 p<0.001) 
and non-ultrasound guided (i.e. anatomical) access method (OR 2.92, 95% CI 1.51 – 
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5.64, p=0.001). Approximately 80% of patients had 3 sheaths placed with a range of 
only 2-4. In two cases both groins were accessed, in other case requiring multiple 
sheaths these were all via a single vein. The modality of the sheath use variable 
precluded it from inclusion in the regression analysis. A Mann-Whitney U test confirmed 
that there was no significant relationship between number of sheaths used and the 
primary outcome.  
Variable Odds ratio 
(95% confidence 
Interval) 
P value 
Age (Years) 1.051 (1.013  - 1.091) 0.008 
Sex (male) 0.631 (0.327 - 1.218) 0.170 
BMI (Kg/m2) 1.003  (0.938 - 1.073) 0.927 
Paroxysmal AF (v. Persistent) 2.211 (0.984  - 4.966) 0.055 
Access by Fellow (v. Consultant) 0.795 (0.422 – 1.498)  0.477 
Periprocedural use of LMWH 1.048 (0.458 – 2.399) 0.912 
Redo procedure (v. De novo) 0.543 (0.874 - 3.882) 0.109 
Procedure Duration (mins) 0.998 (0.992 - 1.004) 0.515 
Peak ACT (seconds) 0.998 (0.995  - 1.002) 0.369 
Uninterrupted Warfarin use 0.964 (0.487 – 1.905) 0.915 
INR (normalised units) 0.916 (0.420 - 1.999) 0.826 
Post procedural Protamine use  0.543 (0.230 - 1.284) 0.165 
Protamine Dose (Units) 0.999 (0.992  - 1.006) 0.798 
Inadvertent Arterial Puncture  4.288 (1.926  - 9.550) <0.001 
Non-ultrasound guided access  2.918 (1.509-5.643) 0.001 
Table 6-3: Univariate regression analysis for predictors of a BARC2+ bleed 
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Multivariable regression analysis was performed using the pre-specified criteria 
detailed above. Results of the analysis are shown in Table 6-4. Having adjusted for 
potential confounding, only non-ultrasound guided access (OR 3.12, 95% CI 1.54 – 5.34, 
p=0.003), and increasing age (OR 1.05, 95% CI 1.01-1.09 p=0.02) remained significant 
predictors of a bleeding complication. 
Variable Odds ratio 
(95% confidence Interval) 
P value 
Inadvertent arterial puncture 2.402 (0.974 - 5.923) 0.057 
Paroxysmal AF 2.152 (0.925 - 5.008) 0.075 
Age 1.046 (1.008 - 1.086) 0.018 
Non-ultrasound guided access 3.121 (1.535 – 5.343) 0.003 
Table 6-4: Multivariable logistic regression analysis for predictors of a BARC2+ bleeds 
6.4. DISCUSSION  
 
To our knowledge, this is the first study assessing the safety benefits of ultrasound 
guidance for femoral venous cannulation in CA and the largest such study in any 
discipline.  Our data, collected in a true real-world setting, have shown the benefits of 
adopting a policy of using vascular ultrasound for all CA procedures. As well as 
significantly reducing the number of actionable (BARC 2/3) haemorrhages, there was 
also a clear reduction in the number of patients suffering groin pain after hospital 
discharge and in those with prolonged unsightly bruising, issues which may not be 
appreciated by physicians but may impact on a patient’s experience of the procedure  
The magnitude of this protective effect of ultrasound appears to be sizeable; only 11 
patients needed to be treated to prevent one  bleeding complication and 7 to prevent 
ongoing groin pain after discharge. It is likely that the reduced risk of complications is 
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due to a reduction in the occurrence of inadvertent arterial puncture, some of which 
may not be recognized at the time. It is also possible that ultrasound allows ‘cleaner’ 
venous punctures through a reduced tendency to perforate the posterior venous wall 
with the modified- Seldinger needle. An important aspect of the use of ultrasound is to 
identify an access point at which the vein is most easily accessible without risk of 
damage to the artery so that, even if the vessels are overlying in one plane the operator 
can chose a different plane in which the vessels are better disassociated. 
 
Because our endpoint included both BARC 2 and BARC 3 complications and we also 
included late complications that occurred in the month following discharge, our 
vascular complication rate, of almost 20% in Group S, seems very high at first glance. 
This endpoint was explicitly chosen in order to assess complications from the 
perspective of the patient rather than the physician. It has been described that 
physician-reported complication rates following PVI appear to miss the majority of 
vascular events considered important to patients217. Our data in this study mirror that 
observation. BARC 3 complications occurred in only 3 patients (1%), in keeping with 
rates reported in large international registries 147,148. 
We believe a universal policy of ultrasound use for all patients undergoing CA is 
preferable to attempts to select high risk patients. It is not possible to reliably identify 
those patients for whom an anatomical approach is entirely safe. Although all three 
patients with BARC 3 complications had a Body Mass Index (BMI) greater than 30 (with 
the patient in Group U having a BMI of 38), overall there was no association between 
BMI and the risk of a bleeding complication. Furthermore, variations in vascular 
anatomy cannot be predicted. This is supported by the results of our multivariable 
regression analysis where, apart from increasing age, only non-ultrasound guided 
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access was found to be significantly associated with the occurrence of a vascular 
complication. None of the published studies looking at ultrasound guided vascular 
access have reported any increased risk with use of ultrasound. These findings are in 
keeping with our own. In our opinion the balance of risk-benefit therefore appears 
firmly in favour of ultrasound use.  
We did not specifically assess resource implications or cost effectiveness from our data. 
However, The UK National Institute for Health and Care Excellence (NICE) concluded 
that the additional cost of using ultrasound equipment for the CVC placement procedure 
is likely to be less than £10 [$16] per procedure 226. The same figure was reached in a 
separate cost effective analysis which concluded that ultrasound use was likely to be 
cost effective, with an approximate saving of £2000 ($3200) per 1000 procedures (2003 
prices)230. Furthermore, the potential for shortening the PVI procedure time by a 
combination of speedier vascular access at the start and shorter groin compression time 
at the end, as seen in our study, would be expected to have a favorable impact on 
precious catheter lab time. 
6.4.1. LIMITATIONS  
The most important limitation of this study is the non-randomised design.  To mitigate 
this, we attempted to minimize selection bias by collecting data on 100% of patients 
during the study period. However, as for any observational study we are inherently at 
risk of confounding and this limits the strength of conclusions that can be drawn. As a 
longitudinal cohort study, it is theoretically possible that the benefits seen in the 
ultrasound-guided phase of the study were exaggerated by a general improvement of 
vascular access skills. However all procedures were performed by highly experienced 
operators and so it is unlikely that this had a significant effect. This notwithstanding, the 
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use of any new tool has the potential to introduce operator bias.  Second, our choice of 
BARC 2+ bleeding as our primary endpoint may be considered too broad.  The reason 
for choosing this was based on the publication of standardised criteria for clinical trials. 
Also, although physicians may be most interested in avoiding life-threatening 
complications, the effect on patient wellbeing of "lesser" events can be significant.  
Furthermore our a priori calculations showed that to demonstrate a difference in 
potentially life-threatening (BARC 3+) complications, we would require an unfeasibly 
large sample size. Indeed, based on our results, an adequately powered study to look for 
a difference in BARC 3+ complications would require a sample size of around 5000 
patients. Another possible limitation of the study is the lack of patient blinding. This was 
inevitable given that most procedures were performed under local anaesthesia and 
conscious sedation. However, in order to minimise potential bias the patient survey 
specifically avoided mentioning that comparison was being made between techniques. 
Finally, at our centre all operators perform venous access using a uniform technique. It 
is therefore not possible to say whether alternative techniques, such as a strategy 
utilizing both groins or with femoral arterial blood pressure monitoring, might have 
demonstrated greater or lesser benefit of ultrasound use.   
6.5.CONCLUSION  
In real-world practice, we found routine use of ultrasound guided vascular access 
during CA to be associated with a significant reduction in bleeding complications, post 
procedural pain and bruising compared to standard care.  
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7 .  I M P R O V I N G  P A T I E N T  O U T C O M E S  B Y  
B E T T E R  U N D E R S T A N D I N G  Q U A L I T Y  O F  L I F E  
I N  A T R I A L  F I B R I L L A T I O N :   
V A L I D A T I O N  A N D  I M P R O V E M E N T  O F  T H E  
E U R O P E A N  H E A R T  R H Y T H M  A S S O C I A T I O N  
S Y M P T O M  C L A S S I F I C A T I O N   
7.1. BACKGROUND  
In the preceding chapters I have focussed on post ablation outcomes, both in times of 
procedural efficacy and safety. In Chapter 2 I found no pre-procedural demographic 
factors that predicted success after both a single and the final procedure. However, at 
present the indication for catheter ablation (CA) is the relief of symptoms over and 
above freedom from recurrent atrial fibrillation (AF).14 Because symptoms can be 
variable in severity, frequency and different patients may experience different 
combinations of symptoms, several systems have been proposed for categorisation and 
quantification.10,162,231 In this final results chapter I undertook the first retrospective 
and prospective validation of the most commonly used scoring system in Europe and, 
importantly, looked at how this may help to select appropriate patients for CA, based on 
the severity of their symptoms. Improving the tools available for patient selection 
means that those who are likely to benefit from CA are put forward for ablation, 
whereas those who are unlikely to benefit, but will still be exposed to the same risks, are 
not and thus the outcomes for both groups should improve. 
 
In 2007 an expert group of the German Atrial Fibrillation Competence NETwork 
(AFNET) and the European Heart Rhythm Association (EHRA) published 
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recommendations for the conduct of clinical trials in AF162. Noting that no accepted and 
easily applicable measure for AF-related symptoms exists, this group of experts 
proposed and described in their recommendations a new scoring system, the EHRA 
Classification, to assess and quantify symptoms related to AF.162 The EHRA classification 
is based on the impact of symptoms on daily activity during presumed episodes of AF.  It 
is simple to use and has a format similar to the New York Heart Association (NYHA) 
symptom classification system for patients with heart failure, making it relatively 
intuitive for practicing clinicians whilst hopefully being more appropriate to AF-related 
symptoms.232 When the EHRA score was published the authors made specific mention 
of the need for validation.162 A similar score was thereafter validated by a Canadian 
group10. Since its initial proposal, the EHRA score has entered widespread use and has 
even been used in European Society of Cardiology guidelines for the management of AF 
in the recommendations for rate and rhythm control.47,51,72,233-235   
 
To put the EHRA score into context with existing tools to assess disease-related quality 
of life in AF patients, we compared the EHRA Score to accepted and validated measures 
of health-related QoL. Specifically we used both a disease specific tool, the Atrial 
Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire, and a general tool, the very 
well established EQ-5D questionnaire.178,236,237 The AFEQT is a well validated, patient-
reported AF-specific symptom questionnaire and as such is very sensitive to changes in 
symptom burden but it cannot be compared with other conditions. EQ-5D, however, is 
applicable to a wide range of health conditions and provides a single index value for 
health status, called the health utility, which can be used to calculate ‘quality-adjusted 
life years’ (QALYs) for health economic evaluation.238 Previous studies have suggested 
that the minimal meaningful difference in EQ-5D derived health utility is 0.07.238 In line 
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with this, a previous study of the cost-effectiveness of catheter ablation in the UK setting 
found catheter ablation to be cost-effective with an estimated utility difference of 0.09 
between symptomatic AF on drugs compared to sinus rhythm following ablation.239 
We aimed to validate the EHRA score using these general and disease-specific QoL 
measures. We hypothesised that the discriminative power of the EHRA score could be 
improved and attempted to achieve this through a simple modification. 
7.2. METHODS  
7.2.1. PHASE ONE  
Consecutive patients with a diagnosis of AF attending designated heart rhythm/ 
Electrophysiology clinics at a single specialist cardiac hospital in England (Liverpool 
Heart and Chest Hospital) were invited to complete the AFEQT questionnaire and EQ-
5D instrument, including the VAS 236,237. At the same clinic visit, the reviewing clinician 
was asked to independently score the patient according to the EHRA symptom 
classification. In keeping with real-world practice, these assessments were completed 
by a range of clinicians experienced in the management of patients with AF, including 
consultant cardiologists, trainee physicians and arrhythmia nurses.  Clinicians were 
provided with, and requested to complete, a classification form that listed the published 
definitions for each class. In order to replicate how the classification is likely to be used 
in routine practice, no specific training was provided beyond that described above and 
access to the original publication in which the EHRA score was proposed. This mirrored 
the methods used to validate an alternative classification system 10 .  
QoL was assessed by the AFEQT score (global), the health-related utility based on the 
EQ-5D instrument, and VAS. For each measure a higher score represents a higher 
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quality of life. AFEQT and VAS are scored from 0-100. Health utility (EQ-5D) ranges 
between 1 (perfect health) through 0 (death) to -0.59 (QoL worse than death, e.g. 
suffering so great that death is considered a “release”). Mean QoL scores were 
compared between neighbouring EHRA classes to assess the score’s accuracy in semi-
quantifying QoL. 
7.2.2. PHASE TWO  
We proposed a modified EHRA (mEHRA) classification by subdividing Class 2 into 2a 
(mild) and 2b (moderate) according to the degree to which the patient was ‘troubled by 
their symptoms’ (Table 7-1). All patients categorised as Class 2 during Phase One of the 
study were independently re-categorised as either 2a or 2b by two clinicians 
(electrophysiology fellows) who were both blinded to the corresponding QoL scores. 
Clinic letters were reviewed with specific attention made to the extent to which the 
patients appeared ‘troubled by their symptoms’, given that their daily activities were 
not affected (which would indicate Class 3 symptoms).  We sought to assess the 
patient’s own perception of the impact of AF on their well-being. Those suffering from 
anxiety, loss of confidence or symptoms that they found unpleasant were graded as 2b. 
There was agreement between the reviewers for all cases reclassified into mEHRA Class 
2a and 2b. Where the clinical letters were lacking in detail, the hospital records were re-
reviewed and a consensus agreed upon. The mEHRA score was assessed and validated 
using the same methods used to validate the EHRA score in the initial phase of the 
study. 
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mEHRA 
Score 
Symptoms Description 
1 None  
2a Mild Normal daily activity not affected, symptoms not troublesome to 
patient 
2b Moderate Normal daily activity not affected but patient troubled by 
symptoms 
3 Severe Normal daily activity affected 
4 Disabling Normal daily activity discontinued 
Table 7-1: Modified EHRA (mEHRA) classification. Underlined text represents the modification to the original 
descriptions of EHRA classes. 
7.2.3. PHASE THREE: 
Having completed Phases One and Two we wished to verify and validate the findings 
from our retrospective scoring of the mEHRA score, by comparing our findings with an 
independent cohort in whom the mEHRA score had been used prospectively.  The 
method of data collection for this phase matched exactly that in Phase One, except that 
clinicians were asked to classify symptoms according to the new, expanded, mEHRA 
score rather than the original EHRA score. We compared the prospective and 
retrospective scores, for the two new mEHRA classes, for each of the three QoL 
measures used in the previous two phases. 
7.2.4. AFEQT  QUESTIONNAIRE  
The Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire is a validated, 
disease-specific, self-administered QoL instrument.178 It has 20 questions with four 
conceptual domains: Symptoms (four questions specifically targeted to assess AF 
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related symptoms), Treatment Concerns (six questions that assess AF treatment 
concerns in patients), Daily Activities (eight questions that evaluate daily function in AF 
patients) and Treatment Satisfaction (two questions asking about how the well current 
treatment controls their AF and relieves symptoms). Each of the 20 questions is marked 
on a seven point Likert scale. A published algorithm exists to allow calculation of a 
score, between 0-100 (where higher is better), for each domain and a global score based 
on the first three domains. The questionnaire specifies a recall period of the preceding 
four weeks. 
7.2.5. EQ-5D  QUESTIONNAIRE (3  LEVEL VERSION)   
EQ-5D is a standardised measure of health status developed by the EuroQol Group in 
order to provide a simple, generic measure of health for clinical and economic 
appraisal.236 243 possible health states can be defined from the five questions and these 
can be converted into a single summary index called the ‘health utility’ based on 
country-specific value sets.240 The health utility measure is of particular interest as it is 
generalisable to other diseases and to the general population.  Therefore, it allows the 
calculation of QALYs and therefore the cost effectiveness of interventions such as 
catheter ablation. 
7.2.6. VISUAL ANALOGUE SCALE (VAS) 
The VAS forms an integral but distinct part of the EQ-5D instrument. Respondents are 
asked to mark a single point on a linear scale that represents their health status on the 
day of completion.  The scale extends from 0 (worst imaginable health state) to 100 
(best imaginable health state). The VAS provides a quantitative measure of health state, 
as judged by the individual patients. 
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7.2.7. STATISTICAL ANALYSIS  
 Analyses were performed using StatsDirect software version 2.7.8. Analysis of QoL 
scores (AFEQT score, EQ-5D derived utility and VAS) using the ShapiroWilk W test 
showed a non-Gaussian distribution that was not corrected by logarithmic 
transformation. However, the central limit theorem is generally taken to imply that an 
assumption of normality is not necessary for parametric testing to be valid if group 
sizes are greater than about 30. This is the case for all but one group in our analysis. In 
addition, presentation of data as means with standard deviation was adjudged to be of 
greater clinical relevance than presentation of medians with inter-quartile ranges. 
Continuous data are therefore presented as mean ± Standard Deviation and compared 
using the t-test. A similar approach has been used in previous work using QoL 
measures241. Two-tailed test were used where there was not an a priori expectation of 
the direction of difference between groups. However, where a comparison was made 
between two adjacent groups, resulting in assessment for a difference in a single 
direction only, one-tailed testing was considered more appropriate.  Analysis of 
variance was compared using one-way ANOVA. Trend across groups was assessed using 
Cuzick's test. Proportions were compared using the χ2 statistic. Intra- and inter-
observer variability was calculated, and assessed using the Kappa statistic. A p value of 
0.05 or lower was considered significant for all tests.  
The study was performed as part of a wider institutionally-approved Patient Reported 
Outcome Measures (PROMs) service improvement programme at the recruiting centre. 
7.3. RESULTS  
QoL and symptom data were collected on 362 patients attending the heart rhythm 
clinics during 2012. All patients received physician-allocated EHRA classification at the 
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same clinic visit. Baseline characteristics are given in Table 7-2. There were no clear 
differences between the groups in terms of age, sex or proportion classified as having 
paroxysmal, as opposed to persistent or permanent, AF.  Previous studies have found 
QoL to be lower in females242. However, in our cohort patient gender did not have a 
significant effect on any of the three QoL measures (EQ-5D p=0.56, VAS p=0.70, AFEQT 
p= 0.14). Hypertension was by far the most common comorbid condition (48.6% of all 
patients) and showed a significant trend towards increasing prevalence in higher EHRA 
classes (p=0.003). Other comorbidities were infrequently present and were also similar 
across Classes. However, there was a clear trend seen whereby those in less severe 
symptom classes were the most likely to have previously undergone ablation and those 
in the most severe classes were considerably more likely to subsequently go on to have 
an ablation for atrial fibrillation (p<0.0001 for both). A small proportion of 
asymptomatic patients went on to have an ablation in keeping with published data from 
the EURObservation study where 13% of patients were asymptomatic, citing a desire 
for drug free lifestyle, improved quality of life and/ or the maintenance of sinus 
rhythm243.  
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 EHRA 1 EHRA 2 EHRA 3 EHRA 4 Total P 
value*  
N, number 149 99 90 24 362 n/a 
Age  (Mean ± SD) 61.1 ± 
11.4 
59.7± 
12.2 
57.9 ± 
13.0 
62.2 ± 9.9 60.0 
±12.0 
NC 
 
Male Gender 70.3% 58.6% 73.0% 62.5% 66.9% NC  
% PAF† 49.0% 65.6% 62.2% 41.7% 56.4% 0.36 
Diabetes 6.8% 7.1% 8.8% 20.0% 8.3% NC 
Heart Failure 5.4% 3.0% 7.7% 12.0% 5.8% NC 
Hypertension 54.4% 36.4% 46.2% 72.0% 48.6% 0.003 
Pacemaker 5.4% 7.1% 9.9% 12.0% 7.5% NC 
COPD 4.8% 6.1% 8.8% 4.0% 6.1% NC 
Previous stroke/ 
TIA 
8.2% 6.1% 13.2% 12.0% 9.1% NC 
Prior  ablation 77.6% 52.5% 25.3% 24.0% 53.9% <0.0001 
Subsequent 
ablation 
6.8% 34.3% 61.5% 76.0% 32.9% <0.0001 
Table 7-2: Baseline Characteristics by EHRA Class. NC = not calculated (where ANOVA revealed no significant 
variance between groups, a test for trend was not performed). †Predominant pattern at time of assessment. 
COPD = Chronic Obstructive Pulmonary Disease, TIA = Transient Ischaemic Attack, PAF = Paroxysmal Atrial 
Fibrillation. * for trend  
7.3.1. PHASE ONE 
Results for the three QoL measures are shown in Table 7-3 and Figure 7-1. Analysis of 
variance and regression analysis confirmed significant negative correlation between 
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EHRA Class and QoL as assessed by all three measures. To determine the ability of the 
EHRA classification as a semi-quantitative tool, each EHRA Class was compared with the 
Class immediately below in terms of QoL (i.e. EHRA 2 with EHRA 1, EHRA 3 with EHRA 
2, and EHRA 4 with EHRA 3). Using the disease-specific AFEQT score, significant 
differences were seen at each grade boundary suggesting that the EHRA score was an 
effective means of categorising patients’ symptoms. Likewise, using the patient-based 
VAS there was a significant difference between each and its immediate neighbour 
suggesting that the EHRA score effectively categorised patients in terms of their own 
assessment of their health state. However, when comparing health-related utility, 
derived from the EQ-5D questionnaire, although there was a significant difference of 
0.12 (P<0.001) between Classes 2 & 3, the difference between Classes 1 & 2 was only 
0.04 (p=0.08). This observation prompted us to develop the mEHRA classification. 
EHRA 
Class 
Utility 
(by EQ-
5D) 
P value VAS P value AFEQT  P value 
1 0.85 
(±0.21) 
n/a 76.2 
(±19.9) 
n/a 78.4 
(±19.0) 
n/a 
2 0.81 
(±0.17) 
0.08 70.3 
(±20.3) 
0.02 63.6 
(±20.0) 
< 0.0001 
3 0.69 
(±0.27) 
<0.001 59.6 
(±21.9) 
<0.001 42.1 
(±21.1) 
< 0.0001 
4 0.59 
(±0.29) 
0.08 46.9 
(±25.9) 
0.03 31.3 
(±18.6) 
0.01 
Table 7-3: Mean (and standard deviation) for each EHRA Class. P values compare each Class with the next 
lowest Class in terms of symptom severity. VAS = Visual analogue Scale, AFEQT = AFEQT Global score 
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Figure 7- 1: Quality of Life scores (mean ± SD) by EHRA Class 
7.3.2. PHASE TWO  
Of the 99 patients originally classified as EHRA Class 2, 90 had sufficient detail in their 
archived clinic letters to be reclassified in accordance with the proposed modified EHRA 
classification into either 2a or 2b. Of these, 43 were classified as 2a and 47 were 
classified as 2b. The sub-division of Class 2 into 2a and 2b, resulted in clearly separate 
groups, with Class 2a patients having AFEQT scores and health utilities much closer to 
Class 1 patients and Class 2b patients having significantly more symptoms as judged by 
AFEQT and a significant reduction in health utility as judged by EQ-5D. The results are 
shown in Table 7-4 and Figure 7-2. 
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mEHRA 
Class 
Utility 
(by EQ-
5D) 
P value VAS P value AFEQT  P value 
1 0.85 
(±0.21) 
n/a 76.2 
(±19.9) 
n/a 78.4 (±19.0) n/a 
2a 0.86 
(±0.18) 
0.41 75.6  
(±19.9) 
0.43 70.9 (±19.8) 0.01 
2b 0.77 
(±0.15) 
0.01 65.2 
(±20.1) 
0.01 58.3(±17.3) <0.001 
3 0.69 
(±0.27) 
0.02 59.6 
(±21.9) 
0.09 42.1 (±21.1) < 0.0001 
4 0.59 
(±0.29) 
0.08 46.9 
(±25.9) 
0.03 31.3 (±18.6) 0.01 
Table 7-4: Mean (and standard deviation) shown for each mEHRA Class. P values compare each Class with the 
next lowest Class in terms of symptom severity. VAS = Visual analogue Scale, AFEQT = AFEQT Global score 
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Figure 7-2: Quality of Life scores (mean ± SD) by mEHRA Class.  Classes 1,3 and 4 are as for Figure 1. Class 2 
has been split into 2a (n=43) and 2b (n=47) 
We also analysed the mEHRA class according to the three subdomains of the AFEQT 
score: Symptoms, Activities and Concerns.  As can be seen in Figure 7-3, there is a clear 
stepwise trend to lower scores as mEHRA class increases. As these components of the 
AFEQT Global score are themselves not individually validated we did not seek to 
analyse these on a Class-by-Class basis. However, ANOVA confirmed a highly significant 
difference between groups for all three subdomains (P < 0.0001 for each) and Cuzick's 
trend test showed a strong, and highly significant trend towards lower scores with 
increasing mEHRA class (P < 0.0001 for each of the three subdomains). 
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Figure 7-3: AFEQT sub-domain scores (mean ± SD) by mEHRA Class 
7.3.3. REPRODUCIBILITY OF THE MEHRA  CLASS  
To assess the reproducibility of the mEHRA score we measured both intra-observer and 
inter-observer variability. Agreement between the two assessors for ratings of 2a or 2b 
was very good at 83.2% (kappa 0.70, 95% confidence interval = 0.53 to 0.87). Inter-
observer variability was assessed by asking each assessor to re-classify a random 
sample of 20 of the original clinic letters used for Phase 2 of the study. This was 
performed after an interval of several months to avoid bias due to recall of previous 
classification. This demonstrated excellent repeatability, with an agreement between 
the original and repeat classification of 90% for one assessor and 95% for the other 
(combined Kappa 0.85, 95% CI for Kappa, 0.54 to 1.16). 
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7.3.4. PHASE 3:  PROSPECTIVE VALIDATION OF MEHRA 
The mEHRA Score was thereafter prospectively applied to a second cohort of patients 
attending the heart rhythm clinics at Liverpool Heart and Chest Hospital. Using the new 
scoring system, 165 patients were classified as either Class 2a (n = 85) or 2b (n = 80). 
These data are shown in Table 7-5. Prospective scoring showed the same pattern as 
retrospective scoring with significantly lower AFEQT, EQ-5D and VAS scores for mEHRA 
Class 2b than 2a.  There were no significant differences between any of the three QoL 
measured between this validation cohort and the initial cohort in either of the two new 
mEHRA classes (2a and 2b).  
QoL Measure  Retrospective 
n=90 
Prospective 
n=165 
P value 
Retro v 
Prospective 
Utility (EQ-5D) 2a 0.86 (±0.18) 0.81 (±0.22) 0.23 
2b 0.77 (±0.15) 0.72 (±0.22) 0.25 
P value 2a v 2b  P=0.01 P<0.0001  
VAS 2a 75.6 (±19.9)  77.9 (±15.9) 0.51 
2b 65.2 (±20.1)  67.0(±16.4) 0.60 
P value 2a v 2b  P=0.01 P=0.009  
AFEQT  2a 70.9 (± 19.8) 67.7 (±22.2) 0.42 
2b 58.3 (±17.3)  54.1(±20.2) 0.25 
P value 2a v 2b  P<0.001 P<0.0001  
Table 7- 5: Comparison of retrospective and prospective Quality of Life scores, for each of the two proposed 
additional mEHRA classes 
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7.4. DISCUSSION  
This comparison of the EHRA symptoms classification with one disease-specific quality 
of life instrument (AFEQT) and another general measure for health-related quality of 
life (EQ-5D, incorporating the VAS ) provides good evidence that the EHRA score can be 
used to assess AF-related symptoms without prior training. It is easily applied in clinical 
practice and has the potential to be useful in clinical trials. However, it does not 
discriminate sufficiently in patients with low level symptoms in terms of health related 
utility. We found that the EHRA classification can be improved by sub-dividing Class 2 
into two separate classes (2a and 2b). Class 2b symptoms then may represent a more 
appropriate threshold for intervention in terms of health economics. 
 
Phase One of this study provides evidence that the EHRA classification, in its originally 
proposed format correlates well with disease-related QoL, as judged by the AFEQT 
questionnaire and with patients’ own perception of their health state (VAS). There is a 
step-wise, negative association between EHRA Class and both of these measures. The 
EHRA score can therefore be considered as a validated tool for symptom classification. 
In a similar manner to the NYHA functional class for heart failure and the CCS angina 
scale, the EHRA score allows clinicians to broadly categorise the severity of patients’ 
symptoms. Where the specifics and complexities of symptoms can be considerable, this 
sort of categorisation provides a simple means of communicating and quantifying 
symptom severity. It allows cross-sectional comparison between patients and 
longitudinal comparison for individual patients or groups of patients.  
 
However, using health-related utility as a measure of QoL, the EHRA score only showed 
significant discriminatory power at the boundary between mild (Class 2) and severe 
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(Class 3) symptoms. To try to improve discriminative ability for patients with mild-
moderate symptoms we subdivided EHRA Class 2 patients (patients with symptoms, 
but symptoms that were either not limiting daily activity) into 2a and 2b, based on the 
degree to which the patient was ‘troubled by their symptoms’, and found the two 
subdivisions were significantly different from each other on all three QoL measures. 
Indeed, the health-related utility showed no significant difference between Class 1 
(asymptomatic patients) and Class 2a (patients with symptoms but which are not 
troublesome and do not affect daily activity). Class 2b patients showed a significant 
reduction (0.09) in health utility compared to Class 2a patients (Table 7-4). As such it 
may be more appropriate for cost effectiveness analyses to base treatment decisions not 
only on the presence or absence of symptoms, but also to consider whether the 
symptoms cause trouble to the patient or not. A scoring system such as mEHRA is 
intended to provide a measure of symptoms/ QoL at a particular point in time. This can 
then be compared with other patients or for the same patient over time to help assess 
the impact of interventions. 
 
At first sight the EQ-5D questionnaire does not obviously represent a useful QoL 
assessment for a patient with AF. The value in its use, however, is the assessment of a 
health utility score at baseline, which can then be reassessed following treatment. This 
allows the calculation of the cost-efficacy of the intervention, and thereby a comparison 
of the effectiveness of medical interventions between different disciplines. There is a 
growing demand in all countries to understand the cost-effectiveness of treatments 
used for common conditions to ensure efficient and appropriate use of health resources.  
This is particularly the case when considering potentially costly treatments such as 
catheter ablation. In addition there is an increasing focus on the patient reported health 
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status as the most relevant outcome of medical interventions, and as clinicians we 
should embrace this method of assessing outcomes.244   
 
The EQ-5D QoL questionnaire has previously been studied in AF, although not in 
association with the EHRA score. Berg et al reported the findings from the EQ-5D in the 
Euro heart survey.245 The EQ-5D was completed by 5,050 patients attending specialist 
hospital departments in 35 European countries. The population studied was somewhat 
older than ours with a mean age of 66 years. The mean utility was 0.75, which would 
suggest most patients had a symptom level around mEHRA Class 2b. A repeat survey 
after 1-year was completed by 3,045 patients showed only a minor (0.013) 
improvement in health utility. A lower health utility was associated with AF specific 
symptoms, but also other variables including increasing age, history of stroke and the 
inability to take regular exercise. Only 2.5% of the patients enrolled into the Euro Heart 
Survey received treatment with catheter ablation.246 A sub-analysis of the Birmingham 
Atrial Fibrillation Treatment of the Aged (BAFTA) study, looking at an older population 
(mean age 82, range 75-99) showed a comparable baseline utility for males (0.77) but a 
lower utility for females (0.68).242   
 
In assessing interventions, doctors are often focussed on observable events, such as the 
frequency and duration of AF episodes, which may not tally with the patients’ 
perspective of their QoL.12,247 The motivation of the patient to seek treatment, however, 
is based on the hope that symptoms will improve. We propose that the reclassification 
of EHRA Class 2 into 2a and 2b can be of clinical use in selected patients with moderate 
AF-related symptoms. Should our findings be validated in other data sets, the 
information may also make health economic sense. The reclassification of EHRA Class 2 
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is focussed on the impact that AF has on the patient, by stating either that AF symptoms 
are ‘not troublesome to patient’ (Class 2a) or that the ‘patient is troubled by symptoms’ 
(Class 2b). This distinction will be intuitive for many clinicians, and appears as easily 
applicable as the original score. From our results we can see that this clearly 
differentiates 2 groups with not only a statistically significant difference in health utility, 
but with an absolute difference of 0.09, a clinically meaningful difference.  
7.4.1. LIMITATIONS  
The EHRA score, and by extension the mEHRA score, is intended to be used for patients 
with either paroxysmal or non-paroxysmal and we did not differentiate between the 
two AF types in our analyses. It is conceivable that, within an individual mEHRA class, 
there is a difference in QoL between the two AF types.  The subdivision of EHRA Class 2 
in Phase Two was performed retrospectively using clinical letters and could be 
considered subjective as it was based on a judgement of whether the patient was 
‘troubled by their symptoms’. This was however performed by 2 independent 
physicians who were both blinded to the QOL scores of patients in Phase 1 of the study. 
In a small minority of cases (n=9), subdivision was not possible because of inadequate 
detail in the clinical letter and therefore these patients could not be included in Phase 2. 
By looking at and comparing a prospective cohort we have shown that retrospective 
scoring is unlikely to have a significant effect on the conclusions drawn. In addition, 
although our assessments were made by a range of health care providers, all were 
experienced in the management of patients with AF. Finally, the population studied is 
from a specialist tertiary centre where a large proportion of patients are managed 
invasively. The classification may be less appropriately used in the hands of others 
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groups of physicians or nurses or in other patient populations. Within these limitations, 
mEHRA appears a practicable and useful addition to the EHRA score. 
7.5. CONCLUSIONS  
The EHRA classification, as originally proposed, is a valid means of quantifying AF 
symptom severity and correlates well with AFEQT and with the generic EQ-5D. 
Subdividing EHRA Class 2 into Class 2a and Class 2b by a single additional question has 
the potential to discriminate two clearly separate groups, with Class 2b patients having 
significantly impaired QoL due to AF, whereas those with Class 2a symptoms do not 
differ significantly from asymptomatic patients. . This simple modification may further 
improve the clinical usefulness of the EHRA score, particularly when considering 
interventions such as ablation, where Class 2b symptoms appear to be the appropriate 
treatment threshold.  
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8 .  F I N A L  D I S C U S S I O N  
 
8.1. TO WHAT EXTENT DID I  ACHIEVE MY AIMS? 
In my introduction I presented this image, to represent what I hoped to achieve through 
this thesis 
 
Figure 8-1: Copy of Figure 1-1 
Throughout the thesis I have attempted to address each of these areas that contribute to 
the central goal of improved patient outcome. I have looked at two ablation strategies 
for substrate-based AF, by means of a randomised controlled trial, and found no 
difference in terms of arrhythmia recurrence or quality of life between the two. 
However the secondary benefits of reduced procedural time, shorter duration of 
ablation and, importantly, lower radiation doses suggest that less may be more when it 
comes to selecting a lesion set likely to produce the optimum outcome overall. I was 
able to demonstrate a significant benefit in terms of patient safety through the use of 
Optimum patient outcome 
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ultrasound to guide vascular access with a clear likely benefit in terms of patient 
outcome. I also found that effective lesions appear to be those in which maximal 
myocardial damage is achieved through minimal application of radiofrequency energy a 
measure of this relationship, the AEQ, has some potential – at least in patients with 
paroxysmal AF - in predicting the risk of future arrhythmia recurrence. Whilst the term 
“good outcome” is commonly used in the AF ablation literature as a synonym for 
freedom from recurrent arrhythmia, the procedure is correctly indicated for the relief of 
symptoms and therefore quality of life (QoL) is at least, if not more, important as a 
measure of a “good outcome”. Through my work on the European Heart Rhythm 
Association symptom score, I was able to show that patients with mild symptoms had a 
quality of life that was not discernably different from those who were asymptomatic 
and therefore concluded that selecting these patients for ablation would be unlikely to 
produce a meaningful improvement for them whilst exposing them to procedural risk. 
Therefore, by selecting only those patients most likely to benefit the outcomes for all 
can be improved.  
8.2. WHAT PROBLEMS WERE EN COUNTERED AND HOW WERE THEY 
OVERCOME? 
8.2.1. CHAPTER 4:  USE OF A MODIFIED INTENTION TO TREAT ANALYSIS  
Intention-to-treat (ITT) analysis for clinical trials dates back to the 1960s and can be 
summarised as “once  randomized,  always  analyzed”.248 and is widely accepted as the 
gold standard for clinical trials, however may not always be appropriate for clinical 
trials in AF.  The ITT principle was developed to account for the problem of incomplete 
compliance in drug trials, because the reasons for non-compliance may be related to 
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prognosis.249 In such circumstances, a per-protocol analysis risks overestimation of the 
treatment effect and may provide an inaccurate estimate of the likely benefit in 
standard clinical practice where the reasons for non-compliance are likely to be at least 
as prevalent as during a closely monitored clinical trial. In a strict ITT analysis after 
randomisation all losses to follow up and withdrawals are ignored and events before 
treatment commences count towards the primary endpoint.  
 
In my RCT (Chapters 3 &4), I performed a modified intention-to-treat analysis.250 In this 
I excluded patients who were lost to follow up (neither of whom attended any follow up 
appointments) or who withdrew prior to undergoing ablation. The reasons for this 
were threefold. Firstly, patients in either of those groups who were not seen again in 
follow up are impossible to clarify in terms of our primary endpoint of AF recurrence. 
Secondly, and notwithstanding the first point, because our intervention was intended to 
“remove” a condition (AF) and our primary endpoint was recurrence of that original 
condition, all patients not undergoing the intervention would be expected to have the 
condition present continuously, i.e. to immediately meet the primary endpoint. Any 
situation in which this does not occur is likely to be due to confounding (e.g. increased 
AAD use) and therefore a strict ITT analysis may potentially risk increasing bias. These 
two issues may not have been relevant if we had chosen a different endpoint, most 
obviously mortality where death would not be routinely expected and data may still be 
obtainable (with appropriate consent and ethical permission) for patients lost to follow 
up through centralised databases. Thirdly, the difference in interventions, from a 
patient perspective, was relatively minor and we did not believe that any patient 
withdrew because of this difference per se.  
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Although strategies exist for mitigating the effect of unknown outcomes data due to loss 
to follow up, none are without some degree of unverifiable assumption, and all risk 
introduction of additional bias.251 True ITT analysis may therefore be impractical where 
loss to follow up occurs.250 In a systematic review by Abraha and Montedori, loss to 
follow up was the most common reason for studies adopting a modified ITT 
approach.250 If a patient who did not receive an intervention is included as a subject 
who received treatment, then it indicates very little about the efficacy of the 
treatment.252 Exclusion of these patients is therefore a common approach may be 
considered an appropriate strategy.251 Where modified ITT is used, sensitivity analyses 
are recommended.251 In my study, I found that both per protocol and as treated 
analyses yielded very similar results to my main analysis.  In addition, I performed a 
further analysis attempting a strict application of ITT. In this, for the reasons given 
above, I assumed that all those who withdrew or were withdrawn from the study met 
the primary endpoint. Although neither patient lost to follow up attended for any follow 
up visits, telephone conversations with them or their relative suggested that neither had 
any further AF and therefore for this analysis I have treated them as being free of the 
primary endpoint. Interestingly, using these criteria gave an overall success rate of 
74.6% with the primary endpoint occurring in  28.8% of patients randomised to PVI + 
linear lesions and 21.9% randomised to PVI alone. The difference between the groups 
was of a similar magnitude (Δ6.9 v. 7.2) to the main analysis with a near-identical level 
of significance (P= 0.37). If, as a worst case scenario, the two patients lost to follow up 
were also considered to have had recurrent AF the difference between the treatment 
arms remained non-significant (28.8% v. 25.0%, P=0.63). Overall, this would seem to 
suggest my approach was valid, although may not have been necessary. 
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8.2.2. CHAPTER 4:  RECRUITMENT AND RETENTION  
Recruitment to my trial was good, although slower than we had originally anticipated. 
In retrospect, this was probably due to a lower than expected number of patients 
meeting criteria for SusPAF. We had expected at least half of participants to come from 
this subgroup but, ultimately, the proportion was only 39%. We screened 200 patients 
in order to recruit 130 and of the 70 not recruited, 53 (76% of non-participants and 
26% of all screened) were found to be ineligible, in keeping with the comments above. 
Only 12 patients declined to participate (17% of non-participants and 6% of all 
screened) suggesting the study was well received by potential participants. Of the two 
patients who were lost to follow up, one had a severe relapse of an unrelated chronic 
condition shortly after his ablation which prevented further participation and, 
unfortunately, led to his death. The other repeatedly failed to attend appointments, 
stating pressure of work and that he felt too well to need to come to hospital. 
In my sample size calculation I allowed for an attrition rate of 5%, but the rate we 
experienced was 6% because of a number of patients who withdrew or were withdrawn 
after randomisation. This problem would have been avoided by delaying randomisation 
until the day of the procedure. However, unfortunately we were unable to do this, partly 
due to the need to initiate AAD therapy at least six weeks in advance. Equally important, 
was the fact that one of our treatment arms entailed a significantly longer procedure 
than the other (a difference of 45 minutes based on as treated data) and early 
randomisation was required by the clinical service in order to allow efficient and 
adequate scheduling. If undertaking a similar trial design in the future these factors 
would need to be taken into consideration, but may not be possible to entirely mitigate 
for in which case a larger allowance could be made for attrition. 
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8.2.3. DURATION OF FOLLOW UP IN AF  TRIALS  
It is clear from our findings in Chapter 2 that we need to continue to look beyond the 
short follow up generally reported in clinical trials. However, there is an inherent 
difficulty in presenting long-term follow up results for a rapidly developing technique 
such as catheter ablation.  Whilst knowledge of the course of the disease several years 
after ablation is essential to truly understand the procedure and to allow us to select 
and inform our patients, long follow up data such as I have presented is at risk of being 
out-of-date as soon as it is available. One example of the problem is illustrated by 
anecdotal evidence of a move away from CT or image integration for CA, which 
contrasts sharply with our finding that this is the only significant predictor of success 
after both a single and the final procedure. This discrepancy could be due to decisions 
based on insufficient or misleading available evidence (I highlighted the limitations of 
previous studies in my discussion of Chapter 2), failure to appreciate the long term 
impact of the strategy (to my knowledge the data in Chapter 2 is by far the longest 
reported study to analyse the effect of image integration), or because our long-term 
data is, inherently and obligatorily, out-dated in that the strategy was previously 
beneficial but improvements in mapping systems have now rendered it superfluous.    
In addition to the ongoing accumulation of experience by operators and centres, since 
we performed the ablations reported in Chapter 2 there have been numerous advances 
in catheter and imaging technology, in methods for verifying lesion integrity and in our 
understanding of the mechanisms of AF to mention but a few.23,253,254 We will not know 
for several years what, if any, benefit these advances bring, by which time they too may 
have been superseded.  
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In Chapter 4 the results presented are based on only a short, six month, follow up 
period. The reason for this is predominantly pragmatic, with a need to complete work 
for this thesis within a manageable timescale. As detailed in the methods chapter 
(Chapter 3), I will continue to follow up study participants for a further six months in 
order to generate the minimum duration recommended for reporting trials in the 
medical literature.162 Until that time, the short-term data presented here should be 
interpreted with caution as early results may not be maintained.  
In Chapter 5, I made my primary analysis at six months, again due to pragmatic reasons 
but also in order to identify early any trends and messages emerging from the testing of 
an entirely novel concept. Having discovered that the relationship between AEQ and 
arrhythmia recurrence was most significant for patients with PAF, I then extended 
follow up to 12 months and found that the early findings were maintained. In Chapter 6 
the outcome of interest was acute, or sub-acute, procedural bleeding complications 
relating to vascular access.  Again the issue of follow up duration is relevant with most 
previous comparable studies reporting only immediately apparent 
complications.219,220,225 In my study I extended follow up to a month post-discharge by 
means of a unique postal questionnaire. In doing so I believe I was able to present a 
much more accurate picture of the true experience of our patients, rather than the 
narrow view gained from looking at only a potentially short list of very major and 
immediate complications. 
8.3. AREAS FOR FUTURE RESEARCH  
As stated at the beginning of this chapter, I set out to provide new knowledge through 
my research to improve outcomes for patients undergoing AF ablation, and specifically 
took a more holistic definition of “outcomes” than simply arrhythmia recurrence.  
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Whilst I hope and believe I have achieved this aim, it is perhaps not surprising that in 
answering one question, other questions develop. One particular point of interest is our 
findings in Chapter 1 that additional linear ablation lesions appeared to reduce the risk 
of arrhythmia recurrence which contrasts sharply with the results presented in Chapter 
4. I have discussed this dichotomy in detail earlier in the thesis so will avoid duplication 
here but if modern ablation techniques for substrate-based AF mean that linear ablation 
provides no additional benefit then we must wonder if PVI is truly the optimum strategy 
or if any other substrate modification techniques have a role. It is interesting to note 
that the most recently published study of complex fractionated electrogram ablation, 
the RASTA study, showed a trend towards increased harm, whereas preceding studies 
had suggested a neutral or non-significantly positive impact.103,142 This mirrors the 
chronological pattern discussed earlier for linear ablation.    
 
In Chapter 7 I showed how a modified version of the European Heart rhythm 
association symptom score may help clinicians better select patients likely to benefit 
from AF ablation. However, I did not test this in a linear manner and future research 
looking at quality of life, before and after ablation, is warranted to verify that my 
conclusions hold true in clinical practice. My work on the Ablation Effectiveness 
Quotient (AEQ) has provided both new insight into what contributes to successful lesion 
delivery and also may turn out to be a useful clinical marker of risk of arrhythmia 
recurrence. Further work to externally verify and expand on my initial exploratory 
findings is ongoing. 
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8.4. FINAL CONCLUSIONS  
Catheter ablation of AF can be an effective treatment, associated with a low risk of 
major complications. However, long term recurrence – at least after ablation of 
persistent AF – remains a risk as long as 5 years after an initially successful procedure. 
For persistent AF, the use of CT integration with 3D mapping systems can reduce 
recurrence risk, and in paroxysmal AF the risk of recurrence appears to relate to the 
effectiveness of ablation, as measured by the AEQ. Quality of life is improved by ablation 
but good patient selection is important as those with non-troublesome symptoms 
(mEHRA Class 2a) may not gain a meaningful benefit by being rendered asymptomatic. 
Patient safety is paramount, and the use of vascular ultrasound significantly reduces the 
risk of bleeding complications. By selecting the most suitable patients, minimising the 
risk of complications and employing an appropriate imaging and ablation strategy 
optimum outcomes for our patients are hopefully a few steps closer. 
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1 0 .  A P P E N D I C E S  
10.1. APPENDIX 1:  FUNNEL PLOTS FOR ANALYSES CARRIED OUT  IN CHAPTER 
1 
 
 
Publication bias funnel plot for Analysis 1 Catheter ablation against medical therapy 
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Publication Bias funnel plot for the effect of PV isolation 
 
 
Publication bias funnel plot for Analysis 3 (WACA v. alternative PVI technique) 
 
 
Publication bias funnel blot for Analysis 4 (Effect of linear lesions) 
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Publication bias funnel plot for the analysis of more extensive or less extensive linear ablation 
 
 
Publication bias funnel plot for Analysis 5 (effect of Complex fractionated atrial electrogram (CFAE) ablation) 
 
Publication bias funnel plot for studies of biatrial ablation  
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10.2. APPENDIX 2:  PATIENT INFORMATION S HEET FOR THE SMAN-PAF  
TRIAL  
Part One 
 
You are being invited to take part in a research study.  Before you decide whether to take part, it 
is important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with others if you 
wish.  One of the members of the research team will go through it with you. Please ask if there is 
anything that is not clear or if you would like more information.  Please take time to decide 
whether or not you wish to take part. 
Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study. 
Thank you for reading this. 
 
Study title 
Substrate modification and remodelling for patients with non- paroxysmal atrial fibrillation 
undergoing radiofrequency ablation 
 
Why have I been invited to participate? 
You have been invited because you are being considered for radio frequency ablation treatment 
for atrial fibrillation.  
 
What is the purpose of the study? 
The results of catheter ablation for atrial fibrillation are generally around 60% after 1 
procedure. This study attempts to look at ways to improve that success rate. We aim to do so by 
comparing two different strategies for Ablation. One strategy involves performing ablation only 
around the areas at which the veins returning blood from the lungs attach to the heart 
(pulmonary vein isolation). The other involves performing additional ablation in other areas of 
the left atrium (the chamber of the heart most associated with atrial fibrillation). An additional 
purpose is to assess how the heart responds to the ablation procedure to see if any measured 
parameters are useful to help predict which patients remain cured of atrial fibrillation in the 
long term.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you will be given 
this participant information sheet to keep and be asked to sign a consent form.  If you decide to 
take part you are free to withdraw at any time, and a decision not to take part will not affect 
your future care in any way. 
 
What will happen to me if I take part? 
Sometimes we don‘t know which way of treating patients is best. To find out, we need to 
compare different treatments. We put people into two groups, give each group a different 
treatment and compare the results to see which is better.  In this study there is an equal 
(random) chance of being placed in either group.   In order to reduce the potential for bias, you 
will not be told which group you have been put into until the end of the trial (blinded). 
 
Many of the tests and treatments you will undergo in this study are part of the standard care 
anyway, and will be offered to you even if you decide not to participate in this study. All trial 
participants will complete a short survey and questionnaire at the beginning of the study and 
provide a small (5ml) sample of venous blood.  They will then receive heart rhythm stabilizing 
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tablets for 6 weeks prior to their ablation procedure. These tablets will be discontinued 6 weeks 
after the ablation.  
 
The ablation procedure will be carried out in a similar manner to what would happen if you 
were not taking part in the trial. The extent of ablation (either isolation of the pulmonary veins 
alone or in combination with additional lines of ablation) will be decided according to a 
randomisation procedure. Some additional measurements will be made at the time of the time 
of the ablation.   
 
An ECG will be performed before and after the ablation.  This will then be repeated, along with 
an echocardiogram (ultrasound scan of the heart) the day after the ablation prior to discharge 
from the hospital. A further blood test will be taken. 
 
You will be asked to return for follow up appointments at 3, 6 and 12 months after the ablation 
and the echocardiogram and ECG will be repeated as well as a continuous heart rate monitor to 
be worn for 24 hours. You may be asked to undergo a repeat MRI scan of the heart after 3 
months. If you have ongoing symptoms you may be given a heart rate monitor to use over 1-2 
weeks. If you are found to have a recurrence of atrial fibrillation you will usually be offered 
electrical cardioversion in the first instance. If this is unsuccessful you will be offered an 
additional ablation procedure.  
 
A flow chart is attached to the back of this sheet to help summarise what will happen. 
 
What are the possible disadvantages and risks of taking part?  
The risks for patients in this study are not expected to significantly differ from any other patient 
having an AF ablation. The procedure may last slightly longer (up to ½ hour) than would 
otherwise be the case but this will not affect when you are discharged from hospital. 
 
Follow up appointments may be more frequent and slightly longer for trial participants than 
might be the case for non participants.   In order to minimise inconvenience, every effort would 
be made to ensure that follow up investigations are carried out on the same day as clinic visits. 
 
If you participate in the trial you will receive a heart rhythm stabilizing medicine (usually 
amiodarone) for a short period before and after your ablation.  This is similar to standard 
practice for all AF ablation patients at Liverpool Heart and Chest Hospital.  
 
Radiation and the Ionising Radiation (Medical Exposure) Regulations – (IRMER) 
In order to perform an ablation we need to use X-rays.  As well as undergoing ablation you may 
also be asked to undergo a cardiac CT scan (usually only if there is a reason only you cannot 
have a magnetic resonance (MRI) scan).  Both of these procedures involve exposure to ionising 
radiation.  
 
It is not expected that you will be exposed to any additional ionising radiation if you participate 
in the study compared to someone who has an AF ablation but is not taking part in the study.   
 
For patients under 70 years of age the lifetime additional risk of fatal cancer from the ablation is 
estimated to be 1 in 4000 (1 in 2300 if a cardiac CT scan is also required). For patients over 70 
years old the risks are approximately 5 times less.  
 
For comparison the overall lifetime risk of cancer in the population is 1 in 3. 
 
What are the possible benefits of taking part? 
We hope to show through the study that additional ablation improves AF ablation success rates 
as compared to ‘standard’ PVI. There is a probability that you might benefit if that does turn out 
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to be the case. In addition trial participants will be followed more frequently in the first year 
after their ablation than non-participants and this may mean earlier detection of problems or 
relapses.  
 
What happens when the research study stops? 
Depending on each individual’s ongoing clinical requirement some people will continue to be 
followed up by the Heart Rhythm Team at Liverpool Heart and Chest Hospital whilst others will 
be discharged back to the care of their GP. 
 
What if something goes wrong? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part Two. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
This completes Part One of the information sheet.   
 
If you are interested in taking part please read Part Two which provides further information which 
you may find useful. 
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Part Two  
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, your 
research doctor might consider you should withdraw from study. He/she will explain the 
reasons and arrange for your care to continue. If the study is stopped for any other reason, we 
will tell you and arrange your continuing care. 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from treatment but keep in contact with us to let us know your progress. 
Information collected may still be used. Any stored blood or tissue samples that can still be 
identified as yours will be destroyed if you wish. 
 
What if there’s a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions. Contact details can be found at the end of this 
information sheet. 
 
In the event that something does go wrong and you are harmed during the research and this is 
due to someone‘s negligence then you may have grounds for a legal action for compensation 
against Liverpool Heart and Chest Hospital NHS Foundation Trust but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be available to 
you (if appropriate). 
 
What will happen to the results of the research study? 
The results of the study will be available after it finishes and will usually be published in a 
medical journal or be presented at a scientific conference. Results may also be made available 
online. They will also form part of a thesis for the degree of Doctor of Medicine at Imperial 
College, London. The data will be anonymous and none of the patients involved in the trial will 
be identified in any report or publication.  
 
Should you wish to see the results, or the publication, please ask your study doctor. 
 
Will my taking part in the study be kept confidential? 
If you consent to take part in this study, the records obtained while you are in this study as well 
as related health records will remain strictly confidential at all times. The information will be 
held securely on paper and electronically at Liverpool Heart and Chest Hospital under the 
provisions of the 1998 Data Protection Act. Your name will not be passed to anyone else outside 
the research team or the sponsor, who is not involved in the trial. You will be allocated a trial 
number, which will be used as a code to identify you on all trial forms. 
 
Your records will be available to people authorised to work on the trial but may also need to be 
made available to people authorised by the Research Sponsor, which is the organisation 
responsible for ensuring that the study is carried out correctly. A copy of your consent form may 
be sent to the Research Sponsor during the course of the study. By signing the consent form you 
agree to this access for the current study and any further research that may be conducted in 
relation to it, even if you withdraw from the current study.  
 
The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority and Independent Ethics Committee; this is to ensure that the study is 
carried out to the highest possible scientific standards.  All will have a duty of confidentiality to 
you as a research participant. 
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If you withdraw consent from further study treatment, unless you object, your data and samples 
will remain on file and will be included in the final study analysis. 
 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely 
archived for a minimum of 10 years. Arrangements for confidential destruction will then be 
made.  
 
With your permission your GP, and other doctors who may be treating you, will be notified that 
you are taking part in this study. 
 
Informing your General Practitioner (GP) 
When you agree to take part in this study a letter will be sent to your GP explaining the details 
of the trial and informing him/ her that you are participating. 
 
What should I do if I want to take part? 
You will have been given this information sheet either via the post along with your clinic 
appointment letter, or in the outpatient department having attended a Heart Rhythm clinic.  
• If you were sent the information prior to your appointment you will be seen by one of 
the research team when you attend clinic and asked if you want to take part. The researcher will 
be able to answer any questions you may have and complete the required paperwork. If you 
have questions you would like answered before you attend you can contact the lead researcher, 
Dr Gareth Wynn using the details at the bottom of this page. 
• If you were given the information sheet in clinic a member of the research team is on 
hand to answer your questions and complete the required paperwork if you wish to take part. If 
you would like to take longer to think about it you may take the paperwork away and return it 
to us by post. 
 
Who is organising and funding the research? 
The study is being carried out by members of staff at the Liverpool Heart and Chest Hospital 
which is acting as sponsor for the study. No external funding has been provided. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable 
opinion by The North West Research Ethics Committee. 
 
Contact for Further Information 
If you have any further questions you can get additional information from Dr Gareth Wynn, 
Electrophysiology Research Registrar via his email address gareth.wynn@lhch.nhs.uk or by 
phone by contacting the Liverpool Heart and Chest Switchboard on 0151 228 1616. 
 
This completes Part Two of the information sheet.   
 
Thank you for taking the time to read this information 
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10.3. APPENDIX 3:  AFEQT  QOL  FORM (CHAPTERS 3,4  &7) 
 
  Page 240 of 266 
 
  
  Page 241 of 266 
10.4. APPENDIX 4:  SF-36  QOL  QUESTIONNAIRE (CHAPTERS 3  &  4) 
 
 
SF-36 HEALTH SURVEY 
 
 
INSTRUCTIONS:  This survey asks for your views about your health.  This information will help keep 
track of how you feel and how well you are able to do your usual activities. 
 
Answer every question by marking the answer as indicated.  If you are unsure about how to answer a 
question, please give the best answer you can. 
 
 
 
1. In general, would you say your health is: 
 
 (circle one) 
 
    Excellent ...................................................................................................................... 1 
 
    Very good .................................................................................................................... 2 
 
    Good ............................................................................................................................ 3 
 
    Fair ............................................................................................................................... 4 
 
    Poor ............................................................................................................................. 5 
 
 
 
 
 
2. Compared to one year ago, how would you rate your health in general now? 
 
 (circle one) 
 
    Much better now than one year ago ........................................................................... 1 
 
    Somewhat better now than one year ago .................................................................. 2 
 
    About the same as one year ago ................................................................................ 3 
 
    Somewhat worse now than one year ago .................................................................. 4 
 
    Much worse now than one year ago........................................................................... 5 
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3. The following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much? 
 
 (circle one number on each line) 
 
 ACTIVITIES 
Yes, 
Limited 
A Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited 
At All 
 a. Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports 
1 2 3 
 b. Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
1 2 3 
 c. Lifting or carrying groceries 1 2 3 
 d. Climbing several flights of stairs 1 2 3 
 e. Climbing one flight of stairs 1 2 3 
 f. Bending, kneeling, or stooping 1 2 3 
 g. Walking more than a mile 1 2 3 
 h. Walking half a mile 1 2 3 
 i. Walking one hundred yards 1 2 3 
 j. Bathing or dressing yourself 1 2 3 
 
 
 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
 
 (circle one number on each line) 
 YES NO 
 a. Cut down on the amount of time you spent on work or other 
activities 
1 2 
 b. Accomplished less than you would like 1 2 
 c. Were limited in the kind of work or other activities 1 2 
 d. Had difficulty performing the work or other activities (for 
example, it took extra effort) 
1 2 
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5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 
 (circle one number on each line) 
 YES NO 
 a. Cut down on the amount of time you spent on work or other activities 1 2 
 b. Accomplished less than you would like 1 2 
 c. Didn't do work or other activities as carefully as usual 1 2 
 
 
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours, or groups? 
 (circle one) 
 
    Not at all ....................................................................................................................... 1 
 
    Slightly ......................................................................................................................... 2 
 
    Moderately ................................................................................................................... 3 
 
    Quite a bit .................................................................................................................... 4 
 
    Extremely ..................................................................................................................... 5 
 
 
 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
 
 (circle one) 
 
    None ............................................................................................................................ 1 
 
    Very mild ...................................................................................................................... 2 
 
    Mild ............................................................................................................................... 3 
 
    Moderate ...................................................................................................................... 4 
 
    Severe .......................................................................................................................... 5 
 
    Very severe .................................................................................................................. 6 
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8. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 
 (circle one) 
 
    Not at all ....................................................................................................................... 1 
 
    A little bit ...................................................................................................................... 2 
 
    Moderately ................................................................................................................... 3 
 
     Quite a bit .................................................................................................................... 4 
 
    Extremely ..................................................................................................................... 5 
 
 
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have 
been feeling.  How much of the time during the past 4 weeks - 
 (circle one number on each line) 
 
All of the 
Time 
Most of 
the Time 
A Good 
Bit of 
the Time 
Some of 
the Time 
A Little 
of the 
Time 
None of 
the Time 
 a. Did you feel full of life? 1 2 3 4 5 6 
 b. Have you been a very nervous 
person? 
1 2 3 4 5 6 
 c. Have you felt so down in the 
dumps that nothing could cheer 
you up? 
1 2 3 4 5 6 
 d. Have you felt calm and 
peaceful? 
1 2 3 4 5 6 
 e. Did you have a lot of energy? 1 2 3 4 5 6 
 f. Have you felt downhearted and 
low? 
1 2 3 4 5 6 
 g. Did you feel worn out? 1 2 3 4 5 6 
 h. Have you been a happy person? 1 2 3 4 5 6 
 i. Did you feel tired? 1 2 3 4 5 6 
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10. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
 
 (circle one) 
 
    All of the time ............................................................................................................... 1 
  
    Most of the time ........................................................................................................... 2 
 
    Some of the time ......................................................................................................... 3 
 
    A little of the time ......................................................................................................... 4 
 
    None of the time .......................................................................................................... 5 
 
 
 
 
 
 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 
 (circle one number on each line) 
 Definitely 
True 
Mostly 
True 
Don't 
Know 
Mostly 
False 
Definitely 
False 
 a. I seem to get ill more easily than other 
people 
1 2 3 4 5 
 b. I am as healthy as anybody I know 1 2 3 4 5 
 c. I expect my health to get worse 1 2 3 4 5 
 d. My health is excellent 1 2 3 4 5 
 
SF-36® Health Survey © 1988, 2002 by JE Ware, Jr., MOT, Health Assessment Lab, QualityMetric Incorporated 
– All rights reserved 
SF-36® is a registered trademark of the Medical Outcomes Trust (MOT) 
(SF-36 Standard U.K. Version 1.0) 
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10.5. APPENDIX 5:  EQ-5D  QOL  QUESTIONNAIRE (CHAPTER 7) 
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